,ticker,content
0,SYK,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
1,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
2,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
3,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
4,SYK,here investing action plan thursday need know investor come day lead amazon amzn technology company tee report earning include microsoft msft intel intc baidu bidu recent ipo iqiyi iq amazon commerce giant report close estimate amazon earning decline
5,SYK,here weekly investing action plan need know investor come week lead tech company facebook fb amazon amzn alphabet googl microsoft msft report earning aerospace defense giant boee ba oil major exxon mobil xom stock watch hot software stock
6,SYK,medical supplier stock collectively topple month low intraday tuesday becton dickinson bdx biggest loser report emerge amazon com amzn be plan sell supply hospital analyst largely doubt amazon put pressure manufacturer higher tech product include implantable device insulate company medtronic mdt stryker syk cantel medical cmd conm cnmd teleflex tfx needham analyst mike matson write note client other industry amazon have typically disrupt middleman more manufacturer say view amazon model work lower tech product be unlikely work higher tech product matson say lower tech product list lower price single use item don require service be typically used sale representative present higher tech item be often implantable need service require sale rep present use perhaps not surprisingly lower tech product be already typically sell distributor such owen minor omi higher tech product be typically sell directly manufacturer say view amazon simply represent distribution channel lower tech product ibd take stock market remain high market still thro correction important keep tab key action visit big picture evercore analyst vijay kumar say amazon be formidable player basic medical supply category include plastic glove drape simple catheter company cover group be becton baxter bax becton baxter be likely happy supply amazon well other distributor say report client close bell stock market today becton sank finish earlier fall much collectively medical supplier stock topple much low last see april group end day baxter trade medical product group dip medical product stock broadly fall much be marginally close related payer win balk price tag vertex new drugis teva pharma restructure plan actually more reasonable regeneron benefit lackluster datum present rival
7,SYK,here investing action plan tuesday need know investor come day fast food leader mcdonald mcd video game publisher electronic art ea open earning season respective sector investor get dose medical chip report president trump deliver state
8,SYK,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
9,SYK,relative strength rs rating stryker syk enter new percentile thursday rise ibd proprietary rs rating identify market leadership show stock price movement last week measure other stock major index decade market research show top perform stock tend have better rs rating early stage move look best stock buy watch start herestryker be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line stryker report earning growth most recent report sale growth come company hold rank peer medical product industry group align technology algn abiom abmd teleflex tfx be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
10,SYK,stryker syk see welcome improvement relative strength rs rating monday rise proprietary rating identify market leadership show stock price action last week measure other stock database history show market biggest winner often have rs rating early stage move see ibd help make more stocksstryker be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line stryker post earning growth latest quarterly report sale growth come stryker hold rank peer medical product industry group align technology algn abiom abmd orasure technology osur be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
11,SYK,many stock mutual fund manager be bask warm glow hot performance number broad market index rise december lift fourth quarter gain cap year dow jone industrial surge year way top first time ever thursday be already so far year dow be diversify stock mutual fund edge average december extend gain accord lipper inc world equity fund power part weaker dollar turn gain december last year general domestic taxable bond fund averaged gain top december move finished year fund manager investment strategist have also turn eye many expect more modest gain overall list mutual fund month leaderstop mutual fund mutual fund category performancewhy buffalo discovery fund keep stock be top fund manager buy fund manager strategist expect rely more foreign stock value equity gain still fund manager certainly have not abandon equity totally have bet stock first solar fslr part amazon amzn key piece nasdaq composite boee ba best perform dow jone industrial average stock reason fund manager strategist expect search further afield overall big return history have rally more annually year time do follow year broad market gain averaged just more reason expect rotation more foreign stock value equity cheaper valuation many foreign equity give more room run forecast faster economic growth abroad re synchronous growth pattern say bob doll chief equity strategist asset management manager co manager stock mutual fund combine asset rare have growth well key market abroad sort economic environment value stock overall beat growth stock stock also continue get tailwind federal reserve slow tempo interest rate hike slow pace be reassure investor say allen bond manager jensen quality growth fund jensx outperformed well past year just fall short past year key reason doll expect value outperform be corporate earning have be roll remain way indicative rise economic tide lift stock stripe include modestly price value oriented one doll say further strengthen economy lift earning type stock investor be likely flock value stock be more attractively price growth stock inflation interest rate have be behave let earning growth go bottom line add doll add tax reform boost corporate earning also corporate ceo consumer confidence be demand be strong many good service especially technology health care certain consumer area ibd take see tax reform impact individual check ibd report much consumer area have be do capital spending improve tax bill enactment accentuate capital spending doll say be good industrial many tech stock tech space doll like software company credit card company use software facilitate digital payment transaction visa mastercard be top holding doll largest portfolio large cap core nlcix nov health care stock highlight diversify biotech company manage care provider say less interested pharmaceutical equipment company prefer diversify biotech pharma have faster growth similar valuation characteristic large cap core also hold cloud compute service provider red hat rht red hat enable client noncloud enterprise software jibe cloud infrastructure amazon aw microsoft azure manage care provider unitedhealth group unh be third hold unitedhealth benefit membership growth drive rise employment increase use manage care government control cost firm also benefit use datum analytic additional holding include first solar amazon boee solar energy company first solar be new fund november post result oct crushed analyst expectation quarters decline earning share ep grow past stanzas hot solar flare stock gain trading first solar be extend have very strong ibd composite rating ibd composite rating be score scale stock poise move higher often have comp rating higher ibd smr rating be mean top stock term sale growth profit margin return equity ratio base ibd proprietary formula amazon soar nearly last year commerce leader slide dec report president trump have call amazon also leader cloud service pay postal service higher fee package delivery separately faang stock say ship more item prime program customer pay year amazon be buy point share break thursday close just flat base buy point now stock be back proper entry aerospace defense titan boee gap more dec say raise dividend share give share dividend yield boee also increase stock buyback program dow component boee be tech sector jensen bond like stock benefit ongoing transition cloud compute like company help make switch make money help other shift cloud microsoft msft be dual beneficiary say oracle orcl enable customer use premise enterprise software shift cloud compute be go database software provider company extremely sensitive information have thing go wrong bond say also like alphabet googl googl be more player cloud infrastructure space say customer need access cloud structure sell most business be core advertising model result ubiquitous position online search online ad buy bond also like specific theme health care such theme be grow affluence emerge market enable patient be able afford better health care health care system start grow develop emerge market needle syringe be first thing need make work say result like becton dickinson co bdx lead maker needle syringe company acquire carefusion maker infusion pump deliver medical liquid time last month becton dickinson say bard have agree divest product line regulatory approval merger bard make catheter biopsy device bond also like stryker syk orthopedic implant surgical tool medical device enable capitalize age population europe japan kinetic internet fund wwwfx be top perform diversify stock mutual fund post gain accord morningstar direct fund have holding include stake bitcoin investment trust gbtc cryptocurrency be volatile rise last year re not afraid be wrong say co manager peter doyle lot person win participate upside consensus money cryptocurrency need outside reinforcement don say cryptocurrency fail control risk control size position doyle say fund stake be much higher have formally disclose due appreciation investment opportunity general fund be look many popular large cap enjoy large run up other recent year high valuation leave insufficient room post additional gain say co manager james davolos thing fund hold stock company note investor liberty global lbtyk chairman john malone hold large block share include liberty medium lsxmk liberty lbrdk liberty global ve trust john malone own share company year almost exception ve do well doyle say kinetic internet also like live nation entertainment lyv company help popular music performer earn live live performance concession sale corporate sponsorship advertising doyle say fund manager also copart cprt conduct salvage vehicle auction company keep gain market share provide value buyer seller vehicle provide price transparency lower transaction cost davolos say index fund lead diversify category average gain tack december world equity fund trail diversify stock fund average advance december return india region fund pace foreign stock fund category soar help december romp global natural resource fund beat other major sector post gain aid december geyser give return year commodity base metal fund do even better gain december year consumer service fund add december lift gain loan participation fund be top general domestic taxable bond category rise december gain be world income fund emerge market hard currency fund enjoy best gain shade better december return municipal bond fund averaged gain return december related stock watch join apple bofa list new buy top do mutual fund perform need much retirement saving age income
12,SYK,stock be quiet ahead long weekend nike nke weigh bitcoin continue volatile week trade apple aapl be flat spdr dow jone industrial average dium powershare qqq trust qqq fall spdr spy give emerge market extend gain third straight session ishare msci emerge market eem rise stock market today nike provide biggest drag dow tumble apple meanwhile be flat enter positive territory less flat base buy point initially crossed monday telecom bank health care lead downside sector fund gold miner energy real estate be biggest gainer gold future leap ounce west texas intermediate crude price be flat barrel bitcoin crash pare loss accord coindesk earlier jump nearly level cryptocurrency have top sunday bitcoin investment trust gbtc have make double digit move past session reversed upward gain track snap session slide pare steep early loss gbtc be now tuesday intraday high look set drop week be tumultuous week cryptocurrency string decline be spark coinbase announce support bitcoin offshoot bitcoin cash subsequent probe possible insider trading grow number global central bank have issue warning potential risk bitcoin other digital currency medical stock be often consider defensive play name such abbott laboratory have also proven growth potential ishare medical device ihi have be testing support day move average month solid advance line mark opportunity buy share rise late september rebound day nov intraday high fund marked anniversary have amassed asset track dow jone select medical equipment index be make maker distributor medical device include magnetic resonance imaging scanner prosthetic pacemaker health care equipment represent lion share asset life science tool service contribute health care supply technology service make rest top holding dec include medtronic mdt abbott lab thermo fisher scientific tmo dhr stryker syk top account asset abbott share have rally year thermo fisher have rise stryker be have advanced ibd take make money catch etf uptrend require knowledge read chart learn ibd university etf ytd gain dec outpace return ihi have deliver healthy performance longer haul average annual return past year respectively have return same period ihi bear expense ratio related apple bank boost dow record bitcoin stop slump apple set sight buy point bitcoin dife nvidia gear here apple be weigh dow techs bitcoin high
13,SYK,current bull market approach ninth year sign sector rotation possible top emerge now be good time see join apple aapl intel intc bank america bac ibd latest list new buy top perform mutual fund last month lead fund manager have continue pick share semiconductor related stock intel texas instrument txn build sector name lead homebuilder pulte group phm construction product manufacturer masco mas well several industrial machinery company include parker hannifin ph illinois tool work itw tension north korea nuclear missile program rise not surprising fund have also be investing defense contractor include aerojet rocketdyne ajrd heico hei apple intel bofa top list term money invest fund invest estimate total intel fund scoop nearly apple share fund put bank america apple break oct short rise have ease back form new flat base show possible entry intel have pull back make solid gain early october chip giant be now testing support week line appear be set new base possible buy point bofa remain extend clear entry financial titan be currently buy point several stock month list be potential buy zone keep mind recent selling pressure major index pullback several lead stock mean current uptrend be start roll correction happen be difficult individual stock make sustain upward climb orthopedic implant maker stryker syk be work first stage base base entry look relative strength line get closer new high ground stock find support day move average stryker close benchmark line thursday rise volume heico have find support week move average try complete flat base entry pattern be part long first stage base base formation fellow defense contractor aerojet rocketdyne be also work base be trading week move average lag rs line regional bank stock synovus financial snv jump past entry nov have now pull back test buy point once again stock list currently pay dividend yielding least annualize basis texas instrument intel new mexico base electricity utility pnm resource pnm dov look generate income stock mutual fund take undue risk see ibd new special report income investing jpmorgan chase jpm top list new sell net seller fund selling buy recent chart action be tell different story bofa other big bank stock jpmorgan have get bump likelihood donald trump republican pass tax reform have rise johnson johnson jnj have net seller selling buy aetna aet merge cvs cvs deal clear regulatory hurdle have selling buy johnson johnson be work flat base part longer first stage base base formation buy point be stock end thursday session entry related find track best mutual fundsincome investing find best dividend stock
14,SYK,dow component johnson johnson jnj surpass wall street third quarter expectation early tuesday strength pharmaceutical unit boost guidance prompt share pop premarket trade xby close bell stock market today stock jump finish share break flat base buy point oct third quarter report sale adjust income share respective vs year earlier quarter metric top consensus analyst poll zack investment research sale share earning rbc analyst glenn novarro attribute sale beat upside pharma unit global sale be forecast consensus pharma revenue top novarro estimate medical device sale lag worldwide pharma sale increase year year basis key product include cancer drug darzalex imbruvica zytiga latter beating novarro view sale new actelion brand be novarro model ibd take isn alone report quarterly result week earning season kick earnest keep tab ibd investing action plan deck day medical device sale grow include shortfall be slightly novarro view orthopedic vision care revenue be light respectively write note client consumer unit grow be just ahead rbc estimate operational basis counter beauty sale grow other category fall highlight continue pressure segment firm also raise guidance sale see adjust income share vs earlier expectation novarro write analyst have modeled sale share earning disclose medical device segment sustain negative impact basis point follow hurricane texas florida puerto rico be number firm manufacturing facility puerto rico investor have be wary effect storm negative impact be attribute lose surgery day area affected stormwater write leerink analyst geoffrey porge note client be supply disruption firm site puerto rico be open generator power run different capacity porge note result extend other biotech space give reliance puerto rico pharmaceutical manufacturing lack disclosure regard demand supply impact be increasingly confident company biopharma coverage not experience material storm related headwind say rbc novarro be bit less bullish result point continue soft market trend medical device diagnostic say exclude acquisition divestiture medical device diagnostic unit grow just year year overall hospital admission be basis point surgical procedure basis point year year basis novarro write orthopedic sale be short weak performance knee spine segment weak knee performance be blame negative impact india implant pricing legislation write estimate sale impact quarter worldwide knee revenue decline year year revenue hip product grow pricing decline likely lose share stryker syk knee product unit novarro say global spine product sale decline lose share spine product segment benefit nuvasive nuva group also suggest continue weak growth quarter spine product market separately look lose share trauma product market stryker worldwide sale grow intuitive surgical isrg medtronic mdt be take piece surgery unit novarro say related be time buy dow dividend machine dow flirt buy point bullish pre earning reportthese medtech player be flail hurricane related headwind
15,SYK,relative strength rs rating stryker syk climb higher percentile thursday get lift ibd unique rs rating measure market leadership used worst best score show stock price performance trail week match other stock history show stock go make biggest gain typically have rs rating north early stage move see stryker continue rebound clear threshold look winning stock try simple stock be work flat base entry see stock break heavy trading company post ep growth latest quarterly report revenue rise keep eye company next round number oct company hold rank peer medical product industry group align technology algn merit medical system mmsi orasure technology osur be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
16,SYK,here investing action plan thursday need know investor come day earning rush hit peak most attention be handful tech company report close amazon com amzn alphabet googl microsoft msft intel intc baidu bidu other heavyweight
17,SYK,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
18,SYK,stryker syk have relative strength rs rating upgrade friday welcome improvement still better score look ibd proprietary rs rating measure market leadership used worst best score indicate stock price performance trail week match other stock decade market research show best perform stock tend have rs rating begin biggest climb see stryker continue rebound hit benchmark stryker be not currently potential buy area see stock go build base launch new move company post earning growth last quarter sale growth come company hold rank peer medical product industry group align technology algn lemaitre vascular lmat merit medical system mmsi be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
19,SYK,monolithic power mpwr post fifth straight gain quiet trade thursday rise narrowly buy point week flat base share rise volume be only have average make new buy area suspect silicon valley outfit develop power management chip condition convert energy used broad
20,SYK,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
21,SYK,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
22,SYK,here be investing action plan thursday need know investor come day xamazon amzn intel intc baidu bidu expedia expe be company report earning be busy day quarterly result variety company casino airline industry also
23,SYK,here investing action plan wednesday need know investor come day xa range industrial tech consumer medical company report wednesday lead boee ba facebook fb paypal pypl edward lifescience ew federal reserve also wrapped policy meeting market await more clue
24,SYK,lantheus holding lnth end week new high extend perform nearly textbook perfect rebound week move average lantheus produce definity liquid design improve result ultrasound diagnostic procedure also manufacture technelite type generator contain radioactive isotope used radiopharmacy
25,SYK,here weekly investing action plan need know investor come week biggest name tech defense energy automotive telecom restaurant industry report include fang stock facebook fb amazon amzn alphabet googl federal reserve hold policy meeting opec
26,SYK,past week stock market struggle dive nasdaq june put market uptrend pressure switch back resume uptrend june prove be head fake go friday session uptrend have carry pressure label previous session condition improve friday
27,SYK,due considerable market volatility past several week investor focus stock pullback be quiet calm orderly longtime ibd sector leader abiom abmd be exemplify trait consolidate recent gain cup handle late april massachusett base medical device maker have stranglehold artificial heart market impella heart
28,SYK,stock index open higher monday dow jone industrial average reach record high nasdaq rise add dow jone industrial average amazon com amzn extend gain rise early nasdaq bellwether announce friday be acquire whole food market wfm amazon ceo jeff bezos be several high profile tech ceo meeting president trump white house today apple aapl tim cook also be attendance share apple rise open minute dow component boee ba rise nearly say paris air show expect get more order worth total more new max early mover include clovis oncology clvs share soar open biotech reveal positive late stage datum ovarian cancer drug rubraca merger oil gas sector make early headline eqt corp eqt announce plan merge rice energy rice share rice jump eqt lose healthcare space stryker syk strike deal acquire small cap novadaq technology nvdq share novadaq soar open novadaq be provider medical imaging solution altaba formerly know yahoo start trading today ticker symbol aaba new york mercantile exchange crude oil give back early gain be mostly unchanged barrel overseas market be also higher europe major average rise brexit talk be set begin new french president emmanuel macron centrist party win parliamentary majority ftse climb germany dax france cac asia japan nikkei climb china shanghai composite gain related clovis oncology soar ovarian cancer drug study rival fallboee snag deal new max jetthese internet giant be flash potential buy signalswhy lockheed stun crowds paris air showthese software giant be buy earning due
29,SYK,index hold gain afternoon trading friday dow jone industrial average manage climb back important chart level add be day move average recall be break line wednesday cause ibd downgrade market outlook uptrend pressure still market need show more improvement dow jone industrial average climb be barely day average nasdaq rise well facebook fb biggest component be climb pullback day move average so call fang stock only buy area small cap russell be higher however index remain day average volume be tracking lower compare same time thursday energy sector be vibrant oil gas industry group top today market so far price crude oil rise nearly design software be day top industry group thank largely autodesk adsk stock surge new high design software company beat expectation autodesk have adjust loss cent share revenue april end quarter analyst expect loss cent share ex item sale therapeutic cort break cup handle pattern buy point volume be tracking well average ibd national beverage fizz be find support day move average first follow entry stock break march stryker syk also be find support day line maker orthopedic product second test line feb related cad software firm autodesk soar quarterly earning beatdeere more double growth view crush estimate
30,SYK,do lead player long run bull market today have be spanking new issue not necessarily scan date stock ibd go public find just name make debut past year baby group floor decor fnd april ipo
31,SYK,stock big cap be situation require patience sound judgment october edward lifescience ew have be form cup handle pattern cup decline william neil book make money stock point usual correction absolute peak vary
32,SYK,stryker syk see improvement ibd smartselect composite rating thursday upgrade mean stock currently top other stock term key performance metric technical strength best stock tend have better grade kick significant move stryker be not currently proper buy zone see stock go form new chart pattern offer new buy opportunity stock sport ep rating meaning recent quarterly longer term annual earning growth top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post earning gain mark straight quarters rise ep performance revenue growth increase prior quarter mark quarter accelerate revenue increase stryker hold rank peer medical product industry group inogen ingn be top rank stock group related company be now outperform stock
33,SYK,xchipotle grill cmg stryker syk wynn resort wynn arconic arnc top analyst estimate late tuesday illumina ilmn meet profit view give weak earning guidance estimate share earning swing year share loss cent revenue fast casual burrito chain emerge aftermath several food bear illness outbreak result ep revenue same store sale jump management say chipotle first dessert be test later month also reveal datum breach outlook full year comp sale gain high single digit stock chipotle rally late significantly pare earlier hour gain share close stock market today close monday stock remain extend buy range clear entry point late last month chipotle isn only restaurant stock back investor menu mcdonald mcd shot tuesday morning now extend past buy point strong earning push burger king parent restaurant brand qsr past own buy point intraday estimate profit fall cent share sale gain result ep cent revenue outlook ep cent wall street view cent revenue growth roughly line consensus growth full year ep line consensus view revenue growth analyst view gain stock illumina fall late share maker gene sequence equipment advanced finished climb monday gapping buy range stock break cup handle base late march initially struggle clear buy point estimate earning rise sale climb result ep revenue outlook ep midpoint consensus stock stryker dip late share medical device maker climb rise monday extend buy territory stryker have break flat base entry late february estimate ep dip cent revenue soar result ep cent revenue billionstock wynn rise late share macau la vegas casino giant advanced extend range breaking consolidation buy point estimate earning climb cent post breakup arconic revenue tumble result ep cent revenue stock arconic gap late share performance metal maker spun alcoa aa late last year rally remain day move average share have pop april ceo klaus kleinfeld abruptly resign public scuffle elliott management lead arconic board seek resignation related arconic jump ceo kleinfeld exit proxy fighttop stock buy zone ahead result investing action plantech industrial giant report euro rally investing action plan
34,SYK,baxter bax stock fall monday worry related department justice investigation potential price fix intravenous fluid allegation analyst deem extraordinary stock market today baxter stock fall justice department send grand jury subpoena baxter employee subpoena be receive friday relate criminal investigation justice department antitrust arm ask document testimony related manufacturing pricing selling shortage intravenous solution baxter communication rival evercore analyst vijay kumar note price fix allegation isn new stem year old investigation begin new york ongoing class action suit northern district illinois related supply shortage shortage be trigger flu season benefit manufacturer hospira third quarter see growth unit produce intravenous fluid kumar say hospira be acquire pfizer pfe class action lawsuit allege manufacturer intravenous fluid falsely create shortage justify spiking price baxter have file motion dismiss suit call allegation extraordinary idea public company voluntarily create supply shortage hope competitor similarly restrict output order raise price seem stretch kumar tell client note ibd take baxter stock trade ibd company medical product industry group be lead medtronic mdt stryker syk boston scientific bsx term market cap medtronic boston edward lifescience ew compete heart valve replacement market check edition sector leader see stack fda regulator regularly inspect manufacturing facility note class action lawsuit seem imply baxter other intravenous fluid manufacturer be able hoodwink inspector post shortage notice say baxter say incur cost comply increase fda regulatory requirement meet supply constraint meanwhile price increase only contribute growth kumar say intravenous fluid solution contribute third segment growth imply pricing be average kumar say assume bag intravenous fluid cost equate increase cent bag apart price collusion prosecutor have argue baxter earning increase intravenous fluid price be reasonable kumar estimate hike price intravenous fluid baxter have margin earning interest taxe related boston scientific make acquisition battle medtronic edward best stock own analyst
35,SYK,johnson johnson jnj zimmer biomet zbh be medtech stock own go earning season several other be put buy list pullback analyst say rbc analyst glenn novarro say wednesday large cap medtech stock johnson zimmer offer best risk reward first quarter earning season zimmer be cheapest arena johnson have lag group investor sentiment have turn more favorable johnson recent week anticipate further multiple expansion back strong first quarter result consensus estimate move higher year write research report consensus analyst poll yahoo yhoo broadly expect johnson report sale year year share adjust earning dip johnson be also cusp close acquisition actelion pharmaceutical second quarter sanofi sny be lock battle late last year take swiss biotech johnson bid win company zimmer company just have hit consensus estimate stock move higher novarro say consensus model year year sale growth adjust earning share novarro however say abbott laboratory boston scientific bsx edward lifescience ew stryker syk be attractive pullback see deliver solid result reaffirm guidance investor likely track ongoing litigation abbott alere alr heart valve replacement sale edward boston likely comment voluntary recall lotus heart valve replacement company recall lotus device discover malfunction result premature release pin implantation medtronic mdt onyx stent launch represent term challenge boston still want own boston novarro say small midsize cap world novarro recommend nuvasive nuva medical group wmgi group potential takeout be likely baked stock price nuvasive say ibd take isn first time edward have be list best stock own head ibd technology page deeper dive edward be hold strong remain top pick small midsize medtech group expect play catch group investor focus shift company impressive new product lineup improve international sale growth company experience distributor issue write novarro needham analyst mike matson also prefer zimmer also have strong buy rating share inogen ingn mimedx mdxg see cardiovascular orthopedic market slow diagnostic market improve quarter matson model cardiovascular market growth decelerate fourth quarter orthopedic market advance vs growth prior quarter diagnostic sale likely grow say be standout matson say model transcatheter aortic valve replacement market boston edward medtronic operate have grow orthopedic matson model growth extremity market related medtronic do heart valve study rival reap benefitsboston scientific make acquisition battle medtronic edward
36,SYK,medtronic mdt edward lifescience ew stock dip monday series bullish report include call heart valve replacement rival stock own term midday trading share medtronic end virtually flat stock market today edward close rbc analyst glenn novarro expect have strong catalyst term note client sunday novarro say see edward medtronic stryker syk zimmer biomet zbh group stock own term call edward medtronic best idea cardiovascular work heart valve replacement recent study medtronic show new method insert heart valve be superior open heart surgery be encourage novarro say result help stoke growth transcatheter aortic valve replacement market say check ibd best mutual fund awardsfollow novarro report evercore analyst vijay kumar upgrade edward stock buy rating raise price target needham analyst mike matson reiterate buy rating price target medtronic stock matson expect medtronic maintain mid single digit sale growth double digit earning growth overcome temporary product cycle competitive issue fiscal third quarter believe medtronic product cycle remain very strong effectively fend competitive product launch investor concern matson write note client medtronic compete edward lifescience smaller outfit heart valve replacement boston scientific bsx also be look break transcatheter aortic valve replacement market doesn yet have fda approval ibd take boston scientific be work catch medtronic edward lifescience strategic acquisition read sector leader next month medtronic have number launch help boost growth company see strong growth emerge market segment make total sale have see double digit growth recent quarters believe medtronic sustain double digit growth market drive market development channel optimization public private partnership matson say saudi arabia see return growth soon rbc novarro expect medtronic continue gain share implantable cardioverter defibrillator market device be used manage tachycardia expect transcatheter aortic valve replacement drug coat balloon perform well novarro call line slightly better first second quarter metric edward expect medtronic launch corevalve evolut drive growth also edward sapien xt device be transcatheter aortic valve implant patient harden heart valf unable undergo open heart surgery novarro recommend own edward stock go second half expectation market growth evercore kumar note edward stock be growth stock therefore volatile nature lower investor expectation believe edward share be poise catch trade offer asymmetric risk reward current level write research report see upside current stock level kumar be previously sideline edward stock competition boston scientific international market boston pull lotus valve market late february give edward first break month still company be likely patent standoff first half related medtronic do heart valve study rival reap benefitsboston scientific win patent battle vs edward german courtboston topple heart valve bug wo boost edward medtronic
37,SYK,medtronic mdt use potential proceed major divestiture add cent earning needham analyst mike matson suggest monday medtronic stock dip stock market today medtronic stock slip share be trading well day move average be year meanwhile ibd company medical product industry group be only bloomberg first report jan medtronic be consider selling covidien acquire medical supply unit business comprise commoditize product include product used nursing care incontinence medical surgical oem product accord insider cite bloomberg deal fetch unit have ebita earning interest taxe amortization matson estimate operate income sale dilute medtronic earning share cent think dilution sale be mostly offset use proceed share repurchase debt retirement needham matson write research report monday additionally sale improve medtronic revenue growth operate margin ibd take medtronic boston scientific edward lifescience be often see battle market share late last year boston scientific say acquire neovasc tissue business take aim rival get bigger scoop ibd sector leader medtronic add cent earning repurchase stock share medtronic use retire debt interest rate add cent ep matson write medtronic also use cash hard predict impact unknown deal write matson keep buy rating price target medtronic stock medtronic be rank first market cap industry group lead stryker syk boston scientific bsx medtronic decline comment rumor potential divestiture ibd related medtronic downgrade increase boston st jude rivalriesedward heart valve guidance lag medtronic boston
38,SYK,be dominate financial stock recent month other type company be reach new high list market uptrend continue notably airline have be take new high improve passenger traffic trend stryker syk medical equipment company pre announce bullish result alaska airline alk jump more
39,SYK,here weekly investing action plan need know investor come week earning appetizer market sample past few week shift rich meaty entree heavyweight alphabet googl alibaba baba microsoft msft intel intc boee ba mcdonald mcd starbucks sbux chevron cvx report quarterly result president trump
40,SYK,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
41,SYK,apple aapl be give overweight rating friday oracle orcl have price target lower fedex fdx have price target raise stryker syk veeva system veev be upgrade piper jaffray resume coverage apple overweight rating price target cite expectation strong demand upcoming iphone next year follow research note needham thursday name apple top stock pick cite several catalyst include iphone improve tax climate apple stock close stock market today oracle have price target lower bmo capital market enterprise software giant report fiscal second quarter result market close thursday beat earning fall short revenue think oracle have mixed quarter balance thought be more negative positive write bmo analyst bachman oracle stock skid finish cowen raise price target fedex shipping giant report fiscal result tuesday final stretch frantic holiday shopping commerce season fedex stock fall stryker be upgrade buy neutral ub stryker be developer orthopedic surgical instrument imaging system stock slip less veeva system be upgrade outperform market perform jmp security veeva report quarterly result last month blow past estimate raise guidance company cater life science client manage clinical drug trial other complex process veeva stock rise move just buy range entry point
42,SYK,zimmer biomet holding zbh monday plunge monday month low medical supplier lower full year forecast weak third quarter earning report warsaw ind base maker orthopedic device say now see diluted earning share previous forecast adjust earning estimate be cut range share bring upper end spread share end day tumble zimmer violent stock reaction parallel other medical supplier have report recent day edward lifescience ew plunge more wednesday earning disappoint abiom abmd stumble more day last week boston scientific bsx slip few point report earning stryker syk see healthy uptick report gain more zimmer expect revenue growth be well exclude company acquisition ldr hold growth be expect run instead previous forecast company say net income quarter be adjust earning be share line analyst estimate revenue fall short forecast analyst survey thomson reuter expect zimmer expect full year earning range share revenue range analyst be predict earning share sale
43,SYK,stock rise modestly midday friday market fail get much juice unexpectedly strong third quarter gdp number nasdaq tack add blue chip dow jone industrial average advanced volume stock market today be run previous session pace gdp surge best growth year estimate problem be gdp estimate be notoriously unreliable last time first read gdp exceed be second quarter last year look happened afterward first read be second take third estimate additional revision july clumsy toddler handful darts do well big cap stock be do well friday ibd big cap list best big cap fundamental technical winner lead loser ratio winner include internet content leader alphabet googl volume average surgical equipment provider stryker syk volume greater usual online travel booker priceline pcln volume more twice routine pace amazon com amzn lead big cap loser gap volume more average company report quarterly result thursday close bell miss badly earning little better line consensus estimate revenue smaller stock telecom play lumentum lite swung wildly stock drop minute friday session then reversed much gain midday action stock be back day line thursday company report quarterly result top estimate top bottom line offer weaker expect outlook blue chip be mostly stock dow stock advanced fall biggest percentage gainer be chevron cvx almost time normal volume chevron report quarterly result trounce earning estimate be roughly line revenue
44,SYK,be huge week earning apple aapl amazon amzn alphabet googl be list headliner slew industrial medical restaurant more also report tesla motor tsla report surprise profit qualcomm qcom buy nxp semiconductor nxpi nasdaq fall week amazon miss apple modest beat fail impress tech heavy index drop day line retake level last week sank dow rise bond continue fall world push year treasury yield multimonth high september quarter apple earn share year year sale analyst expect apple earn share sale holiday quarter apple guide wall street higher revenue profit margin outlook come short apple also unveil new macbook pro notebook computer feature touch screen strip application command shortcut replace function key apple fall week remain day line amazon report earning cent share big gain well short estimate cent commerce giant plow money amazon web service cloud compute unit big expansion fulfillment center head holiday season revenue rise meeting view aw be bright spot earning report revenue rise year year beating consensus revenue guidance also lag amazon share fall friday close day line first time month earning share item rise total revenue climb vs consensus estimate google parent alphabet signale higher investment cloud compute business higher marketing cost tie september launch pixel brand smartphone smart home speaker compete amazon echo google net revenue higher traffic acquisition cost tac cost be top view alphabet share nearly hit record high friday morning close day fractionally higher week fractionally lower still buy range tesla motor earn cent share exclude item soundly beating consensus estimate cent loss revenue climb top estimate elon musk have push tesla boost delivery turn profit analyst be skeptical effort be sustainable tesla maintain guidance vehicle delivery second half plan just tesla solarcity scty late friday be expect unveil integrate product offer solar panel battery storage charger tesla be process buy solarcity elon musk be top shareholder company well spacex tesla find resistance day line reversed end week cent solarcity climb gigamon gimo report third quarter profit revenue blow past estimate raise current quarter guidance santa clara calif base gigamon say ep item rise cent revenue jump analyst have project cent current quarter gigamon forecast ep cent revenue midpoint guidance vs consensus estimate cent profit revenue growth analyst say be new customer join mobile tmus gigamon shot friday hit record high intraday share have fall thursday day line lumentum lite say ep rise cent revenue climb top expectation current quarter revenue guidance be light telecom component shortage unnamed supplier ep guidance cent midpoint be consensus estimate cent lumentum fall late thursday report follow fall thursday acacia communication acia crash day week chinese telecom gear giant zte key acacia customer report weak revenue qualcomm announce deal buy nxp semiconductor create chipmaker revenue intel intc include debt deal be worth mobile communication chipmaker qualcomm say acquisition expand footprint key growth market include automotive internet thing security networking qualcomm nxp transaction mark biggest semiconductor deal ever surpass technology purchase broadcom avgo new oriental education technology edu meet fiscal ep view gain cent revenue climb analyst expectation enrollment boom ibd stock see revenue analyst guidance fellow chinese profit school stock tal education xrs result top estimate total student enrollment jump guide revenue wall street view new oriental stock rise more week blast base new high tal education climb also high related new oriental education break strong revenue guidancetal education stock enter profit take sell territory beatchipotle grill cmg earn cent share revenue fall nearly expect same store sale tumble fast casual burrito chain still struggle recover late food bear illness outbreak share fall wednesday hit year low panera bread pnra beat view send stock higher intraday wednesday reversed lower fall month low thursday buffalo wild wing bwld meet ep view miss sale share rise thursday recent lows food delivery service provider grubhub grub report ep rise revenue top grubhub active diner rise miss estimate slightly share have be month high fall nearly wednesday tumble day line biogen biib post sale ep ex item top view prod share nearly thursday bristol myer squibb bmy rise celgene celg alexion alxn beating earning amgen amgn late thursday beat share tumble nearly friday concern key drug enbrel go forward also friday nordisk nvo dive sanofi sny rise european drugmaker have different view outlook insulin treatment meanwhile drug distributor mckesson mck crash friday big miss blame rival abc heavy competition further pressure political attention drug price fall cardinal health cah nearly report earning next week related bristol myer celgene stock rocket sweeping top alzheimer datum vs eli lilly positivealexion crush expectation stock bound drug trial plansabiom abmd fall short earning send share tumble thursday edward lifescience ew revenue come light sale guidance also light send share plunge boston scientific bsx stock fall modestly ep meet sale top stryker syk narrowly top ep sale view late thursday send share friday third quarter gdp growth top forecast fastest growth year consumer spending growth slow significantly business investment remain weak real final sale exclude inventory gain next export slow separately durable good order edge lower core capital good demand fall most february boee ba say realistic possibility launch new midsize plane longer version max seek counter gain airbus eadsy boee result top analyst view revenue commercial airplane division fall defense revenue fall boee share rise week breaking base high related boee realistic possibility midsize jet stretch stock buy zonelockheed martin lmt top view defense giant raise full year outlook next production batch be split separate contract northrop grumman noc raise full year guidance report result analyst view send stock buy territory raytheon ep top estimate revenue be light patriot missile system maker improve guidance still fall short wall street view related lockheed soar outlook payout next contract see splitnorthrop stock enter buy range strong outlook beatbomb lift raytheon outlook be dud stock divesexxon mobil xom top ep estimate revenue fall well short capital spending fall oil production dip chevron cvx crushed ep view revenue miss slightly downstream profit be oil major refine margin weaken conocophillip cop loss wasn bad expect company raise full year production outlook lower capital spending guidance general electric ge be talk oil service firm baker hughe bhi partnership not purchase baker hughe break buy zone tuesday report better expect earning add friday industrial giant unite technology utx caterpillar cat mmm issue weak financial forecast global economic uncertainty hurt sector broadly general electric ge several other notable industrial firm already have cut guidance general motor gm meanwhile warn impact brexit plateau auto market strong full year ep guidance overall athletic apparel maker earning rise sale top view gross margin dip negative impact timing liquidation increase promotion foreign exchange rate armour ua see revenue growth consensus armour vow invest aggressively share fall more wee hit year low related armour dife growth target exec vow invest aggressively
45,SYK,earning season hit full force market close amazon amzn miss share profit view badly alphabet googl fiber optic play lumentum lite network security firm gigamon gimo top view several highly rate company reportinig here be detail estimate ep cent revenue be rise result ep cent revenue rise outlook amazon see revenue midpoint slightly analyst forecast stock amazon share fall late trading share close stock market today share have be consolidate peak oct amazon web service revenue rise operate profit pacific crest security report earning release say aw field check suggest expand deal size large enterprise government agency related amazon price target raise ahead earning cloud ep revenue result ep be revenue climb cost click fall miss analyst estimate stock alphabet stock rise volatile hour action share close still buy point stock break then moved just pivot week stay point oct alphabet have huge cash hoard announce new stock buyback google parent have recently complete stock repurchase program so analyst have expect new buyback analyst want know google cloud compute business be fare larger rival amazon web service microsoft msft offer azure be expect upside youtube also look hint demand pixel smartphone home assistant other new google device related cash rich google announce new stock buyback earning estimate ep cent revenue rise result ep rise cent revenue rise stock share shot nearly hour action stock have close fall day move average first time month gigamon name rex jackson new cfo succeed mike burn gigamon have expand security communication network appliance analyze datum traffic analyst also expect update product amazon cloud platform ibd take buy stock current choppy market environment be risky especially so earning season ibd swing trader now offer option earning related security provider gigamon aim keep beat streak goingestimate ep rise cent revenue grow result ep rise cent revenue outlook ep cent revenue analyst expect ep cent revenue stock share fall nearly hour action lumentum share close fall just day line first time month stock have be move sideway oct peaked oct provider fiber optic component maker be benefit optical super cycle include verizon communication vz big metro upgrade internet giant datum center network improvement well boom chinese demand acacia communication acia have be white hot fiber optic ipo summer continue tumble fall china telecom gear giant zte major acacia customer report weak sale thursday fiber optic play infinera infn report weaker expect quarterly revenue late wednesday infinera lose related acacia communication hammer customer zte sale missbaidu bidu ep be cent well view cent revenue be vs view miss estimate local currency chinese internet giant have be spending heavily mobile be concern lose ground commerce giant alibaba baba messaging giant tencent tcehy other member china big internet firm baidu see revenue estimate baidu share fall hour action stock close stryker syk ep be revenue be analyst have expect ep sale stryker see ep vs view stryker share rise nearly hour action share close slightly thursday stock have be consolidate mid july week have lose sight day line wednesday stock undercut day line bottom current base silicon motion simo ep rise sale jump be fourth straight quarter accelerate growth profit revenue analyst have expect ep soar cent revenue silicon motion see revenue vs view silicon motion report et fall more late trading share fall fractionally regular session silicon motion make memory chip controller tumble day line earlier month have find support somewhat day line expedia expe ep be revenue analyst have expect ep rise revenue pop expedia stock initially fall hour action turn expedia be form handle big yearlong consolidation share close thursday
46,SYK,stryker syk have relative strength rs rating upgrade tuesday welcome improvement still better score look re research best stock buy watch be sure pay attention relative price strength proprietary rating measure market leadership used worst best score show stock price action last week compare rest market history reveal market biggest winner often have higher rs rating begin largest run see stryker continue show renew price strength hit benchmark look winning stock try simple routinewhile not currently ideal time jump see stock go form consolidation break company show earning growth last quarter sale gain come stryker earn rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
47,SYK,ibd smartselect composite rating stryker syk increase tuesday new score tell company be now outperform stock term most important fundamental technical stock pick criterium stryker break earlier be now prior entry flat base stock re watch clear buy point then retreat more original entry price consider fail base best stock form new base look best stock buy watch start hereone weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company report earning growth mean now generate straight quarters rise ep growth sale be flat match prior report stryker earn rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group related company be now outperform stock see stock just come ibd top stock list
48,SYK,thursday stryker syk get positive adjustment relative strength rs rating re research best stock buy watch keep close eye relative price strength exclusive rating investor business daily measure market leadership worst best score rating show stock price movement last week compare other stock database year market history show market biggest winner typically have rs rating least early stage move look winning stock try simple routinestryker be still buy zone climb entry flat base proper buy range be initial entry once stock move range best set buy opportunity company post earning growth most recent report sale growth come company hold rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
49,SYK,share boston scientific bsx surge monday report wall street journal have be approach stryker syk deal medical device maker unclear boston scientific be open takeover journal say cite source didn identify boston scientific share soar much end regular trading session stryker share fall close trading stock be halter just monday neither company comment merger rumor deal company be latest series large acquisition industry have be consolidate market share package sale hospital doctor health clinic boston scientific make heart device such pacemaker stent other product be worth estimate market value nearly value stryker make orthopedic product artificial hip knee get newsletter deliver inbox more info product service privacy policy term usecombine company let wring cost effort sell product similar set customer also give combine firm more market power merger large health insurer have increase pressure hospital lower expense movement come ongoing debate cost medical care matter company policy do not comment potential stryker jon zimmer say email representative boston scientific didn immediately respond request comment many largest competitor have already execute large takeover recent year abbott laboratory last year buy st jude medical make heart device then month later complete takeover medical testing diagnostic supplier alere medtronic mdt buy covidien make surgical product
50,SYK,medtech player stryker syk say wednesday isn discussion acquire boston scientific bsx prod stryker share pop boston scientific stock topple stryker be not discussion boston scientific corporation regard potential acquisition firm say filing security exchange commission stock market today stryker share climb close stock have slide previous session boston scientific other hand tumble reversed day gain rbc analyst glenn novarro note recent stock decline have make potential boston deal less favorable financially have expect medical supplier have pay share more deal get newsletter deliver inbox more info product service privacy policy term use assume split debt equity deal estimate decline stryker share post wall street journal story have force stryker issue additional share potential boston scientific deal say note overall be strategic rationale deal create value have be challenge novarro say reiterate outperform rating stryker also call pullback monday tuesday buy opportunity dow jone component johnson johnson jnj be better acquirer boston say further valuation potential pure play spine target move higher stryker still have firepower appetite deal say related chart read basic buy point mark time real much money do need start investing sell great stock take profit regularly mostly
51,SYK,dow jone component johnson johnson jnj engage bidding war sweep boston scientific bsx stryker syk analyst say tuesday follow rumor latter merge report emerge monday stryker approach boston takeover bid boston share spiked rumor stryker topple canaccord analyst say stryker be far only medical device maker interest boston headline be substantiated stryker be fact make bid boston scientific see high likelihood emerge potential bidder say note client have be banter potential boston scientific acquirer year bidding war emerge place high likelihood be involved stock market today boston stock dip close stryker share plunge even stock look somewhat dim ease fraction get newsletter deliver inbox more info product service privacy policy term deal have analyst somewhat split tuesday regard materiality report do not find potential such marriage be shocking canaccord analyst say indeed see merit such combination standpoint product line synergy stryker acquisition help add product sector higher potential growth bigger market also help stryker differentiate portfolio technology compete large company medtronic mdt boston case deal cap year turnaround allow end high note canaccord analyst say sum definitively think boston scientific be game do fair deal here say rbc analyst glenn novarro view deal unfavorably acknowledge strategic rationale make sense also likely boston win deal less share combine premier growth company medical device space be limit product overlap say however bar value creation be set high give potential valuation company combine stryker boston scientific have revenue stand grow sustainable higher compound annual growth rate medium term novarro say have enterprise value canaccord analyst call potential deal merger equal stryker be only third larger boston also lead further med tech consolidation consummate create behemoth medical device stryker boston scientific join abbott medtronic say think edward lifescience ew be next potential major acquisition target also highlight nephew snn be last remain pure play total joint operation market related chart read basic buy point mark time real trade stock most penny stock fail make investor basic analyze stock cup handle
52,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
53,SYK,relative strength rs rating stryker syk moved higher percentile tuesday get lift ibd unique rs rating track market leadership used worst best score show stock price performance trail week stack other stock database year market history show best stock typically have rs rating least begin largest run see stryker continue show renew price strength hit benchmark look best stock buy watch start herestryker be still buy range climb entry flat base proper buy range extend initial entry once stock hit benchmark best set buy opportunity stryker show earning growth latest quarterly report sale growth come stryker hold rank peer medical product industry group abiom abmd align technology algn mimedx mdxg be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
54,SYK,welcome move stryker syk see relative strength rating rise thursday exclusive rating investor business daily track market leadership worst best score score show stock price movement trail week compare other stock database year market history show market biggest winner tend have rs rating least begin largest climb see stryker continue show renew price strength hit benchmark see ibd help make more money stocksstryker be trading buy range breaking past buy point flat base once stock move higher initial entry consider proper buy area stryker post earning growth last quarter sale growth come company hold rank peer medical product industry group abiom abmd align technology algn teleflex tfx be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
55,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
56,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
57,SYK,nasdaq composite rise record high fang stock rally slew hot tech ipos soar index be little change dow jone fall trump trade threat weakness many energy financial stock many retailer also fall rh rh canada goose goos etsy etsy soar federal reserve hike rate predict more close takeover time warner federal judge deal adobe system adbe pull back strong earning nasdaq composite advanced techs power ahead index be flat dow jone retreat medium stock health giant rally get court buy time warner many retail stock cool recent run rh rh dave buster play online art craft site etsy etsy soar result guidance fed policymaker see more hike raise rate wednesday federal judge time warner deal condition reject justice department argument merger hurt competition pay tv industry close merger friday landmark ruling boost share price medium firm cbs cbs lionsgate lgf discovery communication disca decision be expect open door more acquisition medium firm telecom giant deal also bode well big vertical health care merger include cvs health cvs buy aetna aet comcast cmsca expect launch takeover bid st century fox entertainment foxa offer cash rupert murdoch entertainment company premium walt disney offer disney november agree buy fox include stake broadcaster sky stock fox board be expect withdraw recommendation disney offer company be unlikely carve fox analyst say get newsletter deliver inbox more info product service privacy policy term video game conference spotlight major title come soon such leader activision blizzard atvi microsoft msft nintendo ntdoy sony sne esport be major topic year show tournament game such fortnite battle royale epic game super smash bro nintendo rise subscription service such electronic art ea origin access premier microsoft msft xbox game pass also be hot topic be future stream video game ea activision clear buy zone take interactive break fed hike key interest rate expect second time year somewhat surprisingly policymaker pencile more hike year chairman jerome powell declare economy be great shape expressed sense hawkish shift policy be risk retail sale rise best gain month back powell assessment spur wall street firm boost second quarter gdp growth projection more meanwhile core consumer price inflation picked year highest early further increase be likely adobe system adbe earn adjust share fiscal year year sale analyst expect digital medium marketing software firm earn adjust share sale current fiscal third quarter adobe guide modestly higher adobe share pull back friday big run last few year share etsy etsy soar thursday art craft online retailer raise revenue guidance announce new subscription package higher seller fee other initiative now see revenue growth prior guidance etsy raise transaction fee seller spend direct marketing last year etsy have active seller platform active buyer earning more double share smash estimate cent share kmg chemical kmg make chemical used chip solar panel consumer electronic also raise full year sale forecast share rocket week blast buy zone canada goose goos swung profit cent share loss cent share year revenue more double analyst expect loss cent sale outerwear company typically make money fall winter lose money warmer month canada goose see fiscal ep growth least revenue more canada goose stock soar friday rh rh furniture purveyor formerly know restoration hardware grow earning share fold vs view revenue dip surprising analyst expect enhance earning guidance strong outlook drive investor confidence share soar tuesday add rh history wild stock swing earning report arcade restaurant chain dave buster play top view ep grow revenue rise same store sale fall narrower decline expect dave buster be roll new virtual reality game tie new movie jurassic world fall kingdom analyst see game changer dave buster ceo steve king retire aug cfo brian jenkin succeed share shot tuesday definitively retake support day line reach month high report opec report rise production saudi arabia raise opec production outlook bpd april report grow shale production international energy agency warn economic turmoil venezuela renew sanction iran lead supply gap late next year opec make lose production president trump blast opec tweet high oil price energy information administration say domestic crude stockpile fall more expect production rise crude fall week barrel private equity giant kkr kkr set buy envision healthcare evhc share cash deal value hospital staffing company include assume debt usg corp usg agree be acquire germany knauf end month talk usg largest investor warren buffett lead berkshire hathaway brkb urge wallboard maker negotiate buffett have rescue usg housing market collapse call investment disappointing last year workday wday pay adaptive insight have be ipo help expand cloud offering business plan stryker syk say not talk fellow medical device company boston scientific bsx potential takeover dispute report have make takeover approach pivotal pvtl report first quarter public company top expectation send share company say lose cent share vs estimate cent loss revenue rise top view share surge astrazeneca azn eli lilly lly tuesday scrap phase study alzheimer disease treatment call lanabecestat drug appear unlikely work early alzheimer disease mild alzheimer dementia also ibd stock invest stock market start simple routinestock buy watch top ipos big small cap growth stock
58,SYK,artificial intelligence now firmly entrench many hospital operate room field robotic surgery be start get competitive giant company alphabet googl johnson johnson jnj medtronic mdt be training sight intuitive surgical isrg king robotic surgery company analyst say boom medical technology segment have lot room run robotic surgery be area grow billion dollar more machine be used treat patient intuitive command space annual sale signature da vinci robotic surgeon however be limit type procedure handle multus limb da vinci be used variety procedure include cardiac colorectal gynecological head neck thoracic urologic surgery only long re minimally invasive big market be be still unclear yet analyst agree potential have yet be tap so more player be move quickly get newsletter deliver inbox more info product service privacy policy term use think investor need understand robotic ai artificial intelligence revolution be happen touch sector economy say jeremie capron director research manage partner robo global index advisory firm specialize robotic industry investment be technological revolution investor afford miss analyst say march auris health become first company formidable threat intuitive catheter base monarch platform gain approval intuitive counterpunch seek approval flexible catheter similar auris device likely year rbc analyst brandon henry say recent report meanwhile other be work area intuitive surgical doesn have foothold nephew snn have robotic assistant knee replacement stryker syk have robotic joint replacement system mazor robotic mzor zimmer biomet zbh have robotic offering brain spinal surgery mazor alone see sale just system player have long way go take intuitive surgical throne intuitive have market cap today worth nearly capron call intuitive amazing stock think investment community have be scratch head try figure impact new entrant intuitive surgical tell investor business daily feel pretty relax size be big enough small player come share medical tech company have be relatively insulate wo frustrate biotech pharmaceutical stock late stock medical equipment maker such intuitive mazor have collectively spiked year date intuitive blowout quarter april help spur excitement evercore analyst vijay kumar say recent note client recent investor day medtronic be help drive frenzy robotic surgery be topic currently medtech blowout quarter intuitive surgical hint pace manual robotic transition be pick kumar say topic competition elicit various response investor intuitive surgical stock be year climb kumar expect intuitive surgical competition become more apparent next month intuitive da vinci surgical system now boast patient count da vinci system be also move deeper hernias be see early stage adoption bariatric surgery perform induce weight loss myriam curet executive vice president chief medical officer intuitive note email ibd estimate prostatectomy be perform robotic assist surgery same be true malignant hysterectomy general surgery be fastest grow specialty be still early stage adoption procedure such ventral inguinal hernia repair colorectal bariatric surgery say believe be substantial opportunity expand robotic usage category be develop additional tool technology do so year intuitive guide first quarter earning conference call growth number procedure perform system year follow many consider strong fourth quarter recur revenue include instrument accessory da vinci system grow recur revenue represent sale pie still even intuitive surgical see early innings expect robotic surgery present huge total addressable market number da vinci procedure perform year grow nearly other robotic surgery company intuitive closest competitor auris doesn trade publicly recently be stealth mode kumar say medical technology company sign agreement division agreement come month auris monarch system grab approval monarch be flexible catheter surgeon thread patient mouth lung remote control approval investor believe credible competitor intuitive be year away kumar say monarch get approval month ahead view intuitive surgical plan seek approval own flexible catheter later year auris say monarch first target be lung cancer expert estimate half lung biopsy be perform year surgeon also use flexible catheter urinary tract procedure number roughly procedure year intuitive isn sweat competition auris chief executive interestingly be frederic moll founder intuitive surgical intuitive current ceo gary guthart joined medical technology firm take ceo have build technology make decision architecture base first principle not look shoulder other person be do really engage customer deeply understand clinical need guthart say recent earning call rbc henry note auris monarch have larger catheter intuitive allow camera intuitive see benefit smaller catheter move deeper lung henry write recent report allow surgeon potentially use remove diseased tissue meanwhile have team google company call verb surgical analyst be unsure system team be create do expect enter robotic surgery market same time medtronic be partner mazor medtronic also expect own robotic surgery system launch not unreasonable suggest intuitive keep market evercore kumar tell ibd new robotic surgery company have differentiate have straightforward too product say investor have put pretty punchy marketable valuation intuitive surgical re still early stage robotic conversation add market be big enough sustain multiple player company mazor zimmer biomet make system call rosa come have system surgeon use brain spinal procedure other mazor ceo ori hadomi say sizing opportunity robotic surgery company be difficult surgeon use mazor system spinal surgery company renaissance system perform spinal brain surgery cost disposable instrument material comprise mazor revenue hadomi tell ibd surgery perform mazor list price be term disposable item estimate half procedure generate stakeholder expect spine procedure grow rapidly person be be more more active say meaning suffer more injury require surgery more often procedure become less invasive safer procedure become more patient be willing interested be treat be operated benefit robotic surgery be plentiful hadomi say revision surgery surgery correct mistake tweak prior surgery be significantly lower robot assist precision robot help curb potential error say last october mazor unveil result patient study find fivefold reduction complication surgery perform mazor robotic surgery technology notably be also sevenfold reduction revision surgery compare freehand lumbar fusion surgery doubt patient perspective not consider go surgery robot know chance go revision surgery be time higher say revision surgery be also costly hospital face reimbursement hurdle agree robotic surgery win replace human surgeon hadomi liken system other toolbox surgeon be simply medical technology tool make operate easier surgeon safer patient say benefit be also grow investor say robo global capron really exciting be fact be inflection point technology enable robotic surgery price point be attractive say now lot action medtronic see confirmation be substantial addressable market related look best stock buy watch start herecan crispr small biotechs cure disease amazon vs walmart locking horn battle retail futurechart read basic buy point mark time real marijuana industry overtake beer legalization spur innovation
59,SYK,here investing action plan thursday need know investor come day be embarrassment rich highest highly rate stock report earning include amazon amzn alphabet googl gigamon gimo lumentum lite silicon motion simo apple aapl also unveil new mac computer apple event apple
60,SYK,here investing action plan thursday need know investor come day lull just earning season begin next week make quiet calendar be several stock near buy point include broadcom avgo thermo fisher tmo stryker syk deutsche bank db also be address major
61,SYK,here weekly investing action plan need know investor come week tech darling apple aapl tesla motor tsla amazon amzn alphabet googl report earning well aerospace defense leader boee ba lockheed martin lmt industrial giant big biotechs medical device maker weigh too oil
62,SYK,plenty action investor keep eye come week ibd big cap launch final week third quarter almost half stock appear big cap past week be fresh high most extend buy point
63,SYK,medical stock particularly drugmaker play key role buoy challenged market first half year year date tuesday ibd medical sector industry group show average loss biotechs ethical drugmaker be hardest respectively have left medical group rank
64,SYK,ishare medical device etf ihi be year top etf leader ride best part mixed health care sector year medical sector have diverged industry fare much better other biotechs other drugmaker be roughly ibd medical product equipment industry group be only diversify medical company be do quite well health care much outperformance medical device owe superior result top manufacturer innovation have play key role ignite industry leader stock etf medtronic mdt be largest hold more portfolio share have climb much buy point april stock have perform decently fact earning have be basically flat quarters outlook be improve analyst expect profit rise fiscal year end april next year investor day june medtronic forecast mid single digit revenue growth develop product pipeline draw diversify market edward lifescience ew be stock have shoulder etf advance share be time high main move year be april company announce sapien transcatheter aortic valve replacement be show reduce death heart attack patient moderate risk open heart surgery share soar news medtronic corevalve compete edward heart valve replacement patient not able have open heart surgery analyst canaccord genuity remain bullish stock follow earning report say dominate market transcatheter aortic valve replacement show potential market expansion share stryker syk have broadest range orthopedic product peer have climb much year fall sharply july earning report be clear explanation slide other softness emerge market other key contributor ishare medical device be thermo fisher scientific tmo make equipment medical research zimmer biomet zbh just post strongest quarter sale growth nearly decade becton dickinson bdx have be trend higher fall sharply thursday cut full year sale forecast cite currency headwind etf be extend april pullback day move average june remain buy point week tight pattern form july ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
65,SYK,many medical stock have be have tough year maker medical device system have be popular lately especially large cap name offer stability uncertain time week biggest name show performance justify investor trust report late tuesday robotic surgery specialist intuitive surgical isrg be expect continue recent growth rebound slower pace year year comparison have be make tougher strong analyst currently expect earning sale grow year earlier quarter grow respectively july preview second half year leerink analyst richard newitter write ll be watch continue uptake da vinci xi surgical system launch help intuitive surgical turn rough couple year importantly see intuitive surgical turn point transition next leg growth general surgery outside expansion stabilization urology gynecology franchise increasingly begin benefit xi new product cycle newitter write intuitive surgical stock hit time high july move flat base june intuitive rise fractionally stock market today wednesday morning medical device titan abbott laboratory company process acquire st jude medical stj be due report earning company have struggle growth department recent quarters st jude top line have be accelerate estimate abbott do not grow previous quarters be expect report single digit percentage growth top bottom line global footprint company hit foreign exchange headwind rbc capital market analyst glenn novarro expect continue report give stronger dollar especially several emerge market currency be lower sale forecast abbott report constant currency novarro write july preview note greater fx headwind expect management reaffirm revenue guidance low single digit report mid single digit constant currency ep guidance range abbott have also say buy diagnostic company alere alr close have be doubt company have admit accounting problem last week alere report preliminary financial leave analyst believe deal go doubt be interested abbott management have say conference call abbott share shave penny close day st jude share inched cent alere slip ibd take medical device stock have lately be mainstay ibd big cap stock choose strong potential gain volatility smaller growth stock see else be big cap list finally late thursday orthopedic giant stryker syk be set report modest accelerate growth estimate sale rise be highest stryker be have gangbuster stock more ibd composite rating putt top stock stryker have be grow top line range last couple year see momentum continue next several year reconstructive volume be stable hospital capital spending be stable recent tuck acquisition drive faster sale growth corporate average analyst novarro write preview note friday raise estimate price target stryker furthermore company be gain share core segment orthopedic medsurg neurotechnology spine styker stock end trading
66,SYK,medical device giant boston scientific bsx hit year high early trading thursday announce restructure plan late wednesday receive favorable initiation report guggenheim boston scientific didn release many detail filing say further company plant network optimization strategy be intend simplify company manufacturing plant structure transfer certain production line facility expect overall reduction head count say reduce annual operation expense rbc capital market analyst glenn novarro write move isn surprising boston scientific have commit margin expansion operate margin be last year company be target long term believe restructure effort announce today help company deliver margin leverage goal help boston scientific produce low mid teen ep growth be industry average novarro write research note company say program incur charge gaap ep revenue guidance year remain same also late wednesday guggenheim analyst chris pasquale launch coverage boston scientific buy rating price target note current ceo mike mahoney take revenue be shrink then growth have averaged resurgence have be propel case improve market condition see bigger driver renew focus innovation have play boston business unit pasquale write initiation report boston scientific be number medtech stock wednesday pasquale launch coverage highlighted stryker syk top pick endologix elgx spectranetic spnc other choice boston scientific boston scientific stock rise stock market today build day move follow earning report april stock hold strong composite rating be rank seventh large medical product industry group
67,SYK,moderate rally monday produce numerous new high few move basis higher average volume coresite realty cor rise close average volume emerge brief consolidation find support week move average stock have make big advance past several month have be
68,SYK,medical sector bury slumping drugmaker still have few big capitalization stock have be shine biotechs be more year ethical drug maker be more generic drug company nearly worry pricing power have contribute bad sentiment pharmaceutical other segment medical sector be fare much
69,SYK,wedbush initiate coverage fitbit fit top rating citigroup upgrade apple aapl chipmaker qorvo qrvo rbc capital upgrade linkedin lnkd raise price target proofpoint pfpt wedbush start coverage outperform rating pt cite expand install base program corporate wellness initiative share fitbit close have swoon more company have ibd composite rating possible citigroup upgrade apple chip supplier qorvo neutral sell downgrading skywork solution swks sell neutral believe qorvo sustain dollar content gain momentum samsung galaxy iphone gain year say citigroup report qorvo share edge skywork fall rbc capital upgrade business social network outperform neutral pt linkedin stock plunge feb mountain view calif company forecast full year revenue consensus estimate owing advertising slowdown rbc mark mahaney say survey human resource professional show linkedin be reasonably well position very large recruitment advertising tam total addressable market linkedin share climb raise pt proofpoint security software firm host analyst day thursday san francisco introduce financial target include reach revenue proofpoint have ibd composite rating possible fall guggenheim security initiate coverage medical product maker boston scientific bsx stryker syk buy rating boston scientific have ibd composite rating possible climb thursday stryker have cr add guggenheim start coverage spectranetic spnc buy rating edward lifescience ew medtronic mdt have neutral rating raymond james longbow research deutsche bank ub downgrade restoration hardware rh neutral home furnishing retailer late wednesday unexpectedly report fiscal loss slash full year profit outlook share plunge other analyst move brean capital downgrade qualcomm qcom hold rw baird upgrade solarcity scty outperform
70,SYK,spinal product stock be move tuesday ldr hold ldrh agree be acquire device giant zimmer biomet zbh come nuvasive nuva make smaller buyout late monday ldr stock soar stock market today roughly price zimmer agree pay deal amount total zimmer say buy ldr technology cervical disc replacement call fastest grow segment spine industry ldr technology be design make spinal surgery simpler less invasive ldr founder be still lose money zimmer say have impact ep year next rbc capital market analyst glenn novarro say buyout boost zimmer profile fragmented spine industry combine portfolio raise zimmer spine market share putt company striking distance strkyer syk nuvasive hold market respectively novarro write research note currently ldr rep cover approximately spine surgeon utilize combine sale force zimmer be able quickly expand coverage footprint mobi mivo suite product locally abroad zimmer stock touch record high close stock rank ibd list top perform stock zimmer stock have highest possible composite rating learn more ibd stock checkup nuvasive stock jump briefly time high early trading tuesday finished close late monday company say agree pay cash biotronic neuronetwork make system monitor patient nervous system surgery nuvasive say buyout expand clinical service arm double footprint supplement surgical product offer spine solution surgeon spine startup globus medical gmed rise unusually high volume tuesday perhaps buoy further buyout possibility space leerink analyst richard newitter also note industry giant medtronic mdt say analyst day monday expect growth pick spine business few year lag see positive smaller player still believe medtronic recent spine growth improvement stem more underlie market stabilization improvement less bad infuse erosion vs enhance competitive position vs smaller player thus have doubt company become sustainably more effective fend market share loss player such nuvasive globus medical newitter write research note newitter write prefer nuvasive globus stock ibd rating system agree nuvasive have composite rating globus have cr
71,SYK,orthopedic giant stryker syk beat wall street estimate raise guidance wednesday send stock hour trading stryker report earning share year earlier quarter top analyst consensus accord thomson reuter sale rise slightly consensus constant currency basis sale grow quarter stryker add half percentage point full year organic sale growth guidance now ep guidance be raise tighten second quarter stryker guide earning share high side wall street estimate stryker sale grow division orthopedic medsurg neurotechnology spine ceo kevin lobo say provide confidence raise organic sale guidance early year feel very good strength entire business portfolio say conference call analyst major weak point be international sale contribute more quarter total revenue decline report basis fraction constant currency basis economic trouble china brazil have be affect company last year lobo say expect impact ease second half year last year be especially strong emerge market sharpen most recent quarter decline say also note inventory bleed eventually bleed analyst be also impressed organic growth neurotechnology unit fastest grow subdivision company bulk business come stryker line catheter stent coil treat hemorrhagic stroke company also be see growth newer product treat ischemic stroke be new market be many stroke hadn be treat prior lobo say call re create new market difficult predict pace growth doubt growth be very significant obviously contribute strong performance neurovascular orthopedic medsurg division surgical product report organic growth quarter spinal product rise analyst call also remark improvement stryker operate margin rise stifel analyst rick wise question sustainable be give up down margin prior quarters lobo sound confident not go promise basis point improvement single quarter be commit drive leverage operate level lobo say ll see year ll see provide guidance interest expense be somewhat higher normal quarter due recent acquisition sage product make oral skin care clean product physio control international make monitor defibrillator synergetic filled neurology spine portfolio stryker management note sage physio control deal have close ahead schedule early april stryker stock be year hit series new high break consolidation last month recent pattern single digit growth have attain strong composite rating regular trading stock market today rise hit intraday high penny short time high hit previous day minute close stock have crack
72,SYK,stock ve easily find excuse go friday index keep cool nasdaq add rise ibd jump volume fall major exchange be normal day day holiday market be close monday memorial day market be look excuse
73,SYK,robotic surgery specialist intuitive surgical isrg beat wall street earning estimate late tuesday stock be hour trading intuitive surgical earning totale share year earlier quarter top analyst consensus share accord thomson reuter sale gain vs analyst intuitive surgical be highest rate stock medical system group be collectively do well ibd ranking industry group share hit lifetime high last wednesday have hover mark then stock close fraction regular trade stock market today intuitive surgical be second hot medical stock report earning week earlier tuesday johnson johnson jnj hit new high beat estimate raise full year guidance due diminish foreign exchange headwind stryker syk also hit new high early tuesday give back gain later be due report earning wednesday close
74,SYK,medical giant johnson johnson jnj beat estimate raise guidance tuesday morning send stock fifth recent record high report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise match consensus say foreign exchange impact knock percentage point sale growth nonetheless forex headwind finally seem be abate cite improve forex outlook reason be raise full year sale guidance also add cent ep guidance now ibd take johnson johnson rate group cr be iffy pharmaceutical business continue deliver impressive level growth have steady improvement consumer business be see momentum medical device business be fuel optimism full year ahead ceo alex gorsky say statement stock be early trading stock market today touch record high intraday stock be more year so far be first medical stock be hit new high be report week other be intuitive surgical isrg evening stryker syk late wednesday morning continue growth momentum company have see recent quarters again deliver organic sale growth acceleration second consecutive quarter double digit ep growth adjust operational basis write leerink analyst danielle antalffy research note note exclude impact foreign exchange activity shrink sale hepatitis drug olysio be make obsolete gilead science gild release harvoni late sale rise operate ep growth be just credit suisse analyst vamil divan write pharma sale beat be drive immunology franchise remicade simponi stelara well stroke prevention treatment xarelto top seller diabetes drug invokana miss consensus investor have be wonder invokana take hit eli lilly lly jardiance last september prove dramatically cut death heart failure didn get sale bump
75,SYK,medical industry have lot prove upcoming earning season last round earning guidance didn do much reassure investor be already nervous other reason however major stock sector have be hit new high lately especially hardware side group here be such company report earning week johnson johnson jnj take traditional place head line report earning early tuesday first big drug company report cycle growth be expect be modest due gigantic size foreign exchange headwind have be drag global company earning year analyst poll thomson reuter estimate revenue rise year earlier quarter earning be estimate share muted growth johnson johnson stock hit record high trading friday close day fraction have maintain ibd relative strength rating last week mood wall street go quarter seem bullish late thursday rbc capital market analyst glenn novarro raise estimate base read drug prescription foreign exchange trend im im script trend several key drug suggest strong pharma quarter year year ex fx olysio novarro write olysio be hepatitis treatment additionally analysis currency movement begin year suggest negative fx impact full year result be less initially expect novarro note likely topic conversation conference call be month fda approval pfizer pfe inflectra biosimilar version blockbuster immunology drug remicade robotic surgery specialist intuitive surgical isrg be due report close tuesday analyst estimate earning rise last year share sale intuitive surgical have also be top perform stock lately company have be make comeback financially rollout da vinci xi surgical system improve procedure growth intuitive surgical stock hit new high wednesday more year boast excellent ibd composite rating close friday head key question investor be stock be baking too much optimism be start new product cycle evercore isi analyst vijay kumar write email client friday expect procedure volume be healthy growth general surgery lead way extra day leap year also help similar concern optimistic market seem be dog orthopedic giant stryker syk be due report close wednesday stock have also be roll wednesday hit new high be wound last year share close friday stryker stock keep climb last week even robert baird downgrade neutral barclay resume coverage underweight latter write stryker valuation appear be full go face more competition rejuvenate zimmer biomet zbh analyst cover stryker estimate sale rise quarter earning share
76,SYK,pocket health care sector be ailing other have perked right ishare medical device ihi bound week high thursday eye fourth straight weekly gain relative strength line gauge performance vs be bolt higher defiance overall stock market mood market uptrend have come pressure week ihi be target bet health care niche invest company manufacture distribute medical device edward lifescience ew be top rate ibd stock industry group base measure technical fundamental health such earning sale growth ihi count edward top holding give portfolio weighting edward stock have jump past month california base company be battle top spot heart valve market sapien receive fda approval treatment high risk patient suffering severe symptomatic aortic stenosis chief rival be medtronic mdt hold ihi portfolio edward report quarterly result april close wall street stock analyst track thomson reuter expect gain earning quarter year
77,SYK,major stock hold ihi report week late tuesday surgical robot maker intuitive surgical isrg beat earning estimate stock hit new high wednesday receive series price target hike wednesday orthopedic giant stryker syk also beat expectation raise guidance stryker intuitive stock have fall then volatile trade ihi also have smaller weighting cantel medical cmn steris ste cynosure cyno device specialist top notch ibd composite rating respectively steris provide product prevent infection control contamination report jump sale latest report quarter help buyout base synergy health small cap cantel medical be also infection control prevention business cynosure develop treatment system hair removal skin rejuvenation ihi have relative strength rating mean outperformed other stock etfs ibd database last month accumulation distribution rating point healthy institutional demand share etf see net inflow first quarter asset have grow year year date april ihi have advanced vs broadly diversify health care select sector spdr xlv xlv largest health care etf have be hurt year hefty combine stake underperform pharmaceutical biotech industry past year xlv produce annual average gain vs ihi
78,SYK,health etfs perked tuesday follow better expect report nation largest health insurer gold price surge boost gold stock material sector help cross keenly watch level first time early december spdr spy post fresh high stock market today highest level dec stock gain follow steadying oil price key earning hearten investor health care select sector spdr xlv jab higher unitedhealth unh earning revenue beat forecast health insurer raise full year forecast strong organic growth good customer retention level xlv slice day move average monday first time health care sector be laggard year trail only financial unitedhealth first health insurer report first quarter be now have report scrutinize clue health care industry be fare company announce remain only handful obamacare public exchange next year state exchange currently unitedhealth stock jump more strong volume johnson johnson jnj also beat earning estimate tuesday revenue match forecast medical product maker add nearly raise full year forecast johnson johnson be hold xlv stock portfolio unitedhealth be medical peer ibd leaderboard stock edward lifescience ew report april meanwhile robotic surgery specialist intuitive surgical isrg report close beat earning estimate stock rise hour orthopedic giant stryker syk be report close wednesday material select sector spdr xlb carved gain tuesday hit fresh high etf have rise session xlb gain come soar gold price boost gold stock include portfolio member newmont mining nem market vector gold miner gdx gap add nearly gdx have soar year date hand profit etf investor buy day global silver miner sil streak ahead highest level more year ishare silver trust slv commodity etf flash more higher highest level june key outside market be bullish posture precious metal tuesday dollar index be weaker crude oil price be higher kitco senior technical analyst jim write tuesday weaker expect housing report give more price upside gold market say here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
79,SYK,medical giant johnson johnson jnj say tuesday restructure device division bid save annually end didn provide many detail press release say discuss project further report earning jan however do specify
80,SYK,medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate
81,SYK,say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus
82,SYK,company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat
83,SYK,device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter
84,SYK,pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note
85,SYK,single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum
86,SYK,imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year
87,SYK,product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus
88,SYK,device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company
89,SYK,also announce stock buyback plan be finance debt issuance
90,SYK,stock open few point late morning be flat
91,SYK,follow amy reeve twitter ibd_areeve facebook medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company also announce stock buyback plan be finance debt issuance stock open few point late morning be flat follow amy reeve twitter ibd_areeve facebook
92,SYK,banking giant citigroup biotech abbvie abbv receive analyst upgrade monday apple aapl chip supplier qorvo qrvo be downgrade
93,SYK,jeffery upgrade citigroup buy price target credit suisse upgrade stock outperform give price target however citi share close stock market today broader sell
94,SYK,qorvo supply chip apple iphone sank be downgrade sector perform overweight pacific crest friday new apple iphone hit store shelve apple sell more iphone handset open weekend company say monday apple share lose monday
95,SYK,abbvie stock price fall be upgrade neutral sell citigroup last week biotech stock get slam democratic presidential hopeful hillary clinton unveil proposal cap prescription drug expense sell continue monday
96,SYK,boston scientific bsx be upgrade buy hold needham medical device maker share still lose monday
97,SYK,india base service provider infosys infy be upgrade hold societe generale share finished higher
98,SYK,micron technology mu decline price target be cut cowen co have market perform rating stock chipmaker be due report fiscal result thursday close analyst poll thomson reuter expect year year decline earning
99,SYK,bp bp be initiate outperform bmo capital oil gas giant stock price still fall
100,SYK,share mindbody mb decline be downgrade equal weight overweight morgan stanley mindbody developer cloud base business management software wellness industry have ipo june
101,SYK,medical device maker stryker syk fall be downgrade hold needham
102,SYK,follow vance cariaga twitter ibd_vcariaga banking giant citigroup biotech abbvie abbv receive analyst upgrade monday apple aapl chip supplier qorvo qrvo be downgrade jeffery upgrade citigroup buy price target credit suisse upgrade stock outperform give price target however citi share close stock market today broader sell qorvo supply chip apple iphone sank be downgrade sector perform overweight pacific crest friday new apple iphone hit store shelve apple sell more iphone handset open weekend company say monday apple share lose monday abbvie stock price fall be upgrade neutral sell citigroup last week biotech stock get slam democratic presidential hopeful hillary clinton unveil proposal cap prescription drug expense sell continue monday boston scientific bsx be upgrade buy hold needham medical device maker share still lose monday india base service provider infosys infy be upgrade hold societe generale share finished higher micron technology mu decline price target be cut cowen co have market perform rating stock chipmaker be due report fiscal result thursday close analyst poll thomson reuter expect year year decline earning bp bp be initiate outperform bmo capital oil gas giant stock price still fall share mindbody mb decline be downgrade equal weight overweight morgan stanley mindbody developer cloud base business management software wellness industry have ipo june medical device maker stryker syk fall be downgrade hold needham follow vance cariaga twitter ibd_vcariaga
103,SYK,google googl be america best place work accord survey forbe magazine job indeed business datum site glassdoor company rating site great place work google be only company appear list ranking
104,SYK,follow google be wegman food market roche rhhby southwest airline luv mayo clinic roche subsidiary genentech burger medical technology firm stryker syk convenience store chain quiktrip financial firm young goldman sachs gs company appear list google googl be america best place work accord survey forbe magazine job indeed business datum site glassdoor company rating site great place work google be only company appear list ranking follow google be wegman food market roche rhhby southwest airline luv mayo clinic roche subsidiary genentech burger medical technology firm stryker syk convenience store chain quiktrip financial firm young goldman sachs gs company appear list
105,SYK,most hire manager have hard time hire keep young worker know millennial elance odesk millennial brand commission study millennial say hire manager report difficulty find retain millennial talent
106,SYK,fortunately recent report find manager attract hold millennial create flexible work environment leverage tech fully used innovative compensation most hire manager have hard time hire keep young worker know millennial elance odesk millennial brand commission study millennial say hire manager report difficulty find retain millennial talent fortunately recent report find manager attract hold millennial create flexible work environment leverage tech fully used innovative compensation
107,SYK,banker lawyer shareholder accustomed hearing ka ching merger acquisition activity be instead get used sound deal be flush toilet apply material amat monday scrap takeover bid tokyo electron just day comcast cmcsa pull plug propose acquisition time warner cable twc apply material japan
108,SYK,abiom abmd cambrex cbm have be standout performer ibd medical product industry group stock be extend now good news be several other name group be set potential move higher head thursday medical product group rank group rank ibd base month price performance
109,SYK,soon be acquire medical device giant covidien cov beat analyst fiscal estimate thursday send stock modestly
110,SYK,quarter end dec profit rise year earlier quarter share exclude time item beat analyst consensus cent accord thomson reuter sale rise estimate adjust foreign exchange fx headwind sale rise
111,SYK,be acquire medtronic mdt covidien didn offer guidance
112,SYK,rbc capital market analyst glenn novarro write fx headwind hit top line be expect give johnson johnson jnj stryker syk have already report similar issue covidien turn high quality beat due gross margin gm expansion
113,SYK,adjust gms be well estimate consensus believe be partly due fx hedge benefit recall fx benefit gms be basis point last quarter novarro write research note thursday cov operate expense ratio be essentially line estimate
114,SYK,overall believe cov report solid quarter operational basis
115,SYK,ireland base covidien stock be more morning trading stock market today time high hit jan
116,SYK,stock have be climb november medtronic assured investor acquisition be go ahead potential restriction tax inversion deal novarro write expect buyout close late january early february
117,SYK,follow amy reeve twitter ibd_areeve soon be acquire medical device giant covidien cov beat analyst fiscal estimate thursday send stock modestly quarter end dec profit rise year earlier quarter share exclude time item beat analyst consensus cent accord thomson reuter sale rise estimate adjust foreign exchange fx headwind sale rise be acquire medtronic mdt covidien didn offer guidance rbc capital market analyst glenn novarro write fx headwind hit top line be expect give johnson johnson jnj stryker syk have already report similar issue covidien turn high quality beat due gross margin gm expansion adjust gms be well estimate consensus believe be partly due fx hedge benefit recall fx benefit gms be basis point last quarter novarro write research note thursday cov operate expense ratio be essentially line estimate overall believe cov report solid quarter operational basis ireland base covidien stock be more morning trading stock market today time high hit jan stock have be climb november medtronic assured investor acquisition be go ahead potential restriction tax inversion deal novarro write expect buyout close late january early february follow amy reeve twitter ibd_areeve
118,SYK,medical device stock be move wednesday high rate player release preliminary number jpmorgan healthcare conference
119,SYK,zeltiq aesthetic zltq startup sell system whittle fat bulge say late tuesday sale be year earlier quarter top analyst consensus company forecast sale ahead consensus estimate last year
120,SYK,preliminary result reinforce view zltq continue have significant growth runway underpenetrated market unique fat freeze technology write leerink analyst richard newitter note tuesday reiterate outperform rating
121,SYK,zeltiq be founder go public turn profit previous quarters help drive ibd composite rating excellent be expect turn first annual profit year earning cent share midmorning stock market today zeltiq stock be
122,SYK,other end size spectrum orthopedic behemoth stryker syk be ep miss expectation late tuesday preliminary range share be analyst consensus firm also say sale rise line estimate
123,SYK,stryker say impact foreign exchange rate be anticipate shaving cent ep estimate cent year ep do not provide further guidance
124,SYK,give ongoing strengthen dollar do not think syk be alone manage fx headwind generally think investor be brace similar currency impact other medtech result likely be theme other medtech earning kick johnson johnson jnj newitter write
125,SYK,have be share cardiovascular giant st jude medical stj pop much wednesday report be merely line market open company say sale rise ep previous guidance range do not offer guidance st jude medical stock be morning trading wednesday
126,SYK,follow amy reeve twitter ibd_areeve medical device stock be move wednesday high rate player release preliminary number jpmorgan healthcare conference zeltiq aesthetic zltq startup sell system whittle fat bulge say late tuesday sale be year earlier quarter top analyst consensus company forecast sale ahead consensus estimate last year preliminary result reinforce view zltq continue have significant growth runway underpenetrated market unique fat freeze technology write leerink analyst richard newitter note tuesday reiterate outperform rating zeltiq be founder go public turn profit previous quarters help drive ibd composite rating excellent be expect turn first annual profit year earning cent share midmorning stock market today zeltiq stock be other end size spectrum orthopedic behemoth stryker syk be ep miss expectation late tuesday preliminary range share be analyst consensus firm also say sale rise line estimate stryker say impact foreign exchange rate be anticipate shaving cent ep estimate cent year ep do not provide further guidance give ongoing strengthen dollar do not think syk be alone manage fx headwind generally think investor be brace similar currency impact other medtech result likely be theme other medtech earning kick johnson johnson jnj newitter write have be share cardiovascular giant st jude medical stj pop much wednesday report be merely line market open company say sale rise ep previous guidance range do not offer guidance st jude medical stock be morning trading wednesday follow amy reeve twitter ibd_areeve
127,SYK,medical giant johnson johnson jnj beat analyst profit estimate tuesday miss topline offer weak guidance send stock more morning trading say earning exclude time item rise year earlier quarter share beating analyst consensus penny accord thomson reuter
128,SYK,income thirsty investor be caravaner struggle desert expect mid start interest rate hike prove be mirage
129,SYK,federal reserve initial short term rate raise be likely be modest rate still be low historical perspective say don taylor lead manager franklin rise dividend fund income equity still be competitive fix income
130,SYK,most mutual fund investor strategist expect dividend general rise next year taylor expect repeat annual increase recent year howard silverblatt senior index analyst dow jone index say be close double digit gain conservative
131,SYK,ben kirby co manager thornburg investment income builder fund expect find prospect higher dividend financial consumer discretionary
132,SYK,like jpmorgan chase jpm see capital adequacy ratio rise same time litigation expense be decline loan growth be anemic kirby say so ll have more cash shareholder
133,SYK,legal cost stem such misstep london whale trading loss practice related mortgage backed security
134,SYK,also like prospect cme group cme rise interest rate tend stoke stock market volatility money manager often hedge defend volatility derivative exchange see more volume say
135,SYK,retailer stock
136,SYK,kirby see potential dividend growth least consumer discretionary sector average yield be be trail earning say retail chain be well build so re not do lot spending leave more return shareholder
137,SYK,add home depot hd be good example consumer discretionary stock benefit tailwind consumer be increasingly comfortable make home upgrade repair home value be economy be stable job feel more secure kirby say
138,SYK,kirby dislike dividend prospect smaller energy exploration production firm low oil price hurt earning
139,SYK,say large multinational integrate major exxon mobil xom royal dutch shell rdsb total tot bp bp be able maintain dividend take debt selling asset reduce capital expenditure total shell don do share buyback leave more pay dividend
140,SYK,taylor like large cap tech name ample dividend yield such intel intc microsoft msft ibm ibm apple aapl
141,SYK,like holding be likely echo year dividend hike cite pump maker pentair pnr insurer erie indemnity erie control device maker johnson control jci medical device maker stryker syk
142,SYK,david spangler run equity part thrivent fund say investor not look highest dividend instead seek company strong enough raise dividend income thirsty investor be caravaner struggle desert expect mid start interest rate hike prove be mirage federal reserve initial short term rate raise be likely be modest rate still be low historical perspective say don taylor lead manager franklin rise dividend fund income equity still be competitive fix income most mutual fund investor strategist expect dividend general rise next year taylor expect repeat annual increase recent year howard silverblatt senior index analyst dow jone index say be close double digit gain conservative ben kirby co manager thornburg investment income builder fund expect find prospect higher dividend financial consumer discretionary like jpmorgan chase jpm see capital adequacy ratio rise same time litigation expense be decline loan growth be anemic kirby say so ll have more cash shareholder legal cost stem such misstep london whale trading loss practice related mortgage backed security also like prospect cme group cme rise interest rate tend stoke stock market volatility money manager often hedge defend volatility derivative exchange see more volume say retailer kirby see potential dividend growth least consumer discretionary sector average yield be be trail earning say retail chain be well build so re not do lot spending leave more return shareholder add home depot hd be good example consumer discretionary stock benefit tailwind consumer be increasingly comfortable make home upgrade repair home value be economy be stable job feel more secure kirby say kirby dislike dividend prospect smaller energy exploration production firm low oil price hurt earning say large multinational integrate major exxon mobil xom royal dutch shell rdsb total tot bp bp be able maintain dividend take debt selling asset reduce capital expenditure total shell don do share buyback leave more pay dividend taylor like large cap tech name ample dividend yield such intel intc microsoft msft ibm ibm apple aapl like holding be likely echo year dividend hike cite pump maker pentair pnr insurer erie indemnity erie control device maker johnson control jci medical device maker stryker syk david spangler run equity part thrivent fund say investor not look highest dividend instead seek company strong enough raise dividend
143,SYK,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
144,SYK,medical giant johnson johnson jnj kick industry earning season strong note sale earning beat early tuesday stock be morning trading stock market today earning exclude time item rise year earlier quarter share beating analyst estimate cent
145,SYK,medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening
146,SYK,conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say
147,SYK,also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market
148,SYK,such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work
149,SYK,third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction
150,SYK,rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition
151,SYK,becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be
152,SYK,follow amy reeve twitter ibd_areeve medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be follow amy reeve twitter ibd_areeve
153,SYK,share medical device giant medtronic mdt british orthopedic firm nephew snn pull back stock market today new high wednesday analyst debate buyout rumor bloomberg first publish anonymously source report wednesday open drive stock medtronic new high follow similar rumor last week
154,SYK,medtronic buyout fellow medical device giant covidien get mostly friendly reception wall street monday analyst foresee further round mega merger change industry landscape late sunday medtronic mdt announce have agree buy covidien cov cash stock deal give covidien shareholder ownership new company
155,SYK,share medical device maker covidien cov jump stock market today medtronic mdt announce late sunday be buy company medtronic cash stock payment amount share base medtronic close price friday create industry heavyweight annual revenue covidien
156,SYK,robotic surgery company mako surgical mako say wednesday have acquire partner pipeline biomedical holding issuance share even mako be process be buy stryker syk last year pipeline have be supply implant technology use mako rio orthopedic surgery system
157,SYK,stryker syk be well know market leader reconstructive knee hip implant company note knee replacement recipient golfer fred funk play last month open bethesda md
158,SYK,not be so well know be year old kalamazoo mich base firm have broaden other medical technology acquisition effort stryker also work area surgical gear endoscopy orthobiologic spine care
159,SYK,analyst meeting ceo stephen macmillan point today single business unit make more company total revenue grow revenue
160,SYK,company traditional orthopedic implant business see unexpected slowdown macmillan note medsurg equipment sale grow unit key product be isuite aim boost user operate room system include lead base surgical light high definition camera conduct image guide surgery procedure
161,SYK,also establish presence macmillan call rapidly grow foot hand segment human extremity market july stryker say close buy french metal alloy firm memometal technology transaction be expect have neutral impact earning exclude acquisition integration charge
162,SYK,close tuesday stryker report result earning grow cent share meeting consensus view rise sale sale neurotechnology spine product grow marked stryker seventh straight quarter low double digit ep growth
163,SYK,stryker have remarkable year earning stability factor scale most stable
164,SYK,stryker pay dividend cent share july shareholder record june tuesday stock have annualize yield
165,SYK,stock break month cup handle week end jan gain march work new base be testing support day move average stryker syk be well know market leader reconstructive knee hip implant company note knee replacement recipient golfer fred funk play last month open bethesda md not be so well know be year old kalamazoo mich base firm have broaden other medical technology acquisition effort stryker also work area surgical gear endoscopy orthobiologic spine care analyst meeting ceo stephen macmillan point today single business unit make more company total revenue grow revenue company traditional orthopedic implant business see unexpected slowdown macmillan note medsurg equipment sale grow unit key product be isuite aim boost user operate room system include lead base surgical light high definition camera conduct image guide surgery procedure also establish presence macmillan call rapidly grow foot hand segment human extremity market july stryker say close buy french metal alloy firm memometal technology transaction be expect have neutral impact earning exclude acquisition integration charge close tuesday stryker report result earning grow cent share meeting consensus view rise sale sale neurotechnology spine product grow marked stryker seventh straight quarter low double digit ep growth stryker have remarkable year earning stability factor scale most stable stryker pay dividend cent share july shareholder record june tuesday stock have annualize yield stock break month cup handle week end jan gain march work new base be testing support day move average
166,SYK,stryker syk be well know market leader reconstructive knee hip implant company note knee replacement recipient golfer fred funk play last month open bethesda md
167,SYK,not be so well know be year old kalamazoo mich base firm have broaden other medical technology acquisition effort stryker also work area surgical gear endoscopy orthobiologic spine care
168,SYK,analyst meeting ceo stephen macmillan point today single business unit make more company total revenue grow revenue
169,SYK,company traditional orthopedic implant business see unexpected slowdown macmillan note medsurg equipment sale grow unit key product be isuite aim boost user operate room system include lead base surgical light high definition camera conduct image guide surgery procedure
170,SYK,also establish presence macmillan call rapidly grow foot hand segment human extremity market july stryker say close buy french metal alloy firm memometal technology transaction be expect have neutral impact earning exclude acquisition integration charge
171,SYK,close tuesday stryker report result earning grow cent share meeting consensus view rise sale sale neurotechnology spine product grow marked stryker seventh straight quarter low double digit ep growth
172,SYK,stryker have remarkable year earning stability factor scale most stable
173,SYK,stryker pay dividend cent share july shareholder record june tuesday stock have annualize yield
174,SYK,stock break month cup handle week end jan gain march work new base be testing support day move average stryker syk be well know market leader reconstructive knee hip implant company note knee replacement recipient golfer fred funk play last month open bethesda md not be so well know be year old kalamazoo mich base firm have broaden other medical technology acquisition effort stryker also work area surgical gear endoscopy orthobiologic spine care analyst meeting ceo stephen macmillan point today single business unit make more company total revenue grow revenue company traditional orthopedic implant business see unexpected slowdown macmillan note medsurg equipment sale grow unit key product be isuite aim boost user operate room system include lead base surgical light high definition camera conduct image guide surgery procedure also establish presence macmillan call rapidly grow foot hand segment human extremity market july stryker say close buy french metal alloy firm memometal technology transaction be expect have neutral impact earning exclude acquisition integration charge close tuesday stryker report result earning grow cent share meeting consensus view rise sale sale neurotechnology spine product grow marked stryker seventh straight quarter low double digit ep growth stryker have remarkable year earning stability factor scale most stable stryker pay dividend cent share july shareholder record june tuesday stock have annualize yield stock break month cup handle week end jan gain march work new base be testing support day move average
175,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
176,SYK,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
177,SYK,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
178,SYK,boston scientific corporation bsx free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have rally compare industry rise also company have surpass breakeven share performance developer manufacturer marketer medical device use interventional medical specialty have market cap company have long term historical earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day only analyst have revise estimate upward movement be noticed opposite direction however earning estimate remain unchanged boston scientific corporation price boston scientific corporation price boston scientific corporation quotelet find recent positive trend be sustainable solid quarterly scientific continue deliver better expect quarterly earning revenue number be upbeat company witness growth business line geography strategic buyout be upbeat boston scientific recent acquisition apama medical deal company aim expand suite arrhythmia solution fall ep sub segment further gain traction ep market boston scientific announce plan acquire securus medical privately hold developer thermal monitoring system continuous measurement esophageal temperature be also look forward company recent agreement acquire cryterion medical privately hold company develop single shot cryoablation platform treatment atrial fibrillation addition cryoballoon platform help boston scientific emerge first entity cryothermal radiofrequency single shot balloon base ablation therapy portfolio geographic expansionboston scientific integral growth strategy be continue pursue developmental opportunity outside unite state expand global presence inclusive emerge market company be gradually fortify footprint emerge market include brazil russia india china first quarter business emerge market register growth company be gain strong ground india well target emerge market additional stimulus boston scientific hope sustain robust overall international performance ride high product launch currently early stage rollout suspension medtech decision house senate suspend medical device tax year have come relief medical device bigwig boston scientific company temporary suspension allow continue investment plan innovative medical product company meanwhile have plan work full repeal medtech tax other stock considerother top rank stock broader medical space include genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have estimate long term earning growth rate zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
179,SYK,jul issue update research report medtronic plc mdt free report be encourage company global accept advanced therapy escalate cost expense raise concern stock have zack rank hold past month share medtronic have outperformed industry stock have grow compare industry rise notably medtronic exit fiscal solid note better expect fourth quarter performance major business group contribute solid top line growth cer highlight sustainability group region addition display successful integration achievement synergy target also gradually stabilize cardiac rhythm heart failure crhf market buoy optimism stock receipt fda approval dbs deep brain stimulation therapy adjunctive treatment reduce partial onset seizure raise hope company target medical market medtronic be also focuse geographical diversification business company be highly positive foray standalone cgm continuous glucose monitoring market guardian connect be currently upbeat latest fda nod minime system patient type diabetes year age significantly medtronic new restructure initiative enterprise excellence plan be aim annual growth run rate saving end fiscal company new program have be design increase effectiveness growth related reinvestment ability provide consistent boost margin expansion well drive ep leverage flip side company have be expose steep cost expense weigh heavily margin also guidance remain conservative apprehension lackluster cardiac vascular group cvg minimally invasive therapy group mitg performance turn dampen investor confidence stock key picksa few better rank stock broader medical sector be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy stryker have estimate long term earning growth rate zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
180,SYK,intuitive surgical isrg free report recently announce fda approval sureform stapler company share climb follow announcement notably share intuitive surgical have rally industry decline year time stock carry zack rank hold back news latest clearance reflect california base manufacturer surgical system commitment minimally invasive innovation sureform be fully wrist mm stapler be first kind stapler offer degree fully wrist articulation new breed da vinci stapling be compatible da vinci xi surgical system sureform used smartfire technology optimize stapler staple line performance market prospectsper minimally invasive surgical instrument market be project reach worth cagr hence latest development have be timely strategic intuitive surgical minimally invasive surgery take medtech stormminimally invasive surgery involve less surgical incision reduce trauma patient late medtech space have be witness increase usage surgical procedure intuitive surgical coveted da vinci platform deserve special mention here system be power robotic technology help surgeon make smaller precise movement meanwhile stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution coveted mako platform recently record strong performance japan south pacific canada globally stryker install mako robot be unite state want more industry few better rank stock medical instrument space specialize minimally invasive surgical solution be masimo corporation masi free report steris plc ste free report masimo innovative noninvasive patient monitoring system have be drive top line stock carry zack rank buy see complete list today zack rank stock here steris harmony hybrid be design accommodate grow utilization demand minimally invasive surgery stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
181,SYK,stryker corporation syk free report second quarter result be schedule release jul market close company acquisition drive strategy be expect boost growth expand product offering segment expect company witness steady growth sale orthopaedic implant major revenue generate component be project drive second quarter earning expect improvement revenue other segment especially medsurg help company drive impressive result notably last report quarter stryker post earning beating zack consensus estimate quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be pin indicate year year increase stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation implant implant contribute net revenue last report quarter last report quarter revenue segment be organically upside be attribute significant year year increase mako robot installation coveted mako platform also record strong performance japan south pacific canada globally stryker install mako robot be unite state zack consensus estimate orthopaedic implant quarter be report be reflect rise year year other factor playmedsurg unit drive growthmedsurg equipment product include surgical equipment surgical navigation system endoscopic communication digital imaging system well patient handle emergency medical equipment last report quarter segment account company net sale revenue segment grow constant currency cc moreover zack consensus estimate medsurg equipment revenue be peg reflect year year growth domestic international revenuesstryker be well balanced high domestic international revenue last report quarter domestic revenue account significant net sale meanwhile international sale account total revenue zack consensus estimate stryker domestic sale be pin year year same international revenue stand year year complete buyout entellus medical entellus be integrate stryker core neurotechnology spine segment enable physician conveniently perform broad range ent procedure however acquisition be expect be dilutive initially stryker adjust earning share approximately cent be likely affect top line quarter be report read more stryker close entellus buyout bolster neurotechnology line stryker be lately news make offer take massachusett base boston scientific corporation bsx free report however further term deal have be reveal stryker stryker also sign agreement acquire safeair ag swiss medical device company recently model predictsour quantitative model do not predict earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated earning esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
182,SYK,jul issue update research report walgreen boot alliance inc wba free report be currently look forward company rite aid store purchase expect benefit company long run stock carry zack rank hold walgreen boot report better expect third quarter fiscal result solid pharmacy sale growth encourage moreover company have be gain strategic tie up be also upbeat walgreen boot alliance express script aim expand company exist group purchasing effort latest pact be likely improve express script supply chain make medicine include biosimilar affordable accessible patient apart rite aid deal seem benefit walgreen boot more way accordingly collaboration allow rite aid buy generic drug source walgreen boot affiliate cost equivalent company year buoy optimism also rite aid provide walgreen boot certain transition service year post deal closure deal financial value be attractive post transaction initial completion synergy be estimate be realize span year amount be derive primarily procurement cost saving other operational matter be hopeful boot global footprint expansion decision acquire stake sinopharm hold guoda drugstore subsidiary china national accord medicine corporation ltd culmination investment add strong impetus walgreen boot worldwide retail pharmacy business notably shanghai base guoda be large national pharmacy chain china however walgreen boot face headwind form fierce competition tough industry condition even company continue reap benefit growth initiative major business tycoon be already advance pharmacy business flaunt fair market share notably slowdown generic introduction last few year have be affect walgreen boot margin also escalate reimbursement pressure generic drug cost inflation have be dent walgreen boot margin significantly june walgreen boot sell interest chinese drug wholesaler guangzhou pharmaceutical corporation alliance be form back equal partnership guangzhou pharmaceutical co ltd legacy alliance boot sell follow lucrative cash return offer overall impact company business induce adverse impact past month share walgreen boot have underperform industry stock have lose wider industry gain key pickssome better rank stock broader medical space be genomic health ghdx free report stryker corporation syk free report integer holding corporation itgr free report genomic health project earning growth rate be report quarter stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy integer holding have expect long term earning growth rate stock hold zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
183,SYK,boston scientific corporation bsx free report recently announce acquisition cryterion medical inc privately hold developer single shot cryoablation platform treatment atrial fibrillation acquisition boston scientific become only company boast comprehensive portfolio cover cryothermal radiofrequency single shot balloon base ablation therapy cryterion medical plan submit clinical evidence ongoing study cryoablation system get ce mark early further company plan submit investigational device exemption application fda seek regulatory approval unite state financial term dealboston scientific have exist investment cryterion medical be go make net upfront payment approximately cash remain stake however transaction be not expect be accretive company adjust earning share glimpse ep businessboston scientific ep business develop less invasive medical technology diagnose treat disorder heart rate well rhythm first quarter revenue division improve year year organically upside be drive higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently launch platform unite state well japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system additionally focus add tool expand reach utility rhythmia hdx different procedure moreover expand ep business boston scientific recently announce acquisition securus medical group inc privately hold developer thermal monitoring system continuous measurement esophageal temperature market potentialboston scientific strategy boost ep business seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect reach value cagr company global ep market be expect worth further grow double digit single shot ablation therapy be estimate be most rapidly grow sub segment ep market thus addition single shot cryoablation platform help boston scientific cash abundant opportunity global cardiac monitoring cardiac rhythm management market share price scientific have be gain investor confidence consistently positive result past month share company have outperformed broader industry stock have rally versus industry increase zack rank other key picksboston scientific currently carry zack rank buy other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
184,SYK,bio rad laboratory inc bio free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare growth industry also company have outperformed fall renown manufacturer global supplier clinical diagnostic life science research product healthcare analytical chemistry life science research other market have market cap company project year growth rate be favorable compare industry solid prospect zack rank buy stock be attractive investment pick now company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate increase share further zack consensus estimate current year revenue reflect improvement year year let find recent positive trend be sustainable solid global prospectsin first quarter bio rad derive net sale globally europe happen be largest international market company first quarter revenue growth region be apparently sluggish offset softness bio rad perform reasonably well primarily north america china asia pacific region growth linesbio rad witness sale growth channel first quarter sale life science segment be drive higher demand droplet digital pcr process chromatography cell biology product line further rise net sale clinical diagnostic indicated growth immunology diabetes quality control product line impressive synergy raindancebio rad complete acquisition raindance technology inc february acquire entity be integrate life science segment bid solidify position droplet digital pcr space further bio rad have begin realize synergy raindance acquisition first quarter bio rad record raindance sale comparison previous year company have also be witness solid growth sale droplet digital pcr solid balance sheeteffective capital deployment have be key contributor ep growth bio rad exit first quarter cash cash equivalent short term investment compare end other key pickssome other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
185,SYK,baxter international bax free report be currently top perform stock medtech space company raise guidance global expansion be major tailwind share upin past year baxter share have rally compare industry growth zack rank buy stock currently have growth score reflect possibility outperformance long haul research show stock growth score combine zack rank strong buy be better pick most last day zack consensus estimate baxter current quarter earning share rise cent baxter international inc price consensus baxter international inc price consensus baxter international inc quotewhat make attractive pick raise guidancebaxter have raise guidance company expect sale growth cc expect adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range acquisition recently complete acquisition hemostat sealant product mallinckrodt plc widen surgical portfolio company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter also recently collaborate international society nephrology isn spread awareness chronic kidney disease international launchesbaxter aim accelerate growth offer service overseas company advanced surgery team recently begin rollout tisseel prima europe japan baxter renal team have initiate launch kaguya peritoneal dialysis technology want more industry other top rank stock medical product space be stryker corp syk free report bio rad laboratory bio free report boston scientific corp bsx free report stryker long term expect earning growth be stock carry zack rank see complete list today zack rank stock here bio rad long term project earning growth be stock carry zack rank boston scientific have expect long term earning growth stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
186,SYK,seem insulet corporation podd free report be pull stop strengthen international operation follow news commence direct commercial operation europe company once again hit headline major development omnipod insulin management systemin canada news release omnipod insulet tubeless insulin pump technology have be select prefer insulin pump diabetic patient province british columbia canada expand british columbia pharmacare insulin pump program be big breakthrough company fortify foothold canada now eligible patient request insulin pump first time replacement receive coverage omnipod system insulin pump prospect canadaomnipod huge market potential canada be evident only tubeless insulin pump system sell region system supply continuous insulin day use tube eliminate worry administer multiple daily injection currently omnipod be available age group british columbia grow prevalence diabetes canada believe development insulet be well time accord research market datum canada insulin pump market have immense growth opportunity value project reach nearly cad mark end report government canada have extend diabetes management policy diabetes technology further boost market insulin pump well continuous glucose monitoring device canada go diabetes canada estimate british columbia show person be affected type diabetes account approximately patient population resort insulin pump therapy coverage widening year age company anticipate insulin pump adoption increase significantly insulet omnipod earn status prefer insulin pump diabetic patient british columbia medtronic minime insulin pump system be popularly used diabetes management device canada tubing category share price performanceover past month share insulet have consistently outperformed industry belong stock have rally compare industry rise zack rank key picksinsulet currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report stryker corporation syk free report integer holding corporation itgr free report genomic health project earning growth rate be report quarter stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy integer holding have expect long term earning growth rate stock hold zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
187,SYK,masimo corporation masi free report be currently top perform stock medtech space company strong fundamental global expansion be major positive moment share upin past year masimo share have rally industry decline zack rank buy stock currently have growth score reflect possibility outperformance long haul research show stock growth score combine zack rank strong buy be better pick most last day zack consensus estimate masimo current year earning share rise masimo corporation price consensus masimo corporation price consensus masimo corporation quotelet find bullish trend sustain stock impressive performance long run make attractive pick fundamental growth storymasimo have be gain strong fundamental company revenue grow cagr furthermore masimo earning see cagr global exposuremasimo have significant international presence california base company flagship eve application have be recently picked uae ministry health prevention mohap read more mohap select masimo eve cchd screening uae earlier year masimo technology be implement nu hospital bangalore base nephrology care center india read more masimo product boost india base nu hospital system furthermore last report quarter masimo secure substantial contract rad blood transfusion center valencia spain raise revenue be estimate previous projection zack consensus estimate be peg guide figure adjust earning share be expect previous guidance zack consensus estimate be pin slightly project figure other key pickssome other top rank medical stock be genomic health ghdx free report stryker corporation syk free report integer holding corporation itgr free report genomic health have expect earning growth rate stock flaunt zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank integer holding long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
188,SYK,insulet corporation podd free report recently announce have commence direct commercial operation europe omnipod insulin management system development be major breakthrough company international portfolio go forward insulet provide sale distribution customer support product service diabetic support system omnipod europe insulin pump market project reach value more end datum market research hub achievement insulet be tout be timely strategic insulet objective assume direct commercial operation europe surface last july previously company used run european business assistance local distributor name ypsomed termination exclusive distribution agreement ypsomed see insulet form european team employee extensive diabetes knowledge expertise european market insulet currently have omnipod user worldwide expect number grow fast latest progress europe company be confident infrastructure believe be well position cash rapidly grow european customer base enhance gross margin context insulet have tie teleperformance healthlink provide local customer care product support distribution logistic service insulet also enter distribution agreement thera group nordic infucare order receive complete service distribution omnipod italy well nordic market insulin pump growth prospect europego market research hub report european insulin pump market have extremely high potential backed surge diabetes population factor contribute growth insulin pump europe be increase agee population rise prevalence diabetes grow awareness benefit insulin pump higher capita disposable income progressive diabetes infrastructure insulin pump gradually gain popularity traditional technique adoption rate have shot diabetes patient europe needless say latest strategic initiative insulet be go reinforce company global operation large extent share performanceover past month insulet have consistently outperformed industry belong stock have rally compare industry rise zack rank key picksinsulet currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have anticipate long term earning growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
189,SYK,henry schein inc hsic free report recently announce have complete earlier announce joint venture jv internet brand kkr portfolio company bid fortify dental business company have name joint venture henry schein however financial term deal have be keep wrapped henry schein have integrate portfolio practice management system dental practice management software company henry schein practice solution internet brand web base software application new company be expect deliver integrate dental technology help improve practice management marketing well patient communication henry schein newly form jv combine henry schein practice solution product service dentrix dentrix ascend easy dental techcentral henry schein international dental practice management system include software excellence logiciel julie infome exan labnet dental business internet brand include web base solution such demandforce sesame communication officite dentalplan com combine entity register pro sale approximately approximately be draw internet brand dental business exclude impact time transfer taxe henry schein have earlier anticipate deal be immaterial rest earning share be accretive bottom line thereafter furthermore annual synergy be expect be realize end third year joint venture initiation dental business major growth driverhenry schein dental business account total revenue last report quarter accordingly have be leave stone unturned strengthen foothold business moreover henry schein sign distribution agreement dentsply sirona inc xray only last year distribute latter entire product line be also encourage henry schein reliance part strategic plan be digital dentistry company be busy promote digital workflow general dentistry well dental specialty management company solid performance be attribute continue focus offer diversify portfolio value add service favorable end market thus believe henry schein latest tie be strategic leap take company market potentialper company rise oral healthcare expenditure dental industry be predict tandem increase middle age population year moreover henry schein be upbeat expect growth dental insurance coverage lower insurance reimbursement rate lead frequent need new technology believe bullish sentiment boost demand henry schein product service moreover transparency market research report global dental practice management software market be likely witness cagr give huge market potential perceive latest development help henry schein cash bountiful opportunity market share price movementover past month henry schein have outperformed broader industry stock have gain compare industry increase zack rank key pickshenry schein currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have skyrocket expect earning growth rate be report quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have estimate long term earning growth rate stock carry zack rank buy look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
190,SYK,jul issue update research report qiagen qgen free report company business be expect get boost flourishing molecular diagnostic market international expansion extend test menu growth drive strategic collaboration meanwhile past month share qiagen have underperform industry stock have lose versus industry increase decline hpv sale unite state persist be drag qiagen slow apac sale also remain soft due sluggish apply testing business moreover qiagen be expose stiff competition company be face severe rivalry firm provide similar pre analytical solution other product used customer incite fierce cut throat contest industry qiagen wo be further aggravate highly aggressive price sensitive market product also heavy reliance collaboration decline hpv human papillomavirus sale unite state act other negative industry player qiagen price qiagen price qiagen quoteon positive note be upbeat qiagen progress test menu expansion strategy april company announce receipt fda pre market approval partosure same month launch qiastat dx europe follow closure recently announce stat dx acquisition completion defined development activity stat dx company be plan launch qiastat dx test unite state well other geography additionally qiagen introduce novel liquid biopsy panel namely adnatest ar kit adnatest lungcancer kit first quarter qiagen announce receive approval japan ministry health labor welfare quantiferon tb gold qft diagnostic detect tuberculosis tb infection further recently change guideline issue world health organization center disease control international panel physician association add impetus rise popularity proactive latent tb screening treatment also look forward implementation recently draw strategy boost top line contribution ngs next generation sequence portfolio zack rank key picksqiagen currently carry zack rank sell better rank stock broader medical space include genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy stryker have estimate long term earning growth rate zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
191,SYK,have be month last earning report stryker corporation syk free report share have add time frame recent positive trend continue lead next earning release be syk due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsstryker report first quarter adjust earning share ep beating zack consensus estimate ep figure exceed high end guidance also increase year year michigan base medical device company report first quarter revenue beating zack consensus estimate narrow margin revenue also increase year year basis organic sale growth be impressive performance japan china australia emerge market be striking well segment segment come cc upside be attribute knee division report sale worth cc moreover organic net sale segment rise management flagship mako total knee platform see significant year year uptick new robot installation segment register revenue cc organic net sale segment increase supply issue related company puerto rico facility ramp growth be mainly drive sub segment instrument endoscopy medical instrument see growth cc endoscopy grow medical rise management medical division witness organic growth drive strong performance core bed power cot product well physio business neurotechnology spinerevenue segment come cc organic net sale segment increase neurotechnology register revenue worth cc spine revenue come cc however report quarter spine business see softness well low double digit price decline core product line segment be also gain recent integration entellus medical geographical detailssale unite state come cc international sale totale cc management stryker perform strongly japan south pacific canada company also register double digit growth year year basis emerge market however company performance europe lack luster first quarter marginsin quarter review operate margin expand basis point bps adjust gross margin improve nominally prior year quarter management gross margin be favorably impact productivity efficiency foreign exchange gain offset business mix price financial continue maintain strong position cash marketable security approximately be hold outside unite state cash flow first quarter be approximately total debt balance sheet end quarter be guidancebuoy stellar first quarter performance stryker now expect second quarter earning share moreover organic net sale growth be expect adjust net earning diluted share range management be also confident bps improvement operate margin have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower stryker corporation price consensus stryker corporation price consensus stryker corporation quotevgm scoresat time syk have average growth score however momentum be do lot better however stock be allocate grade value side putt bottom investment strategy overall stock have aggregte vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor growth investor outlookestimate have be broadly trend upward stock magnitude revision look promising come little surprise syk have zack rank buy expect average return stock next few month
192,SYK,stryker corporation syk free report report first quarter adjust earning share ep beating zack consensus estimate ep figure exceed high end guidance also increase year year michigan base medical device company report first quarter revenue beating zack consensus estimate narrow margin revenue also increase year year basis organic sale growth be impressive performance japan china australia emerge market be striking well meanwhile last month stock have rally compare industry gain stryker corporation price consensus ep surprise stryker corporation price consensus ep surprise stryker corporation quotesegment segment come cc upside be attribute knee division report sale worth cc moreover organic net sale segment rise management flagship mako total knee platform see significant uptick new robot installation year year segment register revenue cc organic net sale segment increase supply issue related company puerto rico facility ramp growth be mainly drive sub segment instrument endoscopy medical instrument see growth cc endoscopy grow medical rise management medical division witness organic growth drive strong performance core bed power cot product well physio business neurotechnology spinerevenue segment come cc organic net sale segment increase neurotechnology register revenue worth cc spine revenue come cc however report quarter spine business see softness well low double digit price decline core product line segment be also gain recent integration entellus medical geographical detailssale unite state come constant currency cc international sale totale cc management stryker have strong performance japan south pacific canada company also register double digit growth year year basis emerge market however company performance europe lack luster first quarter marginsin quarter review operate margin expand basis point bps adjust gross margin improve nominally prior year quarter management gross margin be favorably impact productivity efficiency foreign exchange gain offset business mix price financial continue maintain strong position cash marketable security approximately be hold outside unite state cash flow first quarter be approximately total debt balance sheet end quarter be guidancebuoy stellar first quarter performance stryker now expect second quarter earning share notably zack consensus estimate second quarter earning be peg be pretty encourage moreover organic net sale growth be expect adjust net earning diluted share range management be also confident bps improvement operate margin takestryker strong first quarter show be largely backed solid performance segment moreover company witness high domestic international growth revenue strong guidance current quarter full year buoy optimism company moreover surge operate margin reflect strength company prospect however supply issue puerto rico facility decline gross margin raise concern zack rank other key picksstryker carry zack rank buy few other top rank stock deliver solid result earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank see complete list today zack rank stock here labcorp report first quarter adjust ep beating zack consensus estimate revenue come steering past zack consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
193,SYK,first quarter earning season be fast unfold member elite index have report financial number apr latest earning preview total earning company have increase year year basis higher revenue further whopping company have surpass earning estimate beat revenue mark however number positive revenue surprise season be lag precede year number end week company be set release result medical zack sector be expect deliver strong result medical product space have lately see slew favorable development change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment abolition taxe increase business investment have be drive growth sector so rather be interesting see major medical product company be place ahead report cycle be major factor shape release medical sectormedical product have be very profitable investment space late favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be suppose growth driver latest tax cut job act be finally sign president trump dec have finally cheer healthcare fraternity act have lower corporate tax rate earlier buoy optimism additionally senate decision postpone medical device tax be put effect jan have instilled confidence investor bill also delay so call cadillac tax tax employer insurance let take look major medical product company be set release result apr zack quantitative model stock advantageous combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter baxter international inc bax free report first quarter result be expect show gain hospital product unit solid guidance plethora regulatory approval first quarter zack consensus estimate earning be peg cent indicate year year growth same revenue be fix reflect year year growth further predict earning beat quarter baxter have zack rank earning esp read more hospital product unit aid baxter earning see complete list today zack rank stock here baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quoteresm inc rmd free report be expect gain strong performance domestic international front third quarter fiscal revenue europe asia other market be likely register solid increase banking strong device mask performance moreover company sleep apnea patient volume have consistently witness steady growth third quarter zack consensus estimate earning be pin cent indicate year year growth same revenue be fix reflect year year growth however model resm be unlikely deliver earning beat season resm have zack rank earning esp make surprise prediction difficult read more resm repeat stable device growth earning resm inc price ep surprise resm inc price ep surprise resm inc quotestryker corporation syk free report first quarter result be expect show strong growth back orthopaedic implant sale major revenue component additionally medsurg help company generate impressive result first quarter zack consensus estimate earning be pin indicate year year growth same revenue be fix reflect year year growth quantitative model predict earning beat stryker be stock have earning esp zack rank read more core segmental growth aid stryker earning stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotezimmer biomet holding inc zbh free report first quarter result be expect show strong top line number surgical sport medicine foot ankle extremity trauma arm moreover last november company have receive several fda clearance be particularly excited approval sidus stem free shoulder system first quarter zack consensus estimate earning be pin indicate year year decline same revenue be fix reflect year year growth zimmer biomet have zack rank sell lower predictive power esp have earning esp read more aid zimmer earning supply wo zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quoteinvestor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
194,SYK,boston scientific corporation bsx free report be schedule report second quarter result open bell jul last report quarter company earning share beat zack consensus estimate moreover company deliver positive earning surprise trail quarters average beat be let see thing be shape prior announcement key prior quarter be upbeat solid contribution boston scientific cardiovascular business comprise interventional cardiology ic peripheral intervention pi last report quarter company generate total revenue highest revenue generate segment be optimistic ic business help company maintain impressive global growth courtesy innovative portfolio robust commercial team division perform well last report quarter lotus recall europe worldwide ic growth come back strength structural heart complex pci intervention portfolio however upside be partially offset weak performance drug eluting stent boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotewithin structural heart be look forward boston scientific watchman acurate iris product line be expect contribute top line yet be report quarter company expect revenue watchman acurate tavr franchise total approximately watchman program depict impressive performance first quarter product have be used more implant worldwide moreover company expect continue growth platform back increase utilization geographical expansion additionally recent launch ic business wolverine cut balloon company next generation rotational atherectomy platform rotapro be expect contribute significantly top line upcoming quarterly result zack consensus estimate ic revenue be peg indicate increase year year basis company be expect keep gain strength business last report quarter pi business perform impressively back higher sale drug eluting stent ranger balloon europe geographically company witness strength asia well boston scientific atherectomy jetstream platform also perform well first quarter trend be expect continue be report quarter accordingly zack consensus estimate second quarter pi revenue be peg reflect rise year year overall zack consensus estimate total revenue indicate increase prior year quarter tally also earning estimate cent reflect rise year year basis other factor playamong other segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project surpass market level drive investment strategy key international geography be impressed boston scientific recent acquisition have add several product many be development immense potential nxthera nvision buyout urology pelvic health emcision buyout endoscopy deserve mention company be gradually strengthen presence emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently look forward improve performance ahead china follow recent approval synergy region boston scientific be gain traction india well be currently target emerge market additional emphasis company be also optimistic core cardiology segment be gradually stabilize growth bric nation trend be expect continue yet be report quarter result however immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect top line number upcoming quarters company also provide second quarter financial outlook adjust ep be expect range cent revenue here quantitative model predictsper proven zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter boston scientific have zack rank increase predictive power esp have earning esp make surprise prediction easier combination suggest company be likely beat earning quarter other stock worth lookhere be few other medical stock worth consider right combination element beat estimate resm rmd free report have earning esp carry zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank henry schein inc hsic free report zack rank company have earning esp medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
195,SYK,integer holding corporation itgr free report recently complete sale core advanced surgical orthopedic segment medplast llc follow announcement company share price rise close notably past month share integer holding have rally industry decline stock currently carry zack rank buy rationale divestiture help integer holding reduce debt approximately pay debt management expect integer holding be worth company company be therefore expect see higher margin increase net earning greater return invest capital furthermore increase financial flexibility enable integer holding focus cardio vascular cardiac neuromodulation product line focus cardiac businessinteger holding cardiac business comprise cardio vascular cardiac neuromodulation unit have be significant growth driver notably last report quarter cardio vascular product line see strong year year sale growth robust demand product contract manufacturing component cardiac neuromodulation product line witness growth remain key driver long term growth management company be investing resource product line ensure innovation market holding be expose highly profitable cardiovascular market space research market global market cardiovascular device market be expect reach cagr other key picksa few other top rank stock broader medical space be genomic health ghdx free report stryker corporation syk free report masimo corporation masi free report genomic health have expect earning growth rate stock flaunt zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank masimo have expect long term earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
196,SYK,jul initiate research report insulet corporation podd free report be upbeat company achievement milestone respect expansion omnipod market reach tough competitive landscape raise concern stock carry zack rank hold lead developer manufacturer marketer omnipod insulin management system have be outperform industry past year stock have gain versus industry rise insulet kick start positive reimbursement update begin cms issue guidance january require omnipod be cover medicare part prescription drug benefit program moreover effective apr express script magellan medicare part plan sponsor add omnipod cover benefit start april insulet receive access network coverage omnipod insulet have also take new role direct seller omnipod system europe start jul company be confident infrastructure believe be well position cash rapidly grow european customer base be also upbeat year year revenue growth last report quarter solid uptake omnipod system unite state other geography expand global customer base consistent strength market drive revenue meanwhile insulet operate highly competitive environment dominate firm range large multinational corporation significant resource start up also competitive regulatory condition market company operate limit insulet ability switch strategy price increase company omnipod system primarily compete medtronic plc mdt market lead minime system also company be expose risk associate weaker global economy lower reimbursement rate key pickssome better rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy stryker have project long term earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
197,SYK,cerner corporation cern free report first quarter result be schedule release market close system sale be likely be growth driver improvement other segment also lead better result fourth quarter cerner report adjust earning share cent cent year figure also miss zack consensus estimate cent cerner have average negative earning surprise trail quarters meanwhile revenue rise year year marginally miss zack consensus estimate first quarter zack consensus estimate earning be peg cent same revenue be reflect year year growth cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotelet dig deeper system sale focusin last report quarter segment account total revenue revenue segment totale year year management upside be attribute growth license software moreover full year system sale revenue grow margin increase first quarter zack consensus estimate segment revenue be pin year year other factor playehr prospectscerner electronic health record ehr platform have majorly trigger growth lately company witness slew development ehr platform cerner millenium ehr have be choose be implement new cerner health deployment model texas base menninger clinic cerner be also select illinois rural community care organization ircco implement cerner healtheintent accountable care organization notably healtheintent play significant role drive cerner earning last report quarter company end year healtheintent client resultantly population health booking grow revenue rise furthermore last report quarter company witness record booking growth more be attribute latest ehr deal booking come outside core millennium install base support maintenance servicein last report quarter segment account whopping total revenue revenue segment come year year basis line management expectation first quarter zack consensus estimate revenue segment be peg reflect rise year year guidance solidcerner expect first quarter revenue adjust earning share be project range cent revenue be forecast band full year adjust earning share be estimate range new business booking first quarter be expect range decline margin high debtin last report quarter operate margin come contract basis point bps year year basis downside be cause year year surge operate expense rise be drive personnel expense related revenue generate associate cash item additionally long term debt amount end quarter quantitative model do not conclusively show beat cerner earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cerner be uncover best stock buy sell re report earning esp filter earning esp filter zack rank cerner carry zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
198,SYK,cardinal health inc cah free report third quarter fiscal result be schedule release market open result be likely show decline core pharmaceutical segment growth other segment be likely make partially second quarter fiscal company report adjust earning share prior year quarter also zack consensus estimate revenue come year year basis outpace consensus estimate notably cardinal health have negative average earning surprise trail quarters zack consensus estimate third quarter earning be peg reflect decline year year same revenue be pin indicate growth cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotelet delve deeper pharmaceutical segment focusin last report quarter segment account enormous company revenue revenue segment come year year basis segment witness strong growth specialty business also gain huge number pharmaceutical distribution customer however see drop profit thank generic pharmaceutical pricing recent investment pharmaceutical platform lackluster generic program performance management growth segment be further impede expiration large mail order prime therapeutic current quarter zack consensus estimate revenue sequentially other factor playguidance liftedconsider benefit slash federal tax rate cardinal health raise fiscal outlook company expect adjust earning share continue operation compare previous range medical segmentin fiscal second quarter segment account company revenue revenue segment grow primarily drive patient recovery acquisition medical segment profit increase courtesy higher contribution new exist customer acquisition patient recovery business current quarter zack consensus estimate revenue segment be peg sequentially medical glove unitcardinal health offer robust portfolio medical glove include surgical glove exam glove clean room glove company have be lately face challenge exam glove sub segment last report quarter commodity pricing supply disruption be major draghunt section fiscal lower expectation medical segment due trouble exam glove segment raise concern quantitative model do not conclusively predict earning beat cardinal health earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cardinal health be uncover best stock buy sell re report earning esp filter zack rank cardinal health carry zack rank sell stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
199,SYK,have be pay attention share lemaitre vascular lmat free report share have be move stock past month lmat hit new week high previous session lemaitre vascular have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report february lemaitre vascular report ep versus zack consensus estimate miss consensus revenue estimate current fiscal year lemaitre vascular be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricslemaitre vascular be week high right now future hold lmat key aspect question be take look valuation metric order determine company be due pullback level front look zack style score provide investor additional way sort stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style lemaitre vascular have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective lemaitre vascular inc price consensus lemaitre vascular inc price consensus lemaitre vascular inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately lemaitre vascular currently have zack rank buy thank rise earning estimate recommend investor select stock carry zack rank strong buy style score look lemaitre vascular fit bill thus seem lmat share have potential week month come do lemaitre vascular stack competition share lemaitre vascular have be soar company still appear be decent choice rest industry industry peer be also look good include stryker corporation syk free report icu medical icui free report idexx laboratory idxx free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news lemaitre vascular still fundamental lmat be promising still have potential be week high
200,SYK,perkinelmer inc pki free report first quarter result expect release apr market close be likely show steady growth core diagnostic business prove be major driver decline revenue other segment mar overall result fourth quarter fiscal company report adjust earning cent share beating zack consensus estimate cent meanwhile revenue be approximately beat zack consensus estimate revenue also surpass year quarter notably first quarter zack consensus estimate earning be peg cent reflect year year growth same revenue be pin indicate growth perkinelmer deliver average positive earning surprise trail quarters perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotelet dig deeper diagnostic revenue focusdiagnostic revenue account total revenue last quarter revenue segment rise year also reflect improvement organically segment have be fortify company market position term exclusiveness service respective market diagnostic market company offer product be used detect genetic disorder perkinelmer also provide digital ray flat panel detector infectious disease testing solution diagnostic portfolio first quarter result be likely indicate strong growth diagnostic revenue last report quarter operate profit margin segment percentage revenue be basis point bps year year be also encourage note zack consensus estimate diagnostic segment be sequentially other factor playeuroimmun buyout divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion euroimmun buyout approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing space management euroimmun buyout have expand perkinelmer capability help gain considerable traction have lead increase diagnostic employee more strengthen company platform company be optimistic increase spending be likely account product revenue fourth quarter euroimmun contribute revenue approximately represent growth be also likely add bps perkinelmer organic growth discovery analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da lately company have collaborate helix develop commercialize sequence base test help consumer take proactive health management decision however zack consensus estimate revenue be sequentially guidance company issue adjust earning guidance adjust earning be expect share further expect report revenue range include approximately foreign exchange tailwind euroimmun perkinelmer project organic revenue growth thus perkinelmer be confident improve growth trajectory first quarter quantitative model show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
201,SYK,only handful player have release number so far earning season expect first quarter see strong revenue reflect solid upward trend estimate revision meanwhile back back event quarter have rattle global economy first be china trade war chaos then come tech backlash stem facebook fb datum fiasco finally chemical attack syrium pave way fresh trouble america russia furthermore apprehension related further rate hike fed continue do round be medical device safe haven be say stock market run sentiment unforeseen event particular sector have ripple effect other go notion medical device sector broader medical universe have proven be refuge investor shrug ongoing tension sector have return year date significantly higher return be medical device company have be ride high innovation increase consolidation focus emerge market tax abolition fact latest earning preview give encourage picture broader medical space expect register year year earning growth revenue growth so rather be interesting see medical device company be place ahead report cycle be major factor shape release growth driversgo cision report unite state be largest medical device market world rake more revenue have be very profitable investment space late consider agee population change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment medical device sector appear be pink health here be latest headline space taxe abolish bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have encourage massive investment sector digital revolution take medtech latest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space have be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity evidently company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late buyout rushlately health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer base moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script esrx cigna follow just month drug chain pharmacy giant cvs health corp cvs announcement plan acquire nation third largest health insurer aetna be important becton dickinson company bdx takeover bard be also worth mention zack methodology rescuegiven existence number player medical device industry find right stock have potential beat earning banking factor quite intimidate task proprietary zack methodology however make fairly simple narrow choice focuse specifically medical instrument medical product stock specialize chunk medical device subcategory sport desirable combination positive earning esp favorable zack rank strong buy buy hold earning esp be proprietary methodology determine stock have best chance surprise next earning announcement provide percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high go criterion hereby present stock be poise beat estimate quarter picksedward lifescience corporation ew free report headquarter irvine edward lifescience deal product technology aim treat advanced cardiovascular disease especially structural heart disease critically ill patient company strong pipeline product solid performance deliver tavr market bolster confidence stock edward lifescience higher operate expense have make investor apprehensive be respite fund be used adopt advanced initiative drive overall sale edward lifescience report first quarter result apr market close believe company be set beat zack consensus estimate have zack rank earning esp hologic inc holx free report headquarter bedford hologic develop manufacture supply diagnostic medical imaging system surgical product cater healthcare need woman company be focuse mammography system breast examination osteoporosis assessment company release result second quarter fiscal market close hologic zack rank earning esp raise possibility beat quarter meanwhile see complete list today zack rank stock here stryker corporation syk free report headquarter kalamazoo mi stryker be world largest medical device company operate orthopedic market mako be stryker robotic arm assist surgery platform provide predictable surgical experience perform joint replacement surgery recently stryker launch robotic arm assist total knee arthroplasty application use mako system notably be first only robotic technology be used total knee hip partial knee replacement procedure notably mako total knee utilize stryker robotic platform triathlon total knee system guide ct base modele bone anatomy system also allow intra operative plan assist bone resection procedure stryker report first quarter result apr market close believe stryker be poise trump zack consensus estimate have encourage combination zack rank earning esp teleflex incorporate tfx free report headquarter wayne pa teleflex develop manufacture supply single use medical device common diagnostic therapeutic procedure critical care surgical application worldwide company strong focus high flow nasal cannula therapy hfnct be likely lend competitive edge niche space solid growth preload microbial thrombogenic vps piccs platform be likely strengthen vascular platform surgical segment new product efx ae fortify company foothold finally company flagship lma unique product strengthen anasthesia product line company be expect report first quarter result expect earning beat stock have zack rank earning esp hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
202,SYK,sale growth be important metric company be vital part growth projection instrumental strategic decision make provide insight product demand pricing power monitoring key metric multiple time period easily understand company growth trend sale growth be important justify fix variable expense incur operate business low revenue lead unprofitable business disappointing financial performance stagnant company generate term profit rev enough growth attract new investor also grow economy lack sale growth most likely denote company be not gain market share competitor simple term sustain sale growth be essential support bottom line focuse solely sale growth be not enough healthy sale growth rate be certainly positive indicator pick good stock do not ensure profit so take consideration company cash position sale number prove be more dependable strategy substantial cash hand steady cash flow give company more flexibility respect business decision potential investment cash also enable company endure market downturn most importantly sufficient cash position indicate revenue be be channelize right direction pick winning stocksin order shortlist stock have witness impressive sale growth high cash balance have select year historical sale growth greater industry cash flow greater main screening parameter sale growth cash strength be not absolute criterium select stock so add certain other factor arrive winning strategy price sale ratio less industry metric determine value place dollar company revenue lower ratio better be pick stock investor be pay less unit sale change sale estimate revision week greater industry better industry estimate revision have often be see trigger increase stock price operate margin average last year greater operate margin measure much dollar company sale translate profit high ratio indicate company have good cost control sale be increase faster cost optimal situation company return equity roe greater metric ensure sale growth be translate profit company be not hoard cash high roe mean company be spending wisely be likelihood profitable zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment see complete list today zack rank stock here here be stock qualify screening base lincolnshire il zebra technology corporation zbra free report design manufacture sell range automatic identification datum capture product expect sale growth rate current year be stock sport zack rank tyson food inc tsn free report operate food company springdale ar base company expect sale growth rate fiscal be carry zack rank stryker corporation syk free report headquarter kalamazoo mi operate medical technology company current year expect sale growth rate be stock carry zack rank headquarter southfield mi lear corporation lea free report design develop engineer manufacture assemble supply automotive seating electrical distribution system related component company expect sale growth rate be carry zack rank progressive corporation pgr free report provide personal commercial auto insurance residential property insurance other specialty property casualty insurance related service mayfield village base company sale be expect grow rate stock have zack rank base new york interpublic group company inc ipg free report offer advertising marketing service company have expect sale growth rate current year carry zack rank headquarter los angele cbre group inc cbre free report be commercial real estate service investment company company have expect sale growth rate carry zack rank get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
203,SYK,stryker corporation syk free report neurotechnology spine division have be perform consistently well last quarters expect shape first quarter result be schedule release apr click here here know company overall performance be expect be neurotechnology drive resultsof late neurotechnology spine segment have be witness strong demand product target coil ais cmf neuro power instrument further spine business have be ride high demand ivs print interbody tritanium product stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation first quarter zack consensus estimate neurotechnology spine revenue be peg show increase year year basis last report quarter segment deliver sale year year cc organic growth reflect continue strong demand company product segment here take sneak peek major sub segment neurotechnology spine be poise gain quarter be report spine sub segment stryker deliver advanced technology deformity mis degenerative interventional spine procedure major product spine unit aero al anterior lumbar interbody fixation system acculif pl acculif tl expandable tlif technology es spinal system deserve mention notably es spinal system be stryker latest spinal fixation system lite platform recent past stryker acquire french company vexim portfolio be highly compatible company interventional spine ivs business management remain commit spine division foresee further investment segment current year zack consensus estimate segment current quarter revenue be pin reflect year year increase neurotechnology be combination stryker spinal neurovascular cranial product service segment solid contribution expand customer base have lend company competitive edge medtech industry stryker neurotechnology product include universal neuro iii target detachable coil many more zack consensus estimate segment current quarter revenue be show year year rise zack rank other stock considerstryker carry zack rank buy other top rank stock broader medical space be bio rad laboratory bio free report myriad genetic inc mygn free report abiom inc abmd free report bio rad laboratory sport zack rank strong buy have long term expect earning growth rate see complete list today zack rank stock here myriad genetic have long term expect earning growth rate stock carry zack rank abiom have long term expect earning growth rate stock carry zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
204,SYK,stryker corporation syk free report first quarter result be schedule release apr market close company acquisition drive strategy be expect boost growth expand exist product offering business segment expect company witness steady growth orthopaedic implant sale major revenue component be project drive first quarter earning expect improvement revenue other segment especially medsurg help company generate impressive result notably last quarter stryker post earning share beat zack consensus estimate penny current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg indicate increase year year let delve other factor be likely impact skryker first quarter result orthopaedic implant focus mako implant contribute net revenue last quarter zack consensus estimate orthopaedic implant stand reflect rise year year recently stryker introduce robotic arm assist total knee arthroplasty application use mako system notably be first only robotic technology be used total knee hip partial knee replacement procedure notably mako total knee utilize stryker robotic platform triathlon total knee system guide ct base modele bone anatomy stryker system enable intra operative plan assist bone resection procedure fourth quarter mako total knee platform drive stryker earning mako robot installation totale globally unite state additionally company have first robot sale japan approval mako be expect end company exit mako robot install unite state stryker corporation price consensus stryker corporation price consensus stryker corporation quoteother factor playmedsurg unit drive growthmedsurg equipment product include surgical equipment surgical navigation system endoscopic communication digital imaging system well patient handle emergency medical equipment last quarter management announce medsurg high growth segment zack consensus estimate medsurg endoscopy revenue surge year year acquisition drive strategystryker have be follow acquisition drive strategy drive growth recently stryker acquire entellus medical inc cash transaction share equity value approximately enable physician conveniently perform broad range ent procedure late stryker acquire vexim specialize development sale vertebral compression fracture solution vexim flagship product be spinejack system mechanical expandable vcf implant fracture reduction stabilization vexim portfolio be highly complementary interventional spine business stryker stryker instrument division include extensive innovative portfolio vertebral augmentation vertebroplasty radiofrequency ablation procedure diagnostic tool decompression treatment advance contain disc herniation lower demand healthcare productsstryker persistently face challenge lower demand health care product additionally company spine business unite state be plague supply issue fourth quarter fact stryker expect face headwind be report quarter company have be face challenge economic condition particularly unite state western europe additionally lower reimbursement medical product service impose downward pressure price company product longer sale cycle slower adoption new technology ultimately impact top line model predictsour quantitative model predict earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible other stock worth lookhere be few other medical stock worth consider also have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
205,SYK,edward lifescience corporation ew free report have be gain investor confidence consistently positive result past month stock have gain industry decline also company have outperformed increase manufacturer tissue heart valf repair product used replace repair patient diseased defective heart valve have market cap company historical year growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment style score edward lifescience have growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential let find recent positive trend be sustainable impressive long term growth strategy last december edward lifescience announce outlook focuse long term growth technology pipeline thv edward lifescience expect maintain leadership position global tavr market enhance focus expand patient access actively leverage current valve platform additional indication develop next generation valve platform maintain trust relationship clinician payer regulator long term edward lifescience expect generate organic underlie sale growth meaningfully higher rate industry average margin front company anticipate moderate expansion gross margin improve mix partially offset capacity investment solid global prospectswe believe huge untapped potential emerge market be likely act positive catalyst edward lifescience management be strive strengthen foothold market asia especially japan management continue believe japan hold immense prospect business expansion major emerge nation launch sapien valve japan edward lifescience gas see strong adoption device nation company be look forward launch inspiris resilium aortic valve japan product pipeline development trackwe be encourage edward lifescience focus build pipeline strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy latest development edward lifescience recently announce clinical trial sapien ultra system management expect receive ce mark ultra system second half moreover edward lifescience new ultra system include balloon delivery system next generation sheath technology be expect be available unite state late other key pickssome other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
206,SYK,bioscrip inc bio free report have be gain investor confidence consistently positive result past month company stock have outperformed industry stock have gain compare industry company have also outperformed gain market well lead pure play infusion service provider have market cap solid prospect zack rank buy stock be attractive pick investor moment company earning estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly estimate loss share have narrow cent cent zack style score system bioscrip have growth score reflect company solid prospect research show stock growth style score combine zack rank strong buy offer best upside potential let find recent positive trend be sustainable core turnaround plan bode wellwe be upbeat bioscrip bio free report progress last report quarter courtesy multus faceted core plan improve financial position company launch core initiative plan represent focus identify execute strategy accelerate bioscrip core revenue growth mix drive operational efficiency improve revenue collection increase employee effectiveness organization end first quarter company announce be track achieve goal core revenue mix register core mix quarter grow infusion have be record consistent growth core infusion service business enjoy competitive advantage solid growth business have be primarily account strong organic growth particularly chronic nutrition other therapy order boost infusion service business bioscrip have take number step sale legacy specialty mail service pharmacy sale home health service business divestment pbm business effort expand business look healthcare landscape change rapidly bioscrip have be focuse recent year grow core infusion service platform clinically focuse customer orientated model company focus be drive growth core infusion service be also engage aggressive reduction cost currently company aim emerge smaller more focuse organization significantly improve profitability improve operate cash flow other key pickssome other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
207,SYK,market capitalization approximately medical group wmgi free report have be ride high grow orthopedic market launch new product perform reversed glenoid ortholoc di simpliciti shoulder system however pricing pressure continue trouble medical higher cost related product launch re build infrastructure be expect keep margin pressure problem associate distributor be headwind fiscal zack consensus estimate revenue be currently peg reflect increase year year however zack consensus estimate be peg loss cent stock have zack rank hold here take quick look major factor have be plague medical discuss prospect ensure term recovery medical group price consensus medical group price consensus medical group ex wo plague medicalwright medical derive significant portion revenue international operation be affected fluctuation foreign currency exchange rate foreign exchange wo have be materially impact company international revenue gross margin last quarters hold medical international net sale be expect grow high single digit constant currency basis drive consistent performance biologic acceleration upper extremity growth further company have significant presence key emerge market asia further enhance prospect overall outlook global orthopedic device market be look datum technavio global niche market be expect witness cagr medical top line growth be support series new product launch include internally develop product acquisition company be also investing medical education training program update doctor regard benefit newly launch offering recent development ongoing launch perform reversed glenoid expand blueprint surgical plan module deserve special mention furthermore medical launch invision total ankle revision system be first system develop total ankle revision arthroplasty management perform reversed launch boost revenue price medical have outperformed industry past month notably company share have gain industry decline current level be also higher index riseof key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
208,SYK,medical product industry have be see steady growth late ever increase grey population long life expectancy increase demand technologically superior medical device industry have also gain recent deferral medical device tax accord article publish xtalk medical device tax be responsible reduction spending decline overall sale thus company expect ramp spending likely lend competitive edge long haul baxter international bax free report stryker corporation syk free report be close contender medical product space notably stock carry zack rank buy see complete list today zack rank stock here here make detailed analysis company fundamental determine stock be currently better position market cap baxter be global medical technology company meanwhile michigan base stryker be largest medical device company operate global orthopedic market company have market cap factor drive stocksstryker robotic arm assist mako surgery platform have be consistently drive top line last report quarter platform record new robot installation globally robust demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be major positive price share rally year time edge past stryker return medical product industry return same time frame estimate zack consensus estimate baxter current year earning share be peg year year consensus mark stryker current year earning be pin reflect improvement year year baxter international inc price consensus baxter international inc price consensus baxter international inc solid growth projection clearly show baxter winner here zack consensus estimate baxter current year revenue be peg year year same stryker be pin call growth stryker corporation price consensus stryker corporation price consensus stryker corporation quotethus stryker have competitive edge current year sale estimate be take consideration fundamental growth storyin year time baxter earning share witness negative cagr totale however stryker earning have see cagr time frame come past year baxter revenue have register negative cagr totale stryker revenue have see cagr totale here too stryker win baxter conclusionour comparative analysis indicate stryker be position better baxter consider current year sale expectation fundamental other key picksa couple other top rank stock broader medical space be genomic health ghdx free report inogen inc ingn free report genomic health have expect earning growth rate stock flaunt zack rank inogen have expect long term earning growth rate sport zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
209,SYK,quest diagnostic inc dgx free report be schedule report second quarter earning performance open bell jul last report quarter company earning be line zack consensus estimate however metric outperformed consensus mark trail quarters average beat let take look thing be shape prior announcement factor playon positive note quest diagnostic seem well align growth agenda accelerate growth drive operational excellence new long term growth outlook revenue increase period be expect be growth project acquisition earning period be anticipate rise faster top line mid high single digit range quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate company estimate revenue growth period company increase number partnership other health care leader strategic acquisition be create promising opportunity top bottom line growth improve patient experience reduce overall cost care first quarter company satisfied element mentioned growth agenda strongly expect continue momentum go forward go first element growth strategy inch strategically accretive acquisition company achieve upside fifth consecutive year regard recent buyout mobile medical examination service medxm fortify quest diagnostic mobile provider capability population health management solution health plan transaction further garner favorable result yet be report quarter accounting second element growth strategy expand relationship hospital health system april quest diagnostic other lead health care organization namely humana multiplan unitedhealth group optum launch pilot program apply blockchain technology improve datum quality reduce administrative cost associate change health care provider demographic datum march company enter professional lab service agreement integrate healthcare delivery system new england consider third element company growth strategy offer broadest access diagnostic innovation key growth driver second quarter be prescription drug monitoring quantiferon invasive prenatal screening be also optimistic company successful execution strategy build esoteric testing business well boost profitability fourth element growth strategy be act provider choice consumer company relationship walmart have already start add value higher patient traffic positivity be expect soon find reflection second quarter earning performance walmart location be help quest diagnostic expand different market company expect open many more location ongoing year fifth element quest diagnostic growth strategy be support population health analytic extend care service accord company inclusion medxm be allow close gap patient healthcare professional expect active growth driver replicate company success story upcoming quarterly result also performance be likely drive same primary metric precede quarter strongly believe recent development have significantly contribute company top line second quarter company expect revenue range annualize growth zack consensus estimate same be peg slightly company project band exclude impact special item amortization expense etb excess tax benefit associate stock base compensation adjust ep full year be project be zack consensus estimate fall guide range flip side persistently dull several quarters company revenue requisition performance last quarters see slim rebound however still remain be see upside be here stay not company professional lab service engagement wj barnabas health healthone system hca holding inc hca also carry lower revenue requisition due nature work further take consideration unrelenting headwind unit price be moderately less basis point exclude effect protect access medicare act pama company expect unit price headwind remain basis point pama add extra headwind approximately basis point also get highlighted impending quarterly result overall believe dearth employment slow growth commercially insure life continuously dent company volume measure number requisition economy recover model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp quest diagnostic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning be report quarter uncover best stock buy sell re report earning esp filter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision other stock worth lookhere be few other medical stock worth consider right combination element surpass estimate time resm inc rmd free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank mckesson corporation mck free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
210,SYK,abbott laboratory free report establish pharmaceutical division epd business have be record operational sale growth last few quarters expect strength further get reflect second quarter result schedule release jul click here know company overall performance be likely pan key epd business majorly focus emerge market key area include india russia china numerous region latin america well brazil other country sale key emerge market increase organically drive double digit growth india china brazil last report quarter abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteper company key emerge market represent most attractive long term growth opportunity abbott brand generic product portfolio management believe market continue offer immense opportunity favorable demographic accordingly zack consensus estimate epd revenue key emerge market indicate rise year quarter tally favorable currency translation also left positive impact epd revenue first quarter moreover be encourage note management expect foreign exchange continue act tailwind be report quarter however management seem concern decelerate revenue growth rate epd russia due temporary disruption distribution channel dynamic base certain distributor consolidation company continue second quarter too also ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect sale performance china term overall be upbeat management anticipation double digit organic growth epd sale second quarter furthermore zack consensus estimate epd revenue show increase prior year period epd abbott consistent focus enhance local capability expand product portfolio core therapeutic area be aim specifically address local market need effort company also continue consolidate leadership position epd market abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia have contribute epd business zack rank stock considerabbott carry zack rank hold here be few medical stock worth consider same space comprise right combination element beat earning time resm inc rmd free report have earning esp zack rank strong buy see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank mckesson corporation mck free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
211,SYK,abbott free report medical device business have be go strong late solid sub segmental performance expect strength get reflect second quarter result be schedule release jul market open click here know company overall performance be expect be medical device focusabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotemanagement expect mid high single digit growth medical device second quarter sale continue double digit growth certain sub segment consequently zack consensus estimate medical device revenue unite state indicate rise year quarter internationally consensus estimate show growth last quarter sale improvement segment be drive double digit growth neuromodulation diabetes care moreover company receive approval few product achieve clinical trial milestone let see thing be shape sub segment second quarter result account medical device revenue have be gain strongly recent launch confirm insertable cardiac heart monitor unite state europe furthermore continue uptake ensite precision cardiac mapping system be expect contribute strongly top line second quarter abbott strengthen position business successive receipt fda ce mark new advisor hd grid mapping catheter company have launch product country then currently await commercial launch unite state zack consensus estimate revenue indicate increase year company be expect keep gain strength business last report quarter company witness impressive sale growth heart failure business solid uptake recently launch heartmate system unite state zack consensus estimate heart failure business revenue indicate rise year quarter provide impetus vascular total medical device revenue business unite state abbott recently announce receipt fda approval xience sierra encouragingly note vascular business company have see slew development regard xience sierra coronary stent system company also achieve national reimbursement xience sierra company have also be get positive response xience sierra coronary stent system post launch europe zack consensus estimate vascular revenue show improvement year quarter structural heart business have maintain impressive top line performance last report quarter business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip march abbott announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart positive development be expect boost top line contribution sub segment be report quarter estimate structural heart revenue also indicate rise year quarter diabetes care international sale growth prior quarter be drive abbott freestyle libre company recently initiate launch freestylelibre unite state well proceed initiative boost arm company announce availability freestyle librelink app europe use smartphone iphone android zack consensus estimate diabetes care revenue indicate surge year quarter meanwhile be upbeat abbott kick start receipt fda approval magnetic resonance mr conditional labele quadra assura mp cardiac therapy defibrillator crt fortify assura implantable cardioverter defibrillator icd company most widely used high voltage medical device approval come heel recent mr conditional labele approval assurity mri pacemaker ellipse icd associate mri compatible lead development be expect boost rhythm management business consensus estimate rhythm management revenue show improvement year zack rank stock considerabbott carry zack rank hold better rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
212,SYK,abbott free report be slate report second quarter result market open jul last report quarter company earning share exceed zack consensus estimate moreover abbott deliver positive surprise trail quarters average beat be let see thing be shape announcement factor playover past few quarters abbott have be ride high healthy growth diabetes care business company have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system recent datum number libre user now have reach globe represent unprecedented level patient adoption industry have firmly boost company top line number recent quarters momentum continue second quarter too produce impressive result period company expect see significant growth contribution line recently launch product portfolio zack consensus estimate diabetes care revenue indicate surge year quarter sync prior quarter abbott be anticipate gain strong performance establish pharmaceutical division epd business have be record operational sale growth last few quarters management expect sale rise high single digit second quarter furthermore zack consensus estimate epd revenue show increase year earlier period abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotewe be also upbeat consistently sturdy diagnostic business courtesy solid contribution sub segment namely core laboratory diagnostic molecular diagnostic point care moreover synergy draw alere buyout form revenue rapid diagnostic have be benefit company additionally management estimate rapid diagnostic contribute zack consensus estimate core laboratory diagnostic revenue depict gain comparable quarter last year encouragingly note nutrition be abbott fastest grow business owing age population increase rate chronic disease rise middle class emerge market furthermore abbott pediatric nutrition business continue be robust unite state thus zack consensus estimate nutrition revenue translate improvement year quarter figure favorable currency translation also have positive impact company top line first quarter be also optimistic management expectation foreign exchange appear aid result be report quarter drive revenue turn overall second quarter total revenue be project prior year period model suggestsper zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter abbott have zack rank increase predictive power esp however earning esp make surprise prediction difficult zack consensus estimate earning cent reflect growth year year stock worth lookhere be few medical stock worth consider same space comprise right combination element beat earning time resm inc rmd free report have earning esp be rank stock see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank mckesson corporation mck free report have earning esp stock be zack rank player more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
213,SYK,stryker corporation syk free report be underperform company medtech space past month share company have lose compare industry decline challenge global economic condition supply side issue fluctuation foreign currency exchange rate strengthen dollar major headwind stryker top line growth past day zack consensus estimate earning share drop consequently company have zack rank sell indicate expectation term thus be right time offload stock portfolio offload fall marginsin fourth quarter adjust gross margin come flat year year management gross margin be affected productivity issue associate continue recovery puerto rico manufacturing facility operation facility be disrupt thank natural calamity further unfavorable pricing dent margin stryker corporation price consensus stryker corporation price consensus stryker corporation quoteoperate margin quarter be net sale basis point year quarter decline demand healthcare productsstryker be currently face low demand healthcare product fourth quarter company spine business unite state witness supply issue be expect remain larger part global economic condition western europe be unfavorable moment acquisition long stryker have be follow acquisition strategy lately company close acquisition minnesota base entellus medical enhance revenue opportunity add integration risk putt margin pressure furthermore company be laden high debt add wo key picksa few top rank stock broader medical sector be pharm bhvn free report bio rad laboratory inc bio free report centene corporation cnc free report stock sport zack rank strong buy see complete list today zack rank stock here re have expect growth rate current quarter growth rate next quarter bio rad have expect long term growth rate current year be centene have expect long term growth rate current year be zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
214,SYK,technological progress have be constant decade make life easier currently global mantra success be adapt upgrading trend technology latest craze digital world be printing open new avenue different sphere application start automobile healthcare also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub reebok latest liquid floatride run footwear feature print lace switch bigwig porsche bugattus printing manufacturing rare complex part phenomenon have spread far wide research firm market market expect printing market grow value cagr printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr let delve detail printing have be create new opportunity medtech investor be keen putt money healthcare space longer term gain printing change medtech landscapegrow prominence innovative printing solution have lend mida touch medtech space fda well healthcare professional be fast adopt technology enhance long term patient outcome encouragingly note materialise nv mtls free report be first company receive fda approval software design printing anatomical model diagnostic use major sub industry be try utilize resource come best burgeon printing market have zero be make most trend orthopedic implant device manufacturer be switch printing technique cater rapidly grow demand customize implantable device printing manufacturer be be able develop implant customize size shape short time improve efficacy lower overall cost surgery research firm future market insight expect orthopedic implant market reach worth cagr accord report publish cision pr newswire here appreciate zimmer biomet holding inc zbh free report fda approve unite bridge fixation system quebec city base bodycad texas base web medical be lead name print implant technology space hearing aid device printing be fast take hearing aid device market be expect see cagr orbisresearch com report publish reuter printing enable manufacturer develop device base image defective ear canal sonova hold ag lead provider hearing solution have be actively used printing come next generation hearing aid device company customize titanium print hearing aid deserve mention here dental implant printing be also gain popularity dental industry allow dentist carry procedure more precision efficiency save patient excess trauma notably dental printing be process create dimensional solid dental model such implant surgical guide brace denture crown bridge research firm transparency market research expect global dental printing market see cagr reach value global leader high accuracy dental printer material envisiontech have be actively strengthen hold niche market company recently announce launch orthodontic material lmt lab day chicago stock focuswe have select company believe be well poise provide impressive long term return banking printing trend stryker corporation syk free report have be early adopter printing technology company fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation zack rank hold company have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate increase share see complete list today zack rank strong buy stock here stryker share price movement past month have be favorable company yielded return almost better industry orthofix international ofix free report recently announce fda approval limit market launch forza xp expandable spacer system system consist print porous titanium endplate enable patient bone grow porous plate zack rank company have long term earning growth rate company have deliver positive earning surprise trail quarters average earning beat be past month share orthofix have outperformed industry belong stock have gain compare industry rise conformis inc cfms free report be currently used ifit image implant technology printing platform manufacture ijig furthermore conformis be plan use same make certain component customize knee replacement implant notably company receive fda approval use ifit printing technology manufacture metal femoral implant component itotal cr used direct metal laser sintering zack rank company have long term earning growth rate growth score current year estimate revision trend stock have be encourage estimate move upward compare downward movement past month company have deliver positive earning surprise trail quarters average earning beat be past month share conformis have outperformed industry belong stock have gain compare industry rise go article stratasys medtronic plc mdt free report adopt printing technology concept testing technological development rapid prototyp anatomical modele development test fixture application end technology have result lower project cost faster process time zack rank company have long term earning growth rate company have deliver positive earning surprise trail quarters average earning beat be past month share medtronic have outperformed market stock have gain compare decline conclusiona say strike iron be hot be opportune time cash rapidly rise printing trend investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
215,SYK,point person life need assist medical device age have hip replacement knee replacement pacemaker current context nothing appear be more apt remark make aimee mullin american athlete consider grow prominence orthopedic industry seem prosthetic generation be indeed new market intelligence report bis research publish cision global orthopedic device market be worth be estimate be worth end cagr joint reconstruction replacement device segment be highest revenue generator north america have highest share orthopedic device market be expect lead same encouragingly asia pacific be also estimate catch cagr niche space grand view research report publish becker healthcare thus investor be keen place bet healthcare space long term gain orthopedic market undoubtedly hold immense potential here take look major factor have be drive global orthopedic industry last couple year major market moversagee populaceone major factor drive orthopedic market be age population report publish global market insight population be expect be globally poor life stylepoor eating habit smoking drink lack physical activity also drive demand orthopedic market rise healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand report center medicare medicaid service publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue rise incidence diabetesdiabete obesity also fuel growth market globally diabetes market be expect touch cagr transparency market research report positive tiding regulatory orthopedic market be ride high recent fda nod product launch zimmer biomet holding inc zbh free report reach new milestone field total shoulder arthroplasty recent fda approval sidusstem free shoulder system furthermore company launch vitality vital spinal fixation system unite state global launch persona partial knee system nuvasive inc nuva free report announce receipt fda clearance company precice system nuvasive specialize orthopedic nso further nephew snn free report announce full commercial release cruciate retain journey ii xr total knee arthroplasty tka unite state japan recently robotic surgery boost technology company be try expand robot rather complex surgery report technavio global orthopedic surgical robot market be estimate witness cagr view abovemention factor number bigwig be spending lump sum continuously innovate develop device improve efficacy side effect regard most noteworthy be stryker corporation syk free report mako be stryker robotic arm assist surgery platform recently stryker launch robotic arm assist total knee arthroplasty application use mako system medical device major johnson johnson jnj free report recently announce acquisition orthotaxy be privately hold developer software enabled surgery technology include differentiate robotic assist surgery solution printing technology orthopedic device company be try leverage be printing report future market insight publish cision orthopedic implant application category global print medical device market be expect be worth time frame cagr regard stryker tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation device recently win fda nod stock focuswe have select company believe be well poise give encourage prospect orthopedic market stryker corporation company have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate increase share company year historical growth rate be also favorable compare industry stryker share price movement past year have be favorable company yielded return almost better industry orthofix international ofix free report company have long term earning growth rate company year earning growth rate also compare favorably past month share orthofix have outperformed industry belong stock have gain compare industry rise company recently announce fda approval limit market launch forza xp expandable spacer system johnson johnson company have long term earning growth rate estimate revision current year have be solid estimate move upward compare movement opposite direction past month resultantly consensus estimate increase share company year historical growth rate also compare favorably industry share have increase past month compare favorably increase witness industry more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
216,SYK,medical device tax suspension jan be very few amendment have garner maximum number bipartisan vote house enactment tax have be quite menace medical device industry statement advanced medical technology association lobbying group tax have significant negative impact medical innovation employment consider house place suspension tax january december only bring back jan recently house come bill tax cut include abatement infamous medical device tax medtech fraternity have be cheer latest repeal share price net margin performance medical device manufacturer be show different story let delve deeper glitzy be repeal medtech innumerable report claim repeal ramp domestic production increase hire skilled professional lower nation overdependence offshore production further medtech bigwig be expect enhance improve margin launch product reduce capital depreciation invest early stage medtech company execute clinical trial turn fuel next generation medical device industry reinvest profit tax saving notably johnson johnson jnj free report shell lump sum medical device sale tax meanwhile medical device giant stryker corporation syk free report report net earning paid approximately medical device excise tax nearly earning datum med device online report tax didn exist analyst believe company have used cash expand improve pipeline draw heavy criticism compelling democrat republican lift tax history say different storysince tax be abolish end company be expect rake profit also put impressive show bourse start however price performance margin trend contradict expectation fact tax repeal news create quite stir analyst back deal blow share medical device manufacturer datum show broader medical product industry have underperform market last year industry cut sorry figure comparison here take sneak peek net margin trend company last tax repeal single metric determine profitability business accurately investor count net margin get fair idea amount profit company be make decline net margin post tax repeal amendment throw light enormous risk cost associate compliance requirement medtech manufacturer also raise question tax repeal provide impetus medtech space do nothing significant year back stock grapple decline price net marginhere have medtech stock have witness significant margin contraction tax repeal draw attention share price net margin performance company follow tax abolition past year medtronic plc mdt free report have be observed underperform broader market latest share price movement stock lose compare unfavorably gain company have be face escalate cost expense be weigh margin also company reiteration guidance projection favorable foreign currency translation fail lift investor spirit past year henry schein inc hsic free report have underperform index stock have lose be disappoint continue deterioration company gross operate net margin thank higher cost sale expense also tough competitive landscape pricing pressure weigh stock healthcare product service distribution industry be highly competitive consist principally national regional local distributor north american dental product market company face stiff competition patterson dental business patterson company inc benco dental supply dentsply sirona inc xray free report share price movement have be disheartening past year company have lose period lackluster margin trend same time frame indicate company failure garner profit post tax repeal day comedentsply expect gross operate margin remain flat decline slightly level underlie margin rate improvement be expect be offset adverse foreign exchange target inventory equipment reduction allscript healthcare solution inc mdrx free report have underperform broader market term price past month notably stock have return compare rally further company margin have contract significantly past year allscript also expect modest increase operate expense company face sluggishness international market competition larger player bruker corporation brkr free report have underperform broader market term price past year stock have return just much lower market further company margin have decline steeply past year bruker conduct business international market result currency fluctuation continue result foreign currency transaction loss latest medtech tax overhaul paint different picture stock history repeat analysis clearly show broader industry hasn react positively tax repeal amendment be legislate consider repeal effect medtech space trend be expect continue time well however medtech industry have be favore massive change consumer behavior lately couple change market dynamic lead dramatic transformation healthcare system last couple year be evident rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model further strategic application artificial intelligence sphere healthcare provide boost productivity medtech space company have adopt ai technology witness reduction healthcare cost be expect record strong margin expansion well never know current favorable trend turn table medtech industry more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
217,SYK,align technology inc algn free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare industry company have also outperformed gain market well lead manufacturer marketer system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company earning estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate increase share further zack consensus estimate current year revenue reflect improvement year year zack style score system align technology have growth score reflect company solid prospect research show stock growth style score combine zack rank strong buy offer best upside potential let find recent positive trend be sustainable solid global prospectsalign technology have undertake several strategy drive adoption invisalign technology include product technology development extend clinical effectiveness extension invisalign technology brand drive international growth year year basis align technology international invisalign technology volume last report quarter be reflect continue strong performance emea apac region emea company witness solid adoption invisalign technology market ofiberium france well rapid growth smaller market eastern europe central europe benelux asia pacific region company deliver solid performance lead china japan australia expand invisalign portfolio align technology invisalign portfolio offer orthodontic treatment straighten tooth metal brace bid broaden flagship invisalign portfolio company recently announce addition invisalign first clear aligner treatment younger patient early mixed dentition company plan commercially launch offer invisalign trained doctor unite state canada australia new japan emea region start july same time company extend invisalign clear aligner range latest launch vivera retainer precision bite ramp solid development invisalign be likely lendalign technology competitive edge medtech space grow itero portfolioalign technology have be focuse expand work flow option lead itero scanner further align technology announce receipt china food drug administration cfda approval commercially launch itero element intraoral scanner china be also upbeat company expand itero element portfolio launch itero element itero element flex scanner unite state majority european country include france germany italy spain unite kingdom align technology also announce plan launch invisalign go product improve user interface itero digital chairside experience increase flexibility treat variety mild moderate case other key picksother top rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
218,SYK,abaxis inc abax free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare growth record industry also company have outperformed increase renown manufacturer portable medical human veterinary animal blood analysis system provide clinician rapid blood constituent measurement medical veterinarian market worldwide have market cap company historical year growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate increase share style score abaxis sport growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential let find recent positive trend be sustainable solid veterinary business animal health abaxis exhibit strong consumable growth last report quarter consumable product line total rotor revenue improve hematology reagent rapid assay also drive consumable revenue solid contribution flex rapid assay heartworm feline parvo test canine specific lipase revenue rapid assay be major contributor top line product launch boost growthwe be encourage note company be emphasize product innovation research development abaxis have be gain encourage response latest product urine sediment analyzer flex rapid assay notably january company receive approval usda center veterinary biologic vetscan flex rapid test veterinary business instrument product line abaxis recently introduce urine sediment urine chemistry analyzer company have also launch vetscan sa urine sediment analyzer recently sell unit product quarter end further abaxis plan connect sa urine sediment analyzer newly launch vetscan ua end first quarter fiscal apart sediment analyzer be connect vetscan fuse later management addition product look promising long haul impressive potential piccolo placement abaxis piccolo system be portable multiple routine test capability whole blood serum plasma sample company develop manufacture sell piccolo xpress chemistry analyzer use human patient care provide clinician rapid blood constituent measurement date abaxis piccolo be only point care technology deliver comprehensive diagnostic grade chemistry result minute visit window retailer target company be successfully selling piccolo instrument globally global basis abaxis sell piccolos fourth quarter fiscal compare year other key picksother top rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
219,SYK,market capitalization approximately varian medical system inc var free report have be ride high revenue opportunity grow adoption proton therapy strong overseas presence emerge country however cutthroat competition niche spaceis major headwind fiscal zack consensus estimate revenue be currently peg reflect increase year year notably zack consensus estimate earning be currently peg share show increase year year stock have zack rank hold here take quick look major factor have be plague varian discuss prospect ensure term recovery varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotefactor plague varian competition be expect increase expenditure grow proton therapy market keep margin pressure further varian medical compete large electronic company withsmaller more specialize radiation therapy equipment manufacturer thus cutthroat competition niche space be likely raise company expenditure term oncology business north america be witness drop capital expenditure account uncertainty emanate health care reform anticipate change reimbursement international sale percentage revenue areincreas higher demand lower margin product china india brazil be expect keep margin pressure next several quarters hold stock apart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian medical proton therapy fall particle therapy business recently company announce installation varian medical probeam cyclotron proton beam therapy center university college hospital london nhs foundation trust uclh london england cyclotron be core piece equipment probeam proton therapy system installation be key milestone new proton therapy center varian medical probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor thereby cause lesser side effect surround tissue proton therapy system same interface used thetruebeam platform recently varian medical have upgrade probeam system software probeam version enhance site provide better image generate system integrate imager upgrade product drive company market share go forward mar varian medical announce first patient treatment st petersburg proton therapy center russia important step expand access proton therapy world key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
220,SYK,mckesson corporation mck free report declare preliminary result first quarter fiscal company project adjust earning share range zack consensus estimate earning be peg be guidance company also reaffirm fiscal guidance mckesson expect adjust earning share zack consensus estimate be peg be guidance management fiscal outlook represent mid high single digit percentage growth year year indicate stable market condition free cash flow be expect guidance project full year adjust tax rate range vary quarter quarter mckesson corporation price consensus mckesson corporation price consensus mckesson corporation quotehowever follow announcement company share inched last trading session close not forget fourth quarter earning call management announce pharmaceutical specialty solution be expect deliver low mid single digit revenue growth management european pharmaceutical solution be likely deliver flat mid single digit revenue growth fiscal additionally medical surgical solution be expect deliver low double digit revenue growth past year share mckesson have decline industry rise current level be also lower index gain major factor drive resultsmckesson have be actively pursue deal divestiture acquisition drive growth recently company have sign definitive agreement acquire medical speciality distributor deal be expect close first half fiscal management expect deal expand company manufacturer value proposition specialty capability however company distribute generic pharmaceutical be subject price fluctuation distribution solution segment have experience weaker generic pharmaceutical pricing trend continue persist continue volatility unfavorable pricing trend reimbursement generic drug significant fluctuation nature frequency magnitude generic pharmaceutical launch have material adverse impact mckesson prospect zack rank key picksmckesson have zack rank hold few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
221,SYK,market capitalization approximately intuitive surgical inc isrg free report continue benefit grow adoption company da vinci system increase procedure volume consistent innovation solid recur revenue base however unfavorable foreign exchange procedure adoption risk lower capital spending hospital increase regulatory headwind be major concern fiscal zack consensus estimate revenue be currently peg reflect increase further zack consensus estimate earning be peg show rise stock have zack rank hold here take quick look primary factor have be plague intuitive surgical discuss prospect ensure term recovery intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc mar surgical have be enjoy monopoly market robot used abdominal surgery launch flagship device call da vinci back post regulatory approval transenterix surgical robot abdominal surgery competition intuitive surgical have intensified report suggest news have negative impact company price movement even device be not expect compete directly da vinci medtech giant medtronic be major threat source company have be work surgical robot plan launch hold da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand gesture be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery system have invasive surgery more patient worldwide recently da vinci surgical system have be observed cure patient diagnosed inguinal hernia company launch upgrade flagship vinci xi technology da vinci recently notably xi suite be design seamlessly integrate future innovation such advanced instrumentation surgical skill simulation software upgrade other advancement dynamic platform company now ship xi single site xi millimeter stapler firefly several country minimally invasive surgery be become increasingly popular help patient recover faster reduce hospital cost notably minimally invasive surgical instrument market be project reach worth cagr market market high price system hinder widespread adoption believe benefit minimally invasive surgery propelsurgeon patient use system drive company system sale improve top line growth long run favorable share price surgical have outperformed industry year time company share have surge almost industry decline current level be also higher index rise key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
222,SYK,becton dickinson company bdx free report also know bd recently complete acquisition texas base tva medical financial term deal have be keep wrapped post announcement share bd inched management transaction be not expect be accretive bd financial result fiscal past year company share have rally compare industry rise stock carry zack rank hold come back news tva medical develop minimally invasive vascular access solution patient chronic kidney disease require hemodialysis recent integration be likely boost bd core medical segment additionally buyout enable bd provide tva flagship everlinq endoavf system everlinq endoavf receive marketing clearance fda be used hemodialysis rely open surgery acquisition allow bd serve physician patient provide minimally invasive procedure patient chronic kidney disease market opine be more patient end stage renal disease esrd depend hemodialysis unite state moreover research market minimally invasive surgical device be project reach cagr benefit minimally invasive surgery compare traditional open surgeriesa well asreduction healthcare cost growth market hence bd latest move be timely strategic medtech minimally invasive invasive surgery involve fewer incision reduce trauma patient late medtech space have be witness increase usage surgical procedure bd be major global medtech player have be rake huge profit minimally invasive procedure company flagship mueller snowden pencer laparoscopic instrument be most advanced surgical instrument available market intuitive surgical isrg free report coveted da vinci platform deserve special mention here system be power robotic technology enable surgeonsto make smaller precise movement also stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution want more industry better rank stock medical dental supply space be henry schein inc hsic free report henry schein gain unite state well overseas raise optimism stock carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
223,SYK,stryker corporation syk free report fourth quarter result be schedule release jan market close say quarter company be expect witness year year revenue growth other business segment apart orthopedic medsurg neurotechnology spine report year year decline revenue last quarter company beat zack consensus estimate cent positive earning surprise further company deliver positive earning surprise trail quarters average also favorable price performance last year be also encourage stock have gain compare industry rally company announce upbeat preliminary result stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate stryker corporation price consensus stryker corporation price consensus stryker corporation quoteper company prediction orthopaedic segment be expect generate higher revenue constant exchange rate cer medsurg neurotechnology spine segment be expect see revenue improve respectively cer read more stryker post upbeat preliminary sale figure zack consensus estimate revenue sale be peg reflect increase year quarter also zack consensus estimate revenue international sale be peg reflect increase prior year quarter factor playrobust fundamental growth management be opinion recent acquisition novadaq vexim ensure high end organic sale growth full year organic sale growth be expect range moreover recent definitive merger entellus medical be likely offer more comprehensive portfolio product enable physician conveniently perform broad range ent procedure company continue update robot field total knee application preliminary sale result system stryker have be upgrade mako total knee application continue momentum contribute net sale orthopaedic segment company diversify product portfolio stryker broad spectrum product cushion company significant sale shortfall company pipeline include product hip knee mako robotic arm assist surgery additionally various platform bone cement sport medicine bone substitute etc fortify company market position product recall negative recently stryker announce voluntary recall product oral care lineup offer sage product unit additionally company have place temporary hold certain cloth base product however be encourage note product recall issue not dampen management intention improve growth trajectory fourth quarter quantitative model conclusively show earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible stock worth lookhere be other medical stock worth consider have right combination element post earning beat quarter abbvie inc abbv free report have earning esp zack rank fibrocell science inc fcsc free report have earning esp zack rank bio techne corp tech free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
224,SYK,stryker corporation syk free report recently complete acquisition minnesota base entellus medical share deal be initiate december be subject entellus stockholder approval accord stryker acquisition be likely boost company neurotechnology segment management entellus innovative product line ent ear nose throat segment number minimally invasive procedure aid stryker offer cost effective solution patient acquisition be dilutive initially stryker adjust earning share approximately cent be accretive thereafter stryker corporation price consensus stryker corporation price consensus stryker corporation quote promising marketneurotech report forecast global market neurotechnology product be grow mark compound annual growth rate accordingly believe acquisition be strategic well time recent acquisition focusin october stryker acquire vexim sa french medical device company offer minimally invasive treatment vertebral fracture bid augment interventional spine business september company acquire canada base novadaq technology inc novadaq develop fluorescence imaging technology provide surgeon visualization blood flow vessel related tissue perfusion cardiac cardiovascular plastic microsurgical reconstructive procedure april stryker acquire controlled substance waste management system maker cactus llc acquisition be helpful improve drug diversion effort promote environmentally sustainable disposal practice notably acquisition have bolster company sale marketing execution price performanceover year stryker have outperformed industry stock return compare industry gain zack rank key picksstryker carry zack rank hold few better rank medical stock be bio rad laboratory inc bio free report centene corporation cnc free report mednax inc md free report stock sport zack rank strong buy see complete list today zack rank stock here bio rad have project long term growth rate stock have return past month centene have anticipate long term growth rate stock have return past month mednax have expect long term growth rate stock have return past month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
225,SYK,year bring ample reason american cheer standpoint latest tax cut job act be finally sign president dec effective jan be income tax bracket offer reduce tax rate corporate tax rate too have be slash earlier apart new legislation have almost double standard deduction nation be delighted huge tax slash economist be quite apprehensive damage healthcare community be realize long go vox article bill also include tax cut so large trigger board spending cut include billion medicare last time medicare be hit cut patient lose access critical service chemotherapy treatment congressional budget office cbo apprehend doesn find alternative meet fiscal deficit huge tax cut automatic cut worth mandatory spending include medicare cut be trigger not only latest law also repeal individual mandate be essential part obamacare prove health coverage majority american cbo expect person drop plan repeal vox article care elderly be disrupt bring erratic change health care system device tax back serious threat medtechwithin medtech space situation be more grave medical device community be earlier extremely hopeful trump regulatory agenda have promise complete abolition infamous medical device tax be first include health care reform law dread tax impose selling price instead net profit amount stupendous sum wipe almost quarter profit medical technology company article publish la time congress device tax be unpopular not only republican many democrat state such massachusett minnesota have large number medical device company realize house senate temporarily suspend year begin go available datum be quite evident partial year repeal medical device tax have benefit sector overall development datum provide medical device trade group ken blackwell article publish daily caller period be roughly rise research development investment medtech player temporary suspension however have take account expectation government permanently put end tax obviously be not go happen undoubtedly comeback be additional burden medtech fraternity largely discourage activity la time article advame medical imaging technology alliance tax take bite medical device industry next decade medtech stock be affected most tax backper article matt murphy wbur sector be likely be hampered most re imposition levy be ray mri machine surgical instrument pacemaker such tumultuous scenario have handpick medtech bigwig be play majorly controversial sector hefty investment year be hence expose significant level risk associate tax reinstatement boston scientific corporation bsx free report medical device mammoth lead player field heart stent boston scientific unimpressive pacemaker performance core crm have be drag recent past accord usa today article zack rank sell company estimate reinstatement tax cost firm boston scientific state post temporary suspension tax invest saving project include partnership mayo clinic combine manufacturing expertise idea advanced medical device product however reinstatement tax hint continue investment program boston scientific corporation price boston scientific corporation price boston scientific corporation quotestryker corporation syk free report giant orthopedic device maker be face hiccup reintroduction device tax company recently announce preliminary sale number state respect tax reform anticipate modest headwind stock currently carry zack rank hold see complete list today zack rank stock here stryker corporation price stryker corporation price stryker corporation nephew snn free report orthopaedic reconstruction advanced wound management sport medicine maker be go face intense pressure medical device tax resume earlier report fiercemedical device reveal temporary suspension deal nephew shell medical device tax however post suspension tax company have accelerate investment product development manufacturing rescue money reinstatement definitely act hindrance path nephew new age innovation development stock currently carry zack rank nephew snat inc price nephew snat inc price nephew snat inc quotezack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
226,SYK,stryker corporation syk free report recently announce encourage preliminary net sale result fourth quarter full year company be schedule report fourth quarter result jan company expect preliminary net sale improve year year constant exchange rate cer beating zack consensus estimate fourth quarter orthopaedic segment be expect see hike revenue cer medsurg neurotechnology spine segment be expect see revenue growth respectively cer stryker corporation price consensus stryker corporation price consensus stryker corporation quote net sale be estimate year quarter constant currency basis higher zack consensus estimate orthopaedic segment be expect generate higher revenue medsurg neurotechnology spine segment be expect see revenue growth respectively cer domestic net sale increase respectively report fourth quarter full year international net sale increase report fourth quarter full year constant currency international net sale improve fourth quarter respectively management fourth quarter system stryker be upgrade mako total knee application continue momentum contribute net sale orthopaedic segment tax reform company anticipate modest headwind affect business however expect gradually overcome financial year share shine brightstryker have have solid run bourse last year stock have return higher industry return same time frame zack rank stock considerstryker carry zack rank hold better rank stock broader medical space be bio rad laboratory bio free report centene corporation cnc free report molina healthcare inc moh free report sporting zack rank strong buy see complete list today zack rank stock here bio rad have expect growth rate whopping first quarter last year stock have gain surpass broader industry centene have expect long term growth rate stock performance bourse have be solid last year return molina healthcare have solid project growth rate last month stock have rally higher industry gain zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
227,SYK,nov issue update research report stryker corporation syk free report company acquisition drive strategy be expect boost growth expand exist product offering business segment however challenge global economic condition supply side issue fluctuation foreign currency exchange rate strengthen dollar be likely dent top line growth term stryker currently carry zack rank hold stryker add almost last year much higher broader industry return stryker wide range product shield company significant sale shortfall economic downturn company pipeline include product hip knee mako robotic arm assist surgery fact solid performance mako robotic platform have be boost revenue long end last report third quarter stryker sell total robot continue update robot field total knee application stryker have be follow acquisition drive strategy boost inorganic growth profile recently company announce plan acquire france base vexim vexim portfolio be highly complementary interventional spine business stryker instrument division key product segment include extensive platform vertebral augmentation vertebroplasty radiofrequency ablation procedure september stryker complete buyout novadaq net purchase price boost visualization platform flipside stryker recently announce voluntary product recall oral care lineup sage product unit recall pertain cross contamination issue oral care solution be manufacture stryker sage unit third party supplier notably solution be distribute market july august foreign exchange fluctuation be expect affect net sale nominally adjust earning be expect be impact cent share net sale fourth quarter be expect be impact positively however stryker expect negative impact adjust net earning diluted share fourth quarter approximately cent share share price movement estimate revision trendstryker share price movement past year have be favorable company yielded return almost better broader industry current level be also higher return meanwhile company recent earning estimate have be impressive current quarter have see estimate go higher past day compare lower meanwhile full year estimate have see same time period have nominal impact consensus estimate consensus estimate current quarter rise past month full year estimate inched key picksa few better rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank buy investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
228,SYK,month have go last earning report stryker corporation syk free report share have add time frame outperform market recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst stryker earning revenue beat estimate maintain streak positive earning surprise kalamazoo mi base medical technology company stryker report adjust earning share third quarter comfortably beat zack consensus estimate cent earning improve share year quarter meanwhile trail quarters company post earning beat average be currently stryker carry zack rank hold upside earning be primarily drive rise revenue beat zack consensus estimate constant currency cc net sale improve year quarter segment net sale increase year year report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume be partially offset due lower price medsurg net sale increase report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume neurotechnology spine net sale increase report quarter net sale quarter increase increase unit volume be partially offset due lower price fourth quarter stryker expect adjust earning range share full year company expect adjust earning band stryker expect organic sale growth full year have estimate be move then follow release investor have witness downward trend fresh estimate have be revision higher current quarter compare lower stryker corporation price consensus stryker corporation price consensus stryker corporation quotevgm scoresat time stryker stock have subpar growth score grade same score momentum front however stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be solely suitable momentum investor outlookwhile estimate have be broadly trend downward stock magnitude revision have be net notably stock have zack rank hold expect line return stock next few month
229,SYK,stryker corporation syk free report recently sign agreement acquire safeair ag swiss medical device company provide innovative surgical smoke evacuation solution financial term related deal be still wrapped notably stryker boast comprehensive portfolio surgical smoke evacuation company coveted neptune sep smoke evacuation pencil provide solution smoke evacuation company also develop pneumoclear be first inclusive integrate heating humidification smoke evacuation platform available market study avante health solution inhale surgical smoke cause serious health hazard patient clinician study health care worker be expose risk related surgical smoke year hence stryker latest move be timely strategic management acquisition be highly complementary surgical instrument product line be likely boost stryker core medsurg neurotechnology segment moreover latest buyout be likely consolidate company stand provider high quality care unite state europe stryker medsurg neurotechnology focusstryker medsurg product mainly comprise surgical equipment surgical navigation system neurotechnology spine division include neurosurgical neurovascular device recently stryker complete acquisition entellus medical report neurotechnology spine segment notably buyout be expect be accretive company earning stryker have also be gain consistently medsurg unit last report quarter segment post significant contribution earlier acquire novadaq market prospectsa research reveal global smoke evacuation system market be expect reach cagr rise demand minimally invasive surgery grow grey population be drive growth market price share have rally compare industry rise year time zack rank other key picksstryker carry zack rank buy few other top rank stock broader medical space be genomic health ghdx free report abiom abmd free report integer holding corporation itgr free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock flaunt zack rank integer holding have project long term earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
230,SYK,align technology inc algn free report strategy international expansion get solid impetus company achieve new landmark invisalign adoption company announce have complete shipment case europe middle east africa emea region align be significant milestone company reflect accelerate adoption invisalign clear aligner therapy align note millionth invisalign patient emea be year old julia leibold freiburg germany julia be be treat invisalign comprehensive package change aligner weekly basis follow new breakthrough align launch pro campaign july work doctor emea belt offer invisalign treatment multiple patient disability align intenrational profile glance align have undertake several strategy improve adoption invisalign technology globally include product technology development extend clinical efficacy extension invisalign technology brand recent time company international invisalign volume trend have consistently remain strong growth register first quarter reflect continue strong performance emea apac region emea first quarter volume be solid adoption invisalign technology market iberium france well owing rapid growth smaller market eastern europe central europe benelux asia pacific zone company witness surge first quarter volume lead china japan australia china stand close second largest market unite state align iberium follow third largest destination international case soar year year same quarter notably be sixth straight quarter invisalign teenage patient base grow faster adult patient population not only company late accomplish new feat respect invisalign treatment option introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market canada emea apac fda approval same be expect second half development be indicative grow popularity align dental product foreign market long term expect similar innovation act major catalyst align growth new well exist market share price performance share align have outperformed industry past month stock have surge compare industry rise zack rank other key picksalign currently carry zack rank buy few other top rank stock broader medical sector be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate second quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
231,SYK,becton dickinson company bdx free report have top estimate trail quarters company currently have market capitalization approximately currently company face product recall issue foreign exchange headwind zack rank hold stock have rally outperform industry growth year time here take quick look major factor have be plague becton dickinson discuss factor ensure term recovery probable recall issuebecton dickinson also know bd recently recall product notably bd vacutainer edta lavender bd vacutainer lithium heparin green top tube be withdraw device be used collect blood sample vein product be suspect serious health hazard patient laboratory personnel moreover diabetes care business bd have temporarily pause shipment insulin infusion set be due moderately higher anticipate rate complaint associate insertion occur pilot launch product foreign exchange headwindsbd have strong international presence company generate high share revenue international operation get affected fluctuation foreign currency exchange rate strengthen dollar mar bd prospect regard dent such headwind zack consensus estimate bd current quarter earning share fall last day becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotewhat favore stock view upbeatbd raise fiscal guidance company expect adjust earning share represent growth approximately fiscal zack consensus estimate be peg lie guide range company raise revenue growth guidance fiscal be also high end previous guidance strong fundamentalsbd solid product portfolio strong international presence have help company garner strong revenue earning year notably company revenue have see cagr moreover earning see cagr share such upbeat performance continue provide cushion company stock bottom lineunhinder persistent issue analyst be optimistic bd current quarter revenue zack consensus estimate be peg reflect year year rise key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
232,SYK,jan issue update research report stryker corporation syk free report company solid international foothold be expect boost growth expand exist product offering business segment however company announce voluntary product recall oral care line stryker be focuse international growth significant turnaround company european business backed effective restructure measure indicate potential upside particular company medsurg product line have witness strong demand european australian market further favorable response medsurg product line china have enhance company international prospect stryker international organic sale growth third quarter be year year basis strong international performance come back solid performance europe asia latin america quarter internationally medsurg deliver organic sale growth indicate strong growth medical business primarily europe neurotechnology spine also witness robust organic growth performance be bolster high demand neurotech product europe asia country uk germany italy have be witness solid performance stryker long fact company physio unit launch automate external defibrillator aed europe recently flip side stryker announce voluntary product recall oral care lineup be offer company sage product unit add voluntary recall stryker have place temporary hold certain cloth base product stryker continue witness lower demand health care product company have be face challenge global economic condition particularly unite state western europe additionally lower reimbursement medical product service impose downward pressure price company product longer sale cycle slower adoption new technology dent top line stryker now expect full year organic sale growth lower end previous range adjust net earning band stryker price movement past year have be favorable company yielded return almost better industry rally current level be also higher index return same time frame stock have zack rank hold key picksa few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
233,SYK,conn inc conn free report share increase report fiscal third quarter adjust earning share surpass zack consensus estimate share greif inc gef free report climb post fiscal fourth quarter adjust earning share beating zack consensus estimate lululemon athletica inc lulu free report share rise report fiscal third quarter adjust earning share beating zack consensus estimate centsshare stryker corporation syk free report fall company decide acquire entellus medical inc share cash
234,SYK,jun issue update research report integra lifescience holding corporation iart free report company have be see certain major development overseas however tough competitive landscape raise concern new jersey base company be lead developer manufacturer marketer surgical implant medical instrument use neurosurgery extremity reconstruction orthopedic general surgery stock have be outperform industry past month latest stock movement have gain decline industry spite face foreign exchange fluctuation international business integra lifescience have be successfully grow overseas company be look invest asian market order grow business much faster growth unite state also certain part international business line growth strategy company be prepare launch product china japan turn europe management feel encourage growth potential region tissue technology business cusa clarity product slate launch soon be also upbeat company regenerative technology be largest franchise orthopedic tissue technology first quarter company register mid single digit growth franchise primarily backed double digit growth primatrix product line inpatient outpatient setting end first quarter integra lifescience note performance codman specialty surgical segment have exceed expectation have also successfully complete transition codman business china meanwhile integra lifescience face intense competition surgical implant medical instrument market company need continuously innovate fend competition moreover consolidation industry lead intense pricing pressure also significant margin contraction cause escalate cost expense raise concern key pickssome better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
235,SYK,jun have initiate coverage pra health science inc prah free report notably pra health organic growth remain strong also company international business be capitalize great prospect however escalate direct cost remain concern pra health stock carry zack rank hold past year share renown global contract research organization cro have outperformed industry belong stock have rally compare broader industry rise company continue demonstrate solid organic revenue growth first quarter organic revenue growth be constant exchange rate cer symphony integration process be also progress well pra health expect complete procedure end pra health science inc price pra health science inc price pra health science inc quote pra health be highly optimistic acquisition expect enhance ability serve customer clinical research commercial development process technology provide datum analytic be also encourage company diversify client base top customer represent approximately revenue last report quarter company have be strategically expand asia pacific operation have support clinical trial region site australia china hong kong india japan malaysia new philippine singapore south korea taiwan thailand march company be honour best cro label asia pra health focus emerge market look extremely significant point saturation growth instability continue grip develop market flip side company persistently incur direct cost primarily increase labor related cost clinical research segment continue hire billable staff growth support increase direct cost also include unfavorable foreign currency impact compare year period tally datum solution segment direct cost shot mainly due raise salary benefit moreover company remain pressed tough capital spending environment key picksa few better rank stock broader medical sector be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
236,SYK,steris plc ste free report have be gain investor confidence consistently positive result past year company have rally industry decline also company have outperformed gain developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have market cap company long term historical earning growth rate be higher tally solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward be movement opposite direction however earning estimate remain flat let find latest trend be sustainable solid quarterly exit fourth quarter fiscal better expect earning revenue be also encourage favorable underlie market trend new product service offering company strong organic growth specialty service life science apply sterilization segment also buoy optimism synergy health consolidation tracksteris acquisition base outsourced sterilization service provider synergy health plc have continue remain significant move company combine steris infection prevention service business synergy health hospital sterilization service earlier management say expect save least end fiscal balance evenly divide next fiscal company also anticipate cost synergy year synergy health transaction next fiscal strategic buyout have be late look expand adjacent market acquisition dilution follow synergy health acquisition company sell synergy health healthcare consumable solution hcs business vernacare last november apart company make consolidation fiscal aim strengthen healthcare product healthcare specialty service apply sterilization technology business solid balance sheet positionsteris exit fiscal cash cash equivalent compare end fiscal company long term debt end fourth quarter fiscal be compare year other key picksa few other top rank stock broader medical sector be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
237,SYK,medical device industry trend be reflective extensive discovery innovation life science industry past few year study publish cnbc medical device company have gain importance healthcare world improve research development technology far reach innovation gene therapy newer drug combination patient monitoring help big datum year shape medical fraternity unite state tax suspension fuel medical device market have further gain momentum owing recent year suspension controversial medical device tax excise tax be implement part obamacare medtech manufacturer significantly restrict activity accord article publish xtalk medical device tax be responsible reduction spending decline overall sale however be be see tax be fully eliminate resume year period now deferral encourage activity space bode well medtech company notably past month medical instrument industry have rally index return lead revolution medtechthe medtech space currently offer unprecedented opportunity growth market share expansion solid investment have help manufacturer use benefit big datum artificial intelligence ai medical mechatronic industry be also catch digital datum age enormous size datum be capture technology arrive business insight help healthcare sector provide better care reduce wastage latest trend adopt electronic health record ehr service medtech space have also be gain popularity major hcit healthcare bigwig have carved niche big datum domain be cerner corporation athenahealth inc company be make significant investment boost ehr platform meanwhile medical mechatronic be much await digital evolution global healthcare industry provide innovation healthcare industry reduction size age old medical device development low cost disposable device engineering concern einfochip believe mechatronic be future medical device benefit mechatronic have be see form printing cancer study development better medication deadly disease notably intuitive surgical isrg free report minimally invasive da vinci surgical system stryker corporation syk free report robotic arm assist surgery platform mako deserve mention here choose winning stocksgiven favorable scenario investment medical device stock strong potential seem be wise choice stock strong fundamental solid prospect make reward addition portfolio have take help zack stock screener select favorable stock shortlist stock vast universe medical product have picked one zack rank strong buy buy growth score notably growth score be comprehensive tool come handy screening winning stock broader sector research show stock growth score combine zack rank outperform most stock see complete list today zack rank stock here abiom inc abmd free report sport zack rank stock growth score be indicate outperformance term be underpin fact stock have impressive long term earning growth last day zack consensus estimate abiom current quarter earning share have increase cent abiom inc price consensus abiom inc price consensus abiom inc quotein past month share abiom have sky-rocket industry decline abiom flagship impella world smallest heart pump have continue be growth driver notably fourth quarter fiscal company spend year quarter integer holding corporation itgr free report carry zack rank have growth score long term earning growth be project last day zack consensus estimate integer hold current year earning share have increase integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quotein past month share integer holding have rally fare better industry integer holding have also be enhance profitability area advanced surgical orthopedic power solution focuse sale growth cost structure initiative company plan invest more area cardio vascular neuromodulation accelerate sale market penetration notably first quarter company spend year year basis varian medical system var free report stock have zack rank growth score company long term earning growth be project last day zack consensus estimate varian medical current year earning share have rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotein past month share varian medical have rally significantly beating industry varian medical ride solid growth prospect coveted halcyon radiotherapy treatment system hyperarc platform halcyon be design offer cost effective cancer care hyperarc be high definition radiotherapy technology second quarter fiscal company spend prior year quarter steris plc ste free report have zack rank growth score company current year earning growth be project last day zack consensus estimate steris fiscal earning share have increase steris plc price consensus steris plc price consensus steris plc quotein past month share company have rally considerably better industry company goal be provide infection prevention other procedural product service fourth quarter fiscal company invest year year basis idexx laboratory idxx free report carry zack rank growth score company long term earning growth be project last day zack consensus estimate idexx current year earning share have increase idexx laboratory inc price consensus idexx laboratory inc price consensus idexx laboratory inc quotein past month stock have rally significantly outperform industry company develop manufacture distribute product primarily companion animal veterinary livestock poultry first quarter company spend significant year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
238,SYK,share opko health inc opk free report have gain release first quarter result rally be backed narrower expect loss share solid pharmaceutical business past month stock have rally industry decline quarter review zack rank hold company incur adjust loss cent share narrower zack consensus estimate loss cent however loss widen prior year quarter tally quarter highlight revenue first quarter gross surpass zack consensus estimate nevertheless top line decrease register year quarter segment detail revenue service come year quarter management downside be attribute volume decline approximately clinical lab pharmaceutical product revenue totale year year management company generate revenue sale rayaldee report quarter transfer intellectual property revenue rake slightly prior year quarter opko health inc price consensus opko health inc price consensus opko health inc quotemargin report quarter gross profit totale year year basis gross margin be contract basis point bps operate expense amount year year basis notably opko health incur operate loss prior year quarter guidance second quarter opko health expect revenue service product revenue be anticipate be include rayaldee revenue band revenue transfer intellectual property be project operate expense be expect be line first quarter range effective tax rate be project be single digit take opko health wrapped first quarter tepid note company loss be narrower expect revenue surpass zack consensus estimate moreover company ride pharmaceutical business register year year increase revenue also significant gain rayaldee be noteworthy furthermore opko health be optimistic kscore utilization witness solid growth first quarter year year surge company expenditure reflect increase focus innovation however decline margin be worrisome sale decline company core service segment be add concern key pick few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
239,SYK,jun issue update research report idexx laboratory inc idxx free report company robust worldwide commercial capability best class product include next generation chemistry analyzer catalyst be key growth driver term stock carry zack rank buy past month lead molecular diagnostic company have outperformed industry stock have increase industry decrease notably idexx continue demonstrate strong organic growth drive robust sale companion animal group cag business fuel firm global catalyst uptake international revenue first quarter be organically drive organic gain international cag diagnostic recur revenue reflect continue consumable revenue gain support catalyst instrument base increase average testing utilization sturdy growth european lab revenue companion animal market fundamental remain safe sound tremendous global runway growth additionally be upbeat company expand premium instrument base unite state well international market include growth competitive instrument placement increase utilization consistent customer retention idexx innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth report quarter moreover company healthy top line growth be drive considerable contribution rest business segment raise ep guidance be also encourage additionally company boast strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue be be derive sale product international market thus strengthen dollar exchange rate relative other currency have negative impact revenue derive currency other money well profit draw product manufacture unite state sell internationally adverse currency translation affected adjust earning share tune cent also company heavy dependence third party distributor be drag other key picksother top rank stock broader medical space include genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
240,SYK,stryker corporation syk free report lead player medical technology space be set report third quarter result oct close bell august stryker announce voluntary recall oral care line be offer company sage product unit add voluntary recall company have place temporary hold certain cloth base product mar third quarter result expect improvement revenue major revenue segment help company generate solid result season be important note stryker deliver positive earning surprise past quarters average be meanwhile zack consensus estimate third quarter revenue stand year year basis furthermore zack consensus estimate earning stand share year year stryker corporation price consensus stryker corporation price consensus stryker corporation quote factor playguidance take hit recent product recall be likely impact company sale operate income fact third quarter stryker estimate adjust net earning diluted share low end previously issue band recall decision follow complaint minor irritation allergic reaction consumer however management expect reinitiate full supply capacity end year neurotechnology spine segment stryker have be grapple supply issue spine unit neurotechnology spine segment long major factor hurt segment challenge global economic condition fluctuation foreign currency exchange rate deserve mention precisely foreign exchange volatility affect adjust earning share approximately cent third quarter owing softness spine unit zack consensus estimate neurotechnology spine segment decrease sequentially lower demand health care product stryker have be face challenge global economic condition particularly unite state western europe late ongoing political conundrum pertain repeal obamacare have give rise uncertainty medical product space add lower reimbursement medical product service have be impose downward pressure price company product furthermore longer sale cycle slower adoption new technology mar revenue third quarter medsurg unit decline sale medsurg equipment segment be likely impede revenue growth third quarter notably zack consensus estimate revenue segment stand sequentially however solid prospect canada australia china be likely boost company medsurg instrument unit notably zack consensus estimate segment increase sequentially year year basis be important note last report quarter medsurg whole post organic growth year year basis however quantitative model do not conclusively show earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker currently carry zack rank sell please note caution stock zack rank sell rate go earning announcement stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
241,SYK,nuvasive inc nuva free report receive expand clearance fda tlx interbody system tlx interbody system be insert conventional transforaminal lumbar interbody fusion tlif approach tlx implant be place easily disc space due low profile bullete design tlx be design minimally invasive spine surgery approach tlx interbody be available degree lordotic option be only indicated use allograft receipt approval accord company new clearance include expandable degree interbody broader indication use include use allogeneic bone graft additional level spine tlx system size offer many option vary patient size anatomic consideration tlx interbody system combine integrate global alignment iga suite company software have ability improve overall tlif procedure notably nuvasive be currently leave stone unturned cash rapidly evolve spine market last report second quarter company core spinal hardware business maintain bullish trend growth upside be drive strong adoption reline posterior fixation system company iga platform company also witness steady uptake recently launch expandable interbody cage base ti interfixated alif procedure meanwhile company recently close acquisition vertera spine start company spine space nuvasive also announce commercial launch lessray software technology system particularly work help address overexposure radiation hospital operate room mostly case minimally invasive spine surgery mis accord report globaldata global market spinal fusion be expect rise cagr consider substantial potential market believe latest development be strategic spine market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report rti surgical rtix free report other today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
242,SYK,mazor robotic ltd mzor free report recently receive ce mark approval mazor surgical assurance platform approval allow mazor robotic partner medtronic mdt free report commercialize co promote market mazor platform country recognize ce mark mazor robotic medtronic have sign deal distribute mazor mazor robotic spine surgery system medtronic have make third tranche investment mazor robotic recently regard note mazor robotic recently report second quarter revenue approximately compare year quarter revenue upside be drive strong mazor system sale increase procedure volume last report second quarter mazor robotic receive purchase order mazor system unite state expect ce mark drive order system accord report mordor intelligence global market spinal surgery device have be estimate reach worth cagr period consider opportunity niche see company latest development strategic however company be face tough competition industry well establish player likestryker corporation syk free report zimmer biomet holding inc zbh free report estimate revision trend estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have narrow loss cent share loss cent stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
243,SYK,bid expand advanced material science range nuvasive inc nuva free report recently announce vertera spine buyout however term acquisition agreement have be keep wrapped nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state deal also lend company dimensional porous interbody technology peek titanium material notably company have introduce few new feature modulus xlif build fully porous titanium implant create dimensional manufacturing process design match porosity stiffness bone encouragingly note company spinal hardware business comprise implant fixation product magec eos spinal brace lengthen system precice limb lengthen system register growth last report quarter nuvasive be leave stone unturned gain traction fast grow spine market regard company have be steadily focuse product development moreover company claim have active corporate development pipeline include number strategic investment acquisition partnership opportunity notably first quarter company launch first interbody device mlx tlx used lumbar fusion procedure report becker spine review global minimally invasive spine surgery market be expect witness cagr also report technavio global spinal implant market be expect witness cagr roughly period thus give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery past month nuvasive have underperform broader industry period company have lose compare gain broader industry expect company make comeback latest development zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
244,SYK,aug issue update research report sunnyvale base accuray inc aray free report lead developer designer radiosurgery radiation therapy system treatment tumor company currently carry zack rank sell accuray have have unimpressive run bourse late glimpse recent price performance reveal share decline past month compare unfavorably industry increase company have dismal track record characterize consecutive earning miss trail quarters accuray witness low product margin fourth quarter fiscal end jul basis point bps fact dismal performance product segment cause adjust loss cent share wider zack consensus estimate loss penny additionally unsatisfactory performance cyberknife tomotherapy system japan asia pacific be headwind unfavorable product mix more replacement sale cyberknife exist customer base cause drag moreover time employee severance related expense other time part cost dent service margin recent time accuray top line be highly dependent cyberknife tomotherapy system sale however system require high capital expenditure act deterrent healthcare provider positive note be particularly upbeat company extensive product portfolio grow customer base especially eimea region international expansion initiative be poise drive growth moreover receipt fda approval radixact treatment delivery platform be likely boost product revenue long haul key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
245,SYK,latest earning preview depict bullish run ongoing report cycle oct member total market cap report number total earning member have go higher revenue however investor be concern medical sector zack sector see lot struggle first month year thank political change ongoing policy restructure related battle ensue lack visibility have roil favorable trend sector maintain trail few quarters third quarter expect earning growth rate stand mere revenue growth projection comparison second quarter earning growth be quite impressive revenue growth store medical product space twist turn continue unfold capitol hill scenario medical product space important part medical device subcategory broader medical sector be get gloomier latest executive order release republican point shrink customer base indicate cut demand expensive medical procedure device lead major supply demand disequilibrium space however major medical device player have be pin hope abolition infamous medical device sale tax elimination be far reality consider tax issue investor interested medical product space eagerly await earning report medtech bigwig week let take look major medical product stock slate release quarterly report oct quantitative model stock solid zack rank strong buy buy hold be combine positive earning esp then chance beating estimate be always high uncover best stock buy sell re report earning esp filter boston scientific corporation bsx free report be upbeat medical device stalwart gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally company gain fair share few cardiovascular segment de drug eluting stent continue build momentum worldwide however ahead earning release quarter ic business be likely be grossly impact company product recall issue europe downbeat ic business tangled product recall issue possibly gain boost company recent acquisition switzerland base symetis sa full recovery take time zack consensus estimate third quarter ic revenue be currently peg lower sequentially last quarter report number boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote notably company earning have outpaced zack consensus estimate average trail quarters further zack consensus estimate third quarter earning cent share have remain unchanged last month however have show rally year report figure zack consensus estimate company revenue be peg yet be report quarter improvement year report number boston scientific have earning esp also carry zack rank recall issue hurt boston scientific earning resm inc rmd free report renown worldwide provider generator mask related accessory treatment sleep disordered breathe sdb be expect gain first quarter fiscal strong performance domestic international front company revenue domestic domain be drive solid growth device well low double digit software sale growth previous quarter internationally company receipt french reimbursement approval telemonitoring buoy optimism zack consensus estimate domestic revenue include contribution reflect increase year quarter also zack consensus estimate international revenue indicate rise year quarter overall fiscal first quarter total revenue be project prior year quarter resm inc price ep surprise resm inc price ep surprise resm inc quote notably company earning have outpaced zack consensus estimate average trail quarters resm carry zack rank sell have earning esp see complete list today zack rank stock here read more resm maintain balanced growth earning align technology inc algn free report be upbeat align technology strategic initiative international expansion ensure invisalign treatment grow base patient also last quarter huge increase international case year year encourage investor figure reflect rise demand quarter be report company reach new benchmark patient have adopt invisalign treatment management also anticipate consistent growth asia pacific region bid flourish region company open new invisalign treatment plan facility china align technology inc price ep surprise align technology inc price ep surprise align technology inc quote notably company earning have outpaced zack consensus estimate average trail quarters align have earning esp carry zack rank stock have see zack consensus estimate third quarter earning cent share be revise penny upward last day have also show improvement significant year tally zack consensus estimate company revenue be peg soon be report quarter compare year report figure reflect gain read more invisalign drive align technology earning cerner corporation cern free report cerner be expect show steady growth system sale major revenue component primarily drive third quarter earning expect improvement revenue other segment also help company generate solid result season zack consensus estimate system sale stand third quarter reflect rally almost year quarter growth acute ambulatory ehr sale population health revenue cycle solution service hold promise cerner cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quote last quarter management cerner announce company expect growth support maintenance service segment remain year fact zack consensus estimate segment revenue stand year year basis sequentially notably company earning have outpaced zack consensus estimate average trail quarters zack consensus estimate third quarter earning cent share have remain unchanged last month however have improve year figure zack consensus estimate company revenue be peg yet be report quarter improvement year number cerner have earning esp also carry zack rank read more higher system sale drive cerner earning stryker corporation syk free report august stryker announce voluntary recall oral care line offer company sage product unit add voluntary recall company have place temporary hold certain cloth base product mar third quarter result expect improvement revenue major revenue segment help company generate solid result season stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quote stryker deliver positive earning surprise past quarters average beat be zack consensus estimate third quarter revenue stand year year basis also zack consensus estimate earning stand share year year stryker have earning esp carry zack rank well read more sage unit recall hurt stryker earning mckesson corporation mck free report mckesson major player pharmaceutical medical supply distribution market expect gain gradually stabilize generic brand market company distribution solution segment perform favorably recent time weak pricing trend customer consolidation zack rank company earning have underperform zack consensus estimate average trail quarters mckesson have earning esp mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quote stock have see zack consensus estimate third quarter earning share be revise cent downward last day have also show decline year report figure zack consensus estimate company revenue be peg yet be report quarter compare year figure read more mckesson report earning beat card zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
246,SYK,stryker corporation syk free report largest medical device company global orthopedic market have successfully expand product portfolio time aids company cater evolve demand customer markedly company boast diverse portfolio have be aid top line growth reflect project revenue growth expect momentum continue banking strength portfolio acquisition fact company product portfolio cushion significant sale shortfall economic downturn kalamazoo mi base company pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be unite state furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position meanwhile stryker exclusive navigation platform provide streamline software solution allow surgeon accurately track analyze monitor instrumentation pertain patient anatomy surgical procedure enhance patient outcome expect stryker perform well virtue strong diverse portfolio innovative pipeline strategic acquisition ongoing cost control measure increase operate efficiency stryker have be follow acquisition drive strategy boost growth profile acquisition novadaq technology inc complete september be recent example also stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market however china prove be challenge market flip side stryker peer orthofix international ofix free report female health company veru free report lemaitre vascular inc lmat free report continue be challenged lower demand health care product additionally company spine business unite state witness supply issue have be face challenge global economic condition particularly unite state western europe well go forward lower reimbursement medical product service impose downward pressure price company product be expect have impact top line today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
247,SYK,medtronic plc mdt free report continue hit headline steady strategic development recently company catch investor attention receipt expand clearance company kyphon hv bone cement fixation pathological fracture sacral vertebral body new breakthrough be expect expand company interventional pain therapy business broader restorative therapy group rtg medtronic fixation be do used sacral vertebroplasty sacroplasty expand indication company be able broaden commitment treatment pathological fracture vertebral body cause osteoporosis cancer benign lesion company claim advancement offer clinician more option cure patient sacral insufficiency fracture sif notably sif be common cause debilitating back pain american journal neuroradiology anjr sif be frequent yet often unsuspected reason low back pain elderly patient very recently sacroplasty emerge alternative therapy treatment sif accord anjr prospective study case report suggest be safe effective remedy medtronic sif show symptom lumbar spine pathology go study more third sif patient fail associate pain traumatic event evidently be often be prescribe conservative treatment option include physical therapy prolong bed rest be highly expensive choice induce loss productivity healthcare system also patient put bed rest be rise risk pulmonary embolism dvt well further muscle atrophy bone loss meanwhile sif patient treat sacroplasty experience immediate pain relief allow resume daily activity physical therapy suffering pain physical limitation more encouragingly procedure sacroplasty hv cement be pretty simple owing minimally invasive procedure therapy be perform outpatient set demographic change sifgoing report publish national center biotechnology information ncbi epidemiologic change first second world country inevitably lead constant increase grey populace also unite nation datum global age population age year come more double figure register strength senior citizen be worldwide number be again expect grow twice dense be project reach nearly therefore detection sif elderly adult be markedly gain prominence huge prospect treatment market hence believe medtronic latest innovation space be well time strategic price performance medtronic have outperformed industry month time stock have gain compare industry rise key picksmedtronic currently carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate second quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
248,SYK,medtronic plc mdt free report recently announce fda approval minime system patient type diabetes year age notably approval be base positive datum home pediatric study study multus center study have enrolled participant year age group trial have week run phase study period month notably participant choose continue used system continue access program study result also demonstrated datum pivotal trial minime system patient age year minime glancepost receipt fda approval medtronic have commercially launch minime june be hybrid close loop hcl insulin delivery system type diabetic patient minime system feature medtronic latest guardian sensor glucose sensor increase accuracy enhance performance be only fda approve sensor control hybrid close loop system include diagnostic technology continuously check sensor health system also have medtronic most advanced algorithm smartguard hcl technology diabetes business focusmedtronic be consistently try enhance diabetes business company see rise constant exchange rate diabetes business revenue fourth quarter fiscal company benefit solid uptake new sensor augment insulin pump system unite state international market increase production capacity same recently company announce receipt fda approval guardian connect continuous glucose monitoring cgm system diabetes patient age year notably system be schedule be make available first quarter fiscal july company also announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm be used minime insulin pump notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international introduction minime launch new professional cgm ipro market potentialan agee population unhealthy lifestyle rise awareness higher expenditure healthcare be likely drive highly competitive diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have be strategic share price have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain comparison industry increase zack rank key picksmedtronic carry zack rank hold better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
249,SYK,market capitalization approximately merit medical system inc mmsi free report acquisition drive strategy be expect boost growth expansion product offering business segment favorable prospect hero product line also bode well however higher consolidation healthcare industry exert pressure price merit medical product cutthroat competition lack direct sale many country be other headwind base mixed trend stock have zack rank hold fiscal zack consensus estimate revenue be currently peg reflect increase year year notably zack consensus estimate earning be currently peg share show increase year year here take quick look major factor have be plague merit medical discuss prospect ensure term recovery merit medical system inc price consensus merit medical system inc price consensus merit medical system inc quotefactor plague merit medicalthe medical product industry be highly competitive merit medical compete globally several market area include diagnostic interventional cardiology interventional radiology radiology vascular general well asthoracic surgery cardiac rhythm management interventional pulmonology interventional nephrology orthopaedic spine surgery many more interventional cardiology radiology endoscopy general surgery thoracic surgery pulmonology market merit medical compete large international multus divisional medical supply company such cardinal health boston scientific corporation medtronic abbott teleflex becton dickinson company stryker corporation terumo corporation also company face aggressive competition medium size company braun uresil btg olympus medical edward lifescience argon conm angiodynamic medcomp endoscopy still hold merit medical hero hemodialysis reliable outflow product line have be key contributor growth hero graft super hero adapter hero ally revision kit be platform comprise thehero family dialysis device consider solid global prospect hemodialysis solution product line be likely provide merit medical competitive edge medtech market notably hero product line be acquire merit medical cryolifein management think hero graft training program platform be likely provide substantial scope long run hero line hero graft be most important owing strong cost save efficiency hero graft be fully subcutaneous vascular access system intend use maintain long term vascular access chronic hemodialysis patient have fail fistula graft be catheter dependent due central venous blockage management hero graft enable cost saving more patient year dialysis center convert catheter dependent patient hero graft favorable price medical outperformed industry year time company share have return almost compare industry rise current level be also higher index return key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock flaunt zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
250,SYK,integra lifescience holding corporation iart free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have surge industry fall lead developer manufacturer marketer cost effective surgical implant medical instrument have market cap company have earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be northbound past day analyst have revise estimate upward be movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable global prospect impressivein spite face foreign exchange fluctuation international business integra lifescience have be successfully see certain key development overseas front company be look forward investment opportunity asian market order grow business much faster unite state also certain part international business line growth strategy company be prepare launch several product china japan turn europe management feel encourage growth potential region tissue technology business cusa clarity product schedule be launch europe strength regenerative lifescience regenerative technology be largest franchise orthopedic tissue technology first quarter company register mid single digit growth franchise primarily banking strength primatrix product line increase double digit inpatient outpatient setting earlier integra lifescience introduce several new product have expand company portfolio solution unite state hernia repair market european breast reconstruction market further spur growth solid growth codman specialty surgical css segmentat end first quarter integra lifescience note performance codman specialty surgical segment exceed expectation have also successfully complete transition codman business china business boast largest revenue base also have integrate sale territory associate codman revenue globally end first quarter apart company have open new campus mansfield be home convey codman teammate integra lifescience experience organic growth codman specialty surgical segment first quarter be attribute integration progress globe apart recent addition codman commercial resource company be well poise accelerate growth dural repair other key picksother top rank stock broader medical space include genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
251,SYK,accuray incorporate aray free report recently receive atomic energy regulatory board aerb type approval flagship radixact system india notably approval establish safety standard system enable hospital india import next generation tomotherapy platform radixact system be fully integrate accuray precision treatment plan system tps idms datum management system notably apollo hospital chennai new delhi have acquire radixact system company march read more accuray radixact picked india apollo cancer treatment accuray exposure ai medical mechatronicsthe latest regulatory approval signify continue momentum coveted radixact system strengthen accuray foothold use artificial intelligence ai mechatronic be currently shape medtech fraternity cision global medical device market be expect reach estimate cagr mechatronic high end technology incorporating electronic machine learn mechanical engineering have be vogue late grow prominence ai robotic company organization significant exposure mechatronic have be rake huge profit consequently accuray latest achievement be likely prove beneficial company long haul radixact drife accurayaccuray recently announce launch precision treatment plan system system leverage company flagship radixact cyberknife system platform company also plan build technology precision upgrade fiscal fact third quarter fiscal accuray witness gross order substantial contribution radixact system moreover radixact system represent tomotherapy order volume price performancein past month accuray share have rally industry decline zack rank key picksaccuray currently carry zack rank strong sell few better rank stock medtech space solid exposure medical mechatronic be abiom abmd free report varian medical system var free report stryker corporation syk free report abiom flagship product impella be world smallest heart pump offer hemodynamic support heart stock sport zack rank strong buy see complete list today zack rank stock here varian medical coveted halcyon hyperarc platform deserve mention stock carry zack rank buy stryker fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
252,SYK,be time plastic reconstructive surgery be perform only serious burn case accidental injury now cosmetic surgery be many social circle last few year mass have be pick trend eminent hollywood celebrity millennial baby boomer plenty be interested such procedure aesthetic reason datum cosmetic surgery national datum bank statistic report publish american society aesthetic plastic surgery asaps substantiate fact state first time american have spend more surgical nonsurgical procedure mark rise annual spending datum encourage venturesome investor consider industry have be gain considerable ground late factor drive plastic reconstructive surgery marketthe trend look presentable social medium platform be rise article jim frame publish independent cosmetic procedure be now surgery want not need moreover rapidly age population have be contribute fast grow plastic reconstructive surgery market datum provide asaps cosmetic surgery national datum bank statistic report combine surgical nonsurgical procedure man woman age have rise wide gamut surgical nonsurgical procedure make plastic reconstructive surgery market lucrative space range skin graft modify exist feature cosmetic reason get congenital defect correct procedure fall umbrella niche space notably surgical nonsurgical solution man be also rapidly gain momentum datum provide asaps cosmetic surgery national datum bank statistic report male breast reduction procedure alone treatment gynecomastia have rise measure asaps initiate survey cosmetic surgical datum year back report also state breast augmentation lift surgery dominate chart most popular surgery woman many analyst believe increase awareness rise expenditure healthcare technological advancement be likely drive demand surgery be further substantiated datum provide global market insight project global breast implant market be set reach worth roughly cagr period be not enough report technavio publish business wire say global plastic surgery product market be expect value see cagr stock bet onhere highlight company be strive cash bountiful opportunity plastic reconstructive surgery market hologic inc holx free report headquarter marlborough hologic carry long term earning growth rate year make entry aesthetic market acquisition marketer aesthetic treatment system cynosure inc equity value approximately cynosure develop manufacture market aesthetic treatment system system aid plastic surgeon dermatologist other medical practitioner perform invasive minimally invasive procedure post buyout cynosure have become wholly own subsidiary hologic have result addition new segment hologic diversify business medical aesthetic hologic announce receipt expand fda clearance cynosure clinically proven invasive body contour product sculpsure september advanced body contour laser treatment now stand approve treat double chin june sculpsure get clearance treat problem fat back well inner outer thigh moreover sculpsure treatment have fda approval treatment abdomen love handle hologic inc price hologic inc price hologic inc quoteintegra lifescience holding corp iart free report headquarter plainsboro nj integra have long term earning growth rate year company operate high potential plastic reconstructive surgery market orthopedic tissue technology segment contribute total revenue last report quarter solidify footprint space integra acquire derma science inc tissue regeneration company last february derma science be currently focuse advanced wound burn care provide product treatment chronic deep wound result diabetes poor vascular function continue slew development integra recently announce few product launch space collagen matrix revize revize plastic reconstructive surgery thecollagen matrix surgimend prs mesh feature meshing pattern surgimend prs mesh pre sub pectoral breast reconstruction europe integra lifescience holding corporation price integra lifescience holding corporation price integra lifescience holding corporation quotestryker corp syk free report headquarter kalamazoo mi stryker have long term earning growth rate year be largest medical device company global orthopedic market have successfully expand product portfolio time help company cater evolve demand customer company product portfolio cushion significant sale shortfall economic downturn furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more strengthen company market position stryker medpor plastic surgery portfolio provide surgeon comprehensive expand range option reconstruction augmentation also company provide digital plan solution maxillofacial surgical procedure vsp reconstruction be function partnership system medical modele stryker corporation price stryker corporation price stryker corporation quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
253,SYK,sep issue update research report model modn free report provider cloud base revenue management software model be benefit grow customer base transition cloud base application synergy revita acquisition be evident third quarter result adjust loss cent share be narrower year quarter loss dent figure be also better zack consensus estimate loss cent share revenue increase year year model expect fourth quarter gaap revenue come range fiscal gaap revenue defer revenue adjustment be expect be range management continue expect annualize recur revenue arr be represent year year growth share model have gain year date significantly outperform rally industry key growth driverswe believe model be significantly benefit acquisition revita third quarter revita contribute approximately saas maintenance revenue approximately company license implementation revenue follow revita acquisition company have be able expand product suite turn customer base also frequent contract win exist new customer have boost company top line model inc revenue ttm model inc revenue ttm model inc quotedure last report quarter customer base witness addition icu medical medtech company high tech company call ampleon radio frequency rf power provider moreover significant number system become operational third quarter include nephew edward lifescience ew free report japan stryker syk free report shire notably company have eliminate duplicate general administrative sale marketing cost well redundant product outside life science vertical post acquisition initiative be well reflect cost structure drive bottom line zack rank key pickmodel currently have zack rank buy better rank stock broader technology sector be apply material inc amat free report sporting zack rank strong buy see complete list today zack rank stock here long term earning growth rate apply material be project be hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
254,SYK,idexx laboratory inc idxx free report be schedule report first quarter result open bell last quarter company deliver positive earning surprise notably stock have outperformed zack consensus estimate precede quarters average beat be let take look thing be shape prior announcement key catalyst idexx be expect continue gain momentum first quarter courtesy strong global rise companion animal group cag diagnostic revenue last time upside be drive consistent strong double digit growth reference lab consumable owing high single digit increase register rapid assay sale management vouch trend be retain further idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic expect first quarter result reflect rise productivity new sale representative establish fresh customer relationship also anticipate company report exceptional customer retention rate reference lab well instrument consumable unite state worldwide zack consensus estimate cag diagnostic revenue represent improvement last report quarter notably idexx revenue growth projection quarter be report highlight organic gain overall zack consensus estimate total quarterly revenue be peg other factor predict influence idexx first quarter result be pin considerable hope progress water business lie growth trajectory late backed encourage test result unite state well benefit draw global go direct initiative moreover business witness organic growth last quarter management also eye gain favorable regulatory development pertain wastewater unite state drink water europe company earlier state be perfectly track continue high single digit organic revenue boost business consensus mark water revenue stand yet be report quarter idexx carry expand global footprint have be significantly draw advantage bountiful opportunity emerge companion animal diagnostic market further management consistent share buyback underscore robust free cash flow reserve believe outcome endeavor bear reflection first quarter conference call flip side foreign currency fluctuation be major headwind concern be company heavy reliance third party distributor purchasing dynamic distributor leave significant impact company sale instrument consumable well rapid assay product moreover idexx have be witness rise operate expense due increase head count higher investment portfolio development expansion unite state internationally additionally competitive landscape domestic overseas market weigh idexx performance thus struggle gain market traction be drag first quarter result here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp idexx have zack rank increase predictive power esp however company earning esp leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider right combination element surpass estimate time baxter international inc bax free report have earning esp be zack rank player laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be rank player see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
255,SYK,becton dickinson company bdx free report popularly know bd second quarter fiscal result be schedule release market open result be likely show steady growth core bd medical segment rise revenue other segment also act driver first quarter bd report earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis revenue come beating consensus estimate show rise year quarter second quarter zack consensus estimate earning be peg reflect year year growth same revenue be pin indicate growth bd deliver average positive earning surprise trail quarters becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotelet delve deeper bd medical key growth driverin last report quarter bd medical account whopping company total revenue revenue segment rise cc year year basis management include headwind approximately basis point bps dispense change furthermore add legacy bard have lead accelerate growth segment be also encourage note second quarter zack consensus estimate segment be sequentially medication procedural solution mps revenue grow first quarter second quarter zack consensus estimate be peg sequentially growth be likely be drive continue strength pre filled flush device infection prevention surgical product diabetes care revenue grow growth pen needle yet zack consensus estimate quarter be pin sequentially pharmaceutical system revenue grow first quarter zack consensus estimate second quarter be show rise sequentially revenue medication management solution mms decline zack consensus estimate be sequentially other factor playview solidbd expect fiscal revenue growth range report basis however revenue be expect grow band company expect adjust earning share range previous range current range indicate growth approximately report basis cc management expect bd medical grow life science segment be expect rise growth new bd interventional segment be anticipate acquisition divestituresbd acquisition drive strategy have be instrumental drive growth recently bd acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue closure takeover lead third new business segment bd interventional bd collaborative move fresenius medical care provide sodium chloride saline customer be also worth mention last year bd announce merit medical system have sign agreement acquire certain asset company bd life sciencesrevenue bd life science totale fiscal first quarter cc year segment performance be backed strong number bioscience diagnostic system preanalytical system unit segment also see solid growth outside unite state recently bd announce pre market approval fda bd onclarity hpv assay management be likely boost bd diagnostic system segment zack consensus estimate second quarter be pin sequentially quantitative model predict earning beat bd quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp bd be uncover best stock buy sell re report earning esp filter zack rank bd carry zack rank favorable zack rank increase predictive power esp other stock worth lookhere be few other medical stock worth consider have right combination element post beat earning season stryker corp syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
256,SYK,hologic inc holx free report be slate report second quarter fiscal financial result close bell last quarter company deliver positive surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement key catalystwithin diagnostic hologic once again expect stellar performance banking molecular diagnostic unite state company be likely gain increase market share well utilization fully automate panther system market expansion conform testing guideline global growth molecular diagnostic be attribute panther system hologic fully automate molecular diagnostic instrument also owing frequent utilization aptima woman health assay notably aptima assay have gain huge customer base testing chlamydium gonorrhea hpv human papillomavirus trichomona be also hopeful hologic expand market sexually transmit disease testing hologic inc price ep surprise hologic inc price ep surprise hologic inc quote further be upbeat diagnostic business earn regulatory clearance several new product unite state last quarters include first respiratory assay new fusion platform viral load test hiv human virus hepatitis hepatitis steady pace domestic assay innovation strengthen company position consolidate molecular testing panther system january company again announce pma approval aptima hbv quant assay quantitation hepatitis viral load fully automate panther system development be anticipate contribute significantly company topline be report quarter zack consensus estimate molecular diagnostic revenue reflect increase year quarter other few factor likely influence hologic result fiscal second quarter be follow hologic be optimistic sustain solid earning trend courtesy gain breast health segment sale same have improve basis establish clinical superiority segmental product last quarters company have witness consistent rise market share breast health back direct consumer initiativesand insurance coverage additionally company adoption new mammography system dimension performance encourage new product have already start leverage company genius brand also lure customer upgrade exist system company be build broader portfolio breast health product service core genius system so play instrumental role breast health continuum care noteworthy regard be recent pma approval fda clarity hd high resolution imaging intelligent imaging technology product be now available dimension breast tomosynthesis system zack consensus estimate second quarter fiscal remain ahead prior year tally flip side hologic confront challenge related unfavorable foreign currency movement past few quarters escalate operate expense intense competition particularly tomosynthesis market continue raise concern model suggestsper proven zack model company solid zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp hologic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning quarter uncover best stock buy sell re report earning esp filter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision other stock worth lookhere be few other medical stock worth consider right combination element also surpass estimate time baxter international inc bax free report have earning esp zack rank laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be zack rank player see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
257,SYK,stryker corporation syk free report be currently top stock medical device space past year stryker share have rally compare industry return past day zack consensus estimate earning share rise company have zack rank buy indicate possibility outperformance term stock have vgm style score buoy optimism notably stock growth style score combine zack rank strong buy outperform most stock let find recent positive trend sustain stock impressive performance long run stryker corporation price consensus stryker corporation price consensus stryker corporation quotewhat make attractive pick promising mako platformmako be stryker robotic arm assist surgery platform last report quarter mako robot installation totale globally unite state additionally company have first robot sale japan approval mako be expect end moreover mako total knee procedure be more competitive surgeon used triathlon total knee implant first time stryker exit mako robot install hospital represent customer base guidance solidstryker expect net sale be positively impact courtesy favorable foreign exchange rate adjust earning be expect range first quarter earning guidance be company anticipate organic sale growth range management project capital expenditure range compare approximately strategic buyoutsstryker acquisition strategy have help company gain traction recent buyout minnesota base entellus medical inc be likely help physician conveniently perform wide range ent procedure recently stryker acquire vexim specialize development sale vertebral compression fracture solution other key picksa few other top rank stock broader medical space be bio rad laboratory inc bio free report envision healthcare corporation evhc free report integer holding corporation itgr free report bio rad have expect long term growth rate zack rank strong buy see complete list today zack rank stock here envision healthcare have expect long term growth rate zack rank integer holding have expect long term growth rate zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
258,SYK,market capitalization approximately corporation abc free report have be benefit consistent solid organic revenue growth world courier business acquisition deal walgreen temporary pharmedium slowdown decline dollar generic inflation cutthroat competition niche space lower expect contribution generic launch be dent growth fiscal expect revenue growth range year year basis notably zack consensus estimate revenue be currently peg reflect increase year year company expect adjust earning share range fiscal notably zack consensus estimate earning be currently peg share fall guidance however fiscal earning estimate decline last month buoy mixed trend stock have zack rank hold corporation price consensus corporation price consensus corporation quoteso here take quick look major factor have be plague also brighter prospect indicate term recovery factor plague have recently receive grand jury subpoena attorney office western district tennessee document testing certain type syringe make pharmedium lab be company largest highly automate production facility consequently suspend operation recall product have yet expire recently fda also visit facility same reason sluggishness unit be likely hamper company specialty distribution segment long haul second quarter fiscal segment result be negatively impact pharmedium company witness lower expect revenue profit contribution management contribution adjust ebit ep fiscal be lower anticipate due time certain ongoing incremental expense require perform remedial measure hold adversity pharmedium world courier unit be likely be key driver revenue unit be global leader specialty logistic design execute world class logistic process management world courier position leader global specialty logistic service propel volume growth overall performance company last couple quarters well recently company announce designation flagship world courier unit first logistic company obtain global good distribution practice gdp certification major standard business post impressive result second quarter fiscal end quarter world courier company own office be spread more country investigational drug depot locate emerge market worldwide solid volume growth expand operate margin have favore world courier unit quarter price outperformed industry month time company share have gain compare industry rise current level be also higher index return key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
259,SYK,patterson company inc pdco free report report adjust earning cent share fourth quarter fiscal line zack consensus estimate earning fall year year net sale dip year quarter tally miss zack consensus estimate lower sale gross margin contraction mar result report quarter patterson company have zack rank strong sell patterson company inc price consensus patterson company inc price consensus patterson company inc quotesegmental company currently distribute product subsidiary patterson dental patterson animal health dental segment provide virtually complete range consumable dental product equipment software turnkey digital solution value add service dentist laboratory north america fourth quarter dental sale total sale decline year year approximately change sale force disruption enterprise resource plan implementation expansion company digital equipment portfolio hinder revenue segment however sale be constant currency basis cc dental consumablesale sub segment be year year sale be cc dental equipment softwaresale segment decline year year basis sale be cc other service segment comprise technical service part labor software support service well office supply sale segment decline year year basis sale be cc animal health segment be lead distributor product service technology production companion animal health market north america come fourth quarter performance platform total sale sale increase almost year year basis global companion animal sale inched production animal sale increase reflect strong performance swine beef cattle segment margin profit report quarter be year year percentage revenue gross margin contract basis point bps quarter operate income fourth quarter be year year percentage revenue operate margin contract bps quarter company expect adjust earning share fiscal range share zack consensus estimate be peg share lie guidance patterson company expect deal amortization expense cent share takelackluster sale earning performance dampen patterson company fourth quarter result however company strong fiscal guidance buoy optimism be upbeat animal health segment have be perform well lately company provide wide range consumable supply equipment software value add service broad spectrum product cushion company economic downturn medtech space believe diversify product portfolio strong veterinary business prospect accretive acquisition strategic partnership be key growth catalyst flip side operate margin have be dull decline revenue dental segment be headwind recent fall segment be drive lower sale cerec digital technology product management expect headwind technology base equipment business persist fiscal key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corp syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
260,SYK,investor focuse medical space have likely hear stryker syk free report be stock perform well comparison rest sector peer quick glance company year date performance comparison rest medical sector help answer question stryker be member medical sector group include individual stock currently hold zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank emphasize earning estimate estimate revision find stock improve earning outlook system have long record success stock tend be track beat market next month syk be currently sporting zack rank buy zack consensus estimate syk full year earning have moved higher past quarter mean analyst sentiment be stronger stock earning outlook be improve base latest available datum syk have gain so far year comparison medical company have return average mean stryker be outperform sector whole year breaking thing more syk be member medical product industry include individual company currently sit zack industry rank stock group have gain so far year so syk be slightly underperform industry group term year date return go forward investor interested medical stock continue pay close attention syk look continue solid performance
261,SYK,cerner corporation cern free report be currently plague headwind downbeat guidance stiff competition niche space wonder company be underperform medtech space moment past year cerner stock have lose industry rally last day zack consensus estimate cerner earning ongoing quarter have decline cent share stock have growth score dampen investor confidence stock research show stock growth score combine zack rank strong buy buy outperform most stock further company zack rank strong sell only reflect innate weakness consequently be prudent dump stock portfolio chance favorable return term appear bleak cerner corporation price consensus cerner corporation price consensus cerner corporation quotewhy offload view second quarter cerner expect revenue range zack consensus estimate second quarter revenue be peg expect range cerner expect revenue range previous range notably current year zack consensus estimate revenue guide range cerner anticipate adjust earning share prior guidance zack consensus estimate earning share be peg cent lie project range soft segmental core segment license software subscription have exhibit soft performance late first quarter revenue license software segment fall year year basis management lower anticipate level license software booking quarter impact revenue moreover subscription revenue gross plunge year year basis lower expect subscription booking mar growth segment stiff competitionat present cerner face intense competition industry repute name allscript healthcare solution epic system ge healthcare technology mckesson corp quality system significant challenge dent pricing margin key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate ongoing quarter stock sport zack rank see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
262,SYK,masimo corporation masi free report florida base thermomedic inc recently announce market release tir development masimo reinforce position provider patient monitoring solution follow announcement masimo share price inched close notably share masimo have rally outperform industry decline year time stock currently carry zack rank hold market prospectsper patient monitoring device market unite state be project reach cagr need continuous monitoring detection treatment heart brain lung blood activity be fuel expansion tir glancetir be contact bluetooth enabled thermometer easily integrate masimo root patient monitoring connectivity platform masimo root platform be powerful patient monitoring hub integrate array technology device system tir save cost waste eliminate need purchase additional disposable bluetooth connectivity enable wireless datum transfer connect root monitor help communicate important patient vital sign bedside device warning sign be transfer hospital emrs electronic medical record masimo patient safetynet patient monitoring focuscalifornia base masimo be know develop manufacturing noninvasive patient monitoring technology company new root patient monitoring connectivity platform integrate rainbow set technology root next generation sedline brain function monitoring help clinician monitor state brain anesthesia secondly masimo patient safetynet system be wireless remote monitoring system help clinician effectively monitor patient clinical datum especially general floor hospital regard be note masimo recently launch replica application smartphone tablet work conjunction patient safetynet platform regulatory front masimo have be experience positive tiding company flagship rad pulse co oximeter integrate nomoline capnography recently obtain ce mark read more masimo get ce mark nomoline expand capnography key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
263,SYK,market capitalization approximately dentsply sirona xray free report report line earning trail quarters however company face margin threat foreign exchange headwind zack rank hold stock have lose industry rise month time let take detailed look company performance operation analyze investor hold stock now probable sirona expect adjust earning share range previous projection notably zack consensus estimate earning be currently peg share significantly lower management expectation dentsply sirona expect gross margin operate margin be flat slightly underlie margin rate improvement business be expect be offset foreign exchange effect headwind target inventory equipment reduction end first quarter company confirm expect full year operate margin be basis point year year basis dentsply sirona have significant international foothold particularly europe therefore strengthen dollar especially euro well emerge market currency negatively impact company result believe currency volatility remain headwind company also face significant pricing pressure due intensify competition favore stock dentsply sirona innovation have be consistently drive top line management company spend more thus have robust pipeline furthermore effort dentsply sirona laser team accelerate major innovation deserve mention company commitment clinical education be also praiseworthy denstply sirona plan open state art training center charlotte nc help reach more dental professional year moreover european center bensheim germany be able directly communicate practitioner year supplement continue education effort notably dentsply sirona be come new dental academy second half management be bullish recently complete acquisition orametrix orametrix software uniquely integrate digital scanning ray create customize individual treatment plan orthodontic patient lately american association orthodontist company launch full clear liner integration orametrix omnicam witness positive reviews bottom lineunhinder persistent issue analyst be optimistic dentsply sirona current quarter revenue zack consensus estimate be peg reflect year year rise dentsply sirona inc price consensus dentsply sirona inc price consensus dentsply sirona inc quotekey picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
264,SYK,pacific bioscience california inc pacb free report first quarter result expect release apr be assume show steady growth product revenue wing core business majorly drive growth decline revenue other segment mar company prospect first quarter last report quarter company report loss cent share year year miss zack consensus estimate penny revenue come beating zack consensus estimate year year basis notably first quarter zack consensus estimate be peg loss cent share reflect year year growth other hand zack consensus estimate revenue be pin indicate decline pacific bioscience report average negative earning surprise trail quarters let delve deeper number pacific bioscience california inc price ep surprise pacific bioscience california inc price ep surprise pacific bioscience california inc quoteproduct revenue focuspacific bioscience flagship platform sequel system have be fortify company footprint worldwide fiscal product revenue account whopping company net revenue fourth quarter fiscal segment post revenue worth year year be encourage note current quarter zack consensus estimate segment revenue be fix year year basis consumable revenue fourth quarter be year year basis mark metric eighth consecutive quarter growth continue consumable sale momentum upside be drive increase utilization company grow install base sequel system also know pacbio sequel system however instrument revenue dip year year basis other factor playpacbio sequel system drife growthper management sequel generate revenue grow more fold fourth quarter represent whopping fourth quarter revenue additionally bgi china order sequel system make primary growth driver pacific bioscience past year number study have be used plan use pacbio whole genome sequence goal increase cure rate genetic disease study include stanford university school medicine european solve rd consortium perform individual rare disease study novogene have announce plan sequence chinese genome platform have also witness series development lately flagship pacbio sequel be currently be used alabama base hudsonalpha institute biotechnology support goal dramatically increase diagnostic success rate challenge pediatric clinical case moreover beij base annoroad gene technology have recently place purchase order pacbio sequel system be expect increase annoroad large scale genomic service capability various field view first quarter revenue be expect be slightly lower report count fourth quarter fiscal due seasonality banking better expect fourth quarter show pacific bioscience expect revenue grow year figure translate approximately total revenue shrink service revenue marginsin last report quarter revenue service other segment fall year year basis almost full year fiscal revenue segment deteriorate compare full year zack consensus estimate segment revenue first quarter be fix year year other hand gross margin quarter be basis point year year company incur operate loss wider loss year quarter here be quantitative model predict pacific bioscience carry zack rank buy do not have positive earning esp need increase odd earning beat zack esp earning esp pacific bioscience be uncover best stock buy sell re report earning esp filter zack rank pacifc bioscience carry zack rank increase predictive power esp however also need positive esp be confident earning beat stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corp syk free report have earning esp zack rank see complete list today zack rank strong buy stock here hologic inc holx free report have earning esp zack rank hold edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
265,SYK,maintain streak positive earning surprise stryker corporation syk free report report fourth quarter adjust earning share beating zack consensus estimate penny revenue outpaced zack consensus estimate notably revenue improve year year adjust earning share increase year quarter upside primarily be attribute organic sale growth report quarter organic growth unite state be year year basis same ous be management fourth quarter result be drive research development innovation well stellar performance company mako total knee application stryker corporation price consensus ep surprise stryker corporation price consensus ep surprise stryker corporation quote last year stryker have favorable run bourse stock have return compare industry rally segment revenue segment totale year year constant currency cc revenue increase cc segment deliver organic growth cc courtesy strong performance unite state notably region witness organic growth quarter such gain indicate robust demand company print product foot ankle portfolio mako platform medsurg sale segment totale year year basis cc revenue increase cc internationally medsurg report constant currency growth organic sale growth indicate strong performance europe australia neurotechnology spine segment deliver sale worth year year cc revenue improve cc neurotechnology spine witness growth cc organic growth year year basis show strong demand product target coil ais cmf company neuropowered instrument further spine business unite state also post positive number bolster high demand ivs print interbody tritanium product quarter highlightsmako momentum continue fourth quarter mako total knee platform drive stryker earning mako robot installation totale globally unite state additionally company have first robot sale japan approval mako be expect end surgeon have be trained report quarter integration mako moreover mako total knee procedure be more competitive surgeon used triathlon total knee implant first time mako utilization rate have surge more year year basis company exit year mako robot install hospital represent customer base edge fourth quarter stryker continue invest internal innovation expense totale sale report quarter full year basis marginsadjusted gross margin fourth quarter be flat year year management gross margin be affected productivity issue associate continue recovery puerto rico manufacturing facility operation facility be disrupt thank natural calamity further unfavorable pricing integration risk dent margin operate margin quarter be net sale basis point year quarter glanceon full year basis revenue grow adjust earning increase orthopedic segment report net sale medsurg account total sale neurotechnology spine contribute total revenue fy guidancestryker expect net sale be positively impact courtesy favorable foreign exchange rate adjust earning be expect range first quarter earning guidance be company anticipate organic sale growth range management announce capital expenditure range compare approximately financial positionstryker continue maintain strong balance sheet cash cash flow operation be approximately total debt end year amount takestryker corporation exit fourth quarter full year impressive earning revenue figure company solid product portfolio outstanding mako total knee performance initiative buoy optimism however high debt sage product recall issue be concern zack rank key picksstryker carry zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter improve year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
266,SYK,fourth quarter earning season have commence positive note most sector decent picture participant have report jan total earning company be year year higher revenue beating earning estimate surpass top line expectation notably company be report earning week latest earning preview overall earning fourth quarter be expect increase growth revenue indicate improve growth projection previous quarter drive corporate tax overhaul relatively healthy job datum factor have boost corporate earning stoke investment base pattern fourth quarter be expect register modest double digit percentage earning growth year year basis medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight abbott free report intuitive surgical isrg free report company exit fourth quarter solid note beating zack consensus estimate count upbeat fy guidance also instill confidence fourth quarter earning growth rate medical sector be peg revenue growth upcoming releaseslet take look major other medtech stock slate release quarterly report jan stryker corporation syk free report result be schedule release market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be year year basis stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate buoy prospect quantitative model indicate earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate stryker earning esp be uncover best stock buy sell re report earning esp filter stryker carry zack rank read more core segmental growth aid stryker earning stryker corporation price consensus stryker corporation price consensus stryker corporation quotezimmer biomet holding inc zbh free report be set report result market open notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be project year year basis solid prospect company surgical sport medicine foot ankle extremity trauma arm macroeconomic uncertainty unfavorable currency fluctuation have be dent sale past few quarters company have be deal pricing pressure regard zimmer biomet witness negative pricing pressure approximately last quarter absence favorable change line headwind reflect company fourth quarter result read more arm drive zimmer biomet earning result proven model do not conclusively show earning beat zimmer biomet quarter zimmer biomet have earning esp stock carry zack rank sell see complete list today zack rank strong buy stock here zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc quotealign technology inc algn free report be set report result market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be cent year year basis align technology achieve milestone patient undergo treatment flagship clear aligner system invisalign november company have be adopt several strategy drive adoption core invisalign product line company receive patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align technology collaborate digital design recent past read more invisalign drive align technology earning positive development proven model do not conclusively show align technology be likely beat earning quarter align technology have earning esp stock carry zack rank align technology inc price consensus align technology inc price consensus align technology inc quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
267,SYK,effort strengthen global presence nuvasive inc nuva free report be plan renovate extend san diego global headquarters lead medical device company also aim add highly sophisticated innovation center excellence facility nuvasive further plan add world class surgeon education lab apart expand work space company intend introduce educate surgeon globe company highly sophisticated spine technology procedure innovation center excellence nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery have be steadily strengthen global position company open center excellence amsterdam be follow build new sq ft medical device facility west carrollton moreover company own sq ft facility be used central distribution hub tn nuvasive have be ride strength international business interestingly company witness year year improvement top line front second quarter account robust growth international business encouragingly note quarter marked third consecutive quarter more growth international business thus company effort solidify global footprint seem be strategically align report becker spine review global minimally invasive spine surgery market be expect witness cagr give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery however past month nuvasive share price have underperform industry stock have decline contrast broader industry gain company have also underperform gain market same time frame zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
268,SYK,kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market recently announce voluntary product recall oral care lineup be offer company sage product unit add voluntary recall stryker have place temporary hold certain cloth base product decision follow complaint minor irritation allergic reaction consumer however management expect reinitiate product shipment september expect begin full supply capacity end year share price stryker slip close follow news release lead recall recall pertain cross contamination issue oral care solution be manufacture sage third party supplier notably solution be distribute market july august however stryker affirm have close business third party supplier fact sage have resume production oral care solution come temporary hold decision cloth base product fda expressed concern regard ongoing microbiological testing method product sage platform now fda have instruct stryker product be verify used new compendial microbiological method undoubtedly new method be more time consume complex previously used sage notably fda have warn stryker issue july product recall hurt recall be likely adversely impact company sale operate income full year stryker now expect organic sale growth low end previously issue guidance band add company announce net earning diluted share be expect low end range third quarter stryker estimate adjust net earning diluted share low end previously issue band stryker have be grapple supply issue spine business long prove be major drawback quarters ahead fact international growth company spine segment second quarter be partially affected supply headwind stock performance glancestryker share price movement past year have be favorable company yielded return almost better broader industry only solid performance medsurg neurotech segment last report quarter hold promise strength international segment strong momentum europe china also buoy optimism zack rank key picksstryker have zack rank hold few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
269,SYK,varian medical system var free report recently install varian probeam cyclotron university college hospital london nhs foundation trust uclh proton beam therapy center notably cyclotron be particle accelerator accelerate proton third speed light clinical use uclh feature treatment room commence treat patient earlier varian medical deliver cyclotron first national health service high energy proton therapy center latest move california base provider cancer care further consolidate global foothold provide proton therapy solution believe such positive development further boost varian share have gain industry decline past month market prospectsper grand view research global proton therapy system market be expect reach increase number proton therapy center rise prevalence cancer hospital focus investment be believe be primary growth driver varian proton therapy magnatevarian medical probeam system be forefront industry have create world first commercially available pencil beam scanning system notably be first kind deliver intensity modulate proton therapy management fiscal varian medical sale pipeline have remain solid proton order company have also be focuse education training continue growth proton therapy world recently varian medical university school medicine reach first educational milestone proton treatment center more medical professional have be trained joint venture furthermore recently st petersburg center nuclear medicine sergey berezin medical institute successfully complete first pediatric patient treatment varian probeam proton therapy system read more varian medical probeam platform gain traction russia earlier varian medical probeam be also select penn medicine academic medical center university pennsylvania additionally company coveted aria information management system eclipse treatment plan system be also picked penn medicine zack rank other stock considervarian medical currently flaunt zack rank strong buy few other top rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
270,SYK,medtronic plc mdt free report brain therapy business get boost recent fda approval company latest deep brain stimulation dbs clinician programmer application approval have come close heel european ce mark approval same march notably dbs therapy be surgical procedure place medical device deliver electrical stimulation accurate lead location brain order reduce most disable motor symptom medtronic application design use samsung galaxy tab tablet incorporate input clinician globally therefore treatment be helpful streamline workflow enhance clinical programming experience company also claim program be useful provide support neurologist neurosurgeon treat parkinson dystonia patient used company dbs system therapy apart neurological disease medtronic dbs clinician programmer be also approve use medtronic dbs system treat medically refractory epilepsy therapy be launch later year unite state approximately medtronic device have be globally implanted so far needless say latest fda ce mark approval application immediately improve programming interaction be critical post implant care thousand patient programmer also enable upgrade rechargeable implantable neurostimulator service life year provide patient additional year next device replacement medtronic brain therapyin brain therapy medtronic be lead development endovascular therapy market treatment ischemic stroke result high teen growth neurovascular last report fourth quarter fiscal company also have great quarter neurosurgery low double digit growth highlight strong demand stealthstation navigation system mazor robotic guidance system visualase mri guide laser ablation system worldwide medtronic dbs therapy have already gain much popularity have win approval several place internationally include unite state europe cure disable symptom essential tremor parkinson disease company announce receipt health canada license suretune software dbs europe canada australia dbs therapy already own license treat refractory epilepsy transparency market research report global deep brain stimulation device market be estimate reach value worth cagr company clearly boast huge growth potential market share price performanceover past month share medtronic have outperformed industry belong stock have grow compare industry increase zack rank key picksmedtronic currently carry zack rank strong sell few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report stryker corporation syk free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate zack rank stryker have project long term earning growth rate stock carry zack rank buy medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
271,SYK,unite state be world largest medical device market be expect improve further aid long track record chronic disease also suspension controversial medical device tax year industry be currently ride high optimism research emergo medical device industry be project reach market value stryker corporation syk free report surmodic inc srdx free report be close contender space notably stock carry zack rank buy raise investor optimism stock also have vgm score research show stock vgm score combine zack rank strong buy be profitable pick here make detailed analysis company fundamental determine stock be currently position better medical product space market cap stryker be lead medical device company operate global orthopedic market other hand base minnesota surmodic be lead provider medical device diagnostic ivd technology company have market cap price performancein past year stryker share have gain compare industry rise stock have also surpass index increase meanwhile share surmodic have sky-rocket period price see complete list today zack rank stock here earning zack consensus estimate stryker current year earning be peg share reflect project growth same surmodic be peg cent indicate decline moreover stryker earning share have witness cagr surmodic earning project negative cagr totale cent hence stryker win round sale zack consensus estimate stryker current year revenue be peg show growth same surmodic be pin reflect growth stryker revenue witness cagr reach surmodic revenue depict negative cagr here too stryker win surmodic factor drive robotic arm assist mako surgery platform have be consistently drive top line last report quarter platform record new robot installation globally notably mako tka knee platform drive orthopaedic segment deliver organic growth recently company raise guidance second quarter buoy optimism stryker corporation price consensus stryker corporation price consensus stryker corporation have be acquisition spree recently company announce have reach agreement embolitech acquire innovative thrombectomy platform technology be likely enhance company focus develop highly differentiate whole product solution medical device customer recently company receive approval fda low profile percutaneous transluminal angioplasty pta balloon dilation catheter notably device be design broad range peripheral vascular application moreover partnership medtech bigwig abbott be also major positive surmodic inc price consensus surmodic inc price consensus surmodic inc quotein conclusionour comparative analysis indicate stryker be position better surmodic consider price performance well earning sale growth other key picksa few other top rank stock broader medical space be genomic health ghdx free report intuitive surgical inc isrg free report genomic health have expect earning growth rate stock flaunt zack rank intuitive surgical have expect long term earning growth rate sport zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
272,SYK,medical instrument industry broader medical universe have be gain innovation higher consolidation focus emerge market tax abolition industry increase month time higher index rise fundamentally industry have benefit massive change consumer behavior well be evident rise minimally invasive surgery higher demand liquid biopsy test well use quick improve patient care shift payment system value base model be interesting analyze best medical instrument stock be likely yield solid return day come first let glance latest headline space latest medical instrument headline glance stryker takeover plan boston medical instrument fraternity have be ride current merger acquisition trend recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more however possibility deal be uncertain thre be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific company acquire boston scientific neurovascular unit indicate probability second collaboration read more stryker likely acquire boston scientific stryker have zack rank buy deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience reduce pricing pressure competition further company strong acquisition policy gain rapidly expand customer base moderate leverage enhance cash flow glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention abiom reserve slot lead medical instrument player abiom inc abmd free report replace wyndham worldwide corp enter global industry classification standard gic health care supply sub industry index research report globe mail abiom be follow trend medical device technology company reserve top slot index remind investor align technology inc algn free report top index abiom currently have market capitalization further company financial viability adequate liquidity reasonable price sector representation have lend competitive edge medical instrument industry read more abiom replace wyndham benchmark tax abolition boost da bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief tax take toll entire medical device industry enactment advanced medical technology association lobbying group tax have negative impact medical innovation result loss defer creation job now deferral encourage activity space repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have invoked massive investment sector top medical instrument existence number player medical instrument industry choose right stock potential yield return be daunting task proprietary zack methodology make fairly simple have take help zack stock screener select favorable stock have select stock have favorable growth style score carry zack rank strong buy research show stock style score combine zack rank offer best investment opportunity see complete list today zack rank stock here varian medical system inc var free report outperformed industry month time stock have return have zack rank zack consensus estimate full year earning be currently peg year year june varian medical system demonstrated comprehensive portfolio advanced brachytherapy solution american brachytherapy society annual meeting development be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system company have be gain consistently coveted halcyon platform cost effective radiotherapy cancer treatment system notably company also launch halcyon kilovoltage imaging solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian have also be go global acquisition agreement recent buyout include sirtex australia coop taiwan partnership ministry health brazil solid guidance fiscal instill confidence intuitive surgical inc isrg free report outperformed industry month stock have rise almost sport zack rank zack consensus estimate full year earning be currently peg year year grow adoption company da vinci system increase procedure volume continuous innovation solid recur revenue base be key catalyst intuitive surgical da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand movement be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have make available minimally invasive surgery more patient worldwide recently system have cure patient diagnosed inguinal hernia integer holding corporation itgr free report outperformed industry last month stock have return industry decline zack consensus estimate full year earning be currently peg year year company witness impressive start high organic year year growth earning revenue cardio vascular arm deserve special mention here other segment have also be deliver solid performance strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove profitable quarters ahead company have multus year plan long term development impressive guidance decline operate expense clear debt be other major positive hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
273,SYK,aug issue update research report kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market company currently have zack rank buy stryker have impressive run bourse last month trading industry term price performance glimpse price movement reveal stryker share have gain compare favorably rise industry belong company have diverse product portfolio cushion significant sale shortfall economic downturn stryker pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be unite state furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position stryker have be follow acquisition drive strategy boost growth profile june company announce definitive agreement acquire novadaq technology inc share net purchase price transaction be structure arrangement canada business corporation act be subject customary close condition include approval novadaq shareholder stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market second quarter flip side china prove be challenge market stryker strong guidance be also catalyst third quarter company expect adjust earning range share full year company estimate adjust earning band stryker expect organic sale growth full year other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month steris have positive earning surprise trail quarters stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
274,SYK,headquarter sunnyvale accuray inc aray free report recently announce boise base summit cancer center have initiate cancer treatment radixact treatment delivery system notably radixact system leverage company flagship tomotherapy platform radixact system provide complex treatment such craniospinal total marrow irradiation add functionality summit cancer center have capability perform stereotactic radiosurgery srs stereotactic body radiotherapy sbrt spare normal tissue maintain optimal treatment efficacy radixact system have be design deliver image guide intensity modulate radiation therapy extremely precise form radiation therapy platform gain japanese regulatory approval shonin approval last quarter be expect start formal treatment fourth quarter regard glimpse preliminary fourth quarter result reveal accuray expect approximately gross product order solid growth gross order be buoy full commercial launch radixact system continue strong demand company flagship cyberknife system stock price estimate revision trendaccuray have have unimpressive run bourse last year company have lose way wider broader industry rally almost moreover current level compare unfavorably gain furthermore estimate revision stock have be unfavorable full year estimate deteriorate cent loss cent share owing bearish analyst sentiment accuray carry zack rank sell signify term takeaccuray top line growth be highly dependent cyberknife tomotherapy system sale however system involve significant capital spending many healthcare provider be reluctant spend primarily due sluggish macro economic condition mar revenue long haul however company have be gain ground series positive tiding regulatory front recently notable one accuray receive clearance fda idms datum management system july key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
275,SYK,base audubon pa lead musculoskeletal implant company globus medical inc gmed free report announce receipt approval excelsius gps robotic guidance navigation system fda fact positive tiding regulatory front have favore globus medical company have already clinch ce mark excelsius gps january system support minimally invasive open orthopedic neurosurgical procedure screw placement application system be exclusively design limit radiation exposure reorganize assist implant placement excelsius gps system work different imaging modality excelsius gps integrate globus medical implant instrument be compatible pre operative ct intra operative ct fluoroscopic imaging modality globus medical be gear worldwide launch include logistic supply chain manufacturing support excelsius gps system fact technology have encourage globus medical increase investment technology acquisition distribution channel share performance estimate revision trendover last month globus medical have be trading broader industry company have lose much wider broader industry decline current level also compare unfavorably decline only same time frame estimate revision trend globus medical have be unfavorable late current quarter analyst moved south compare movement opposite direction last month result magnitude current quarter estimate fall cent share same time frame viewpointa research report technavio expect global musculoskeletal disorder therapeutic market see cagr approximately believe globus medical latest regulatory progress lend competitive edge global niche space meanwhile stock have zack rank sell signify probability term contrary stock long term expect earning growth rate instill confidence investor add positive company be debt free end just report second quarter globus medical reaffirm guidance full year sale approximately adjust earning share key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent solid year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
276,SYK,medical device manufacturer cardiovascular system inc csii free report recently release year datum liberty clinical study late breaking presentation amputation prevention symposium amp chicago liberty be prospective observational multus center post market study study be base more patient site include patient claudication patient critical limb ischemia cli patient most severe form cli study examine acute long term clinical economic outcome peripheral vascular intervention pvi peripheral artery disease pad patient liberty include fda approve endovascular device treat pad month datum study demonstrated peripheral endovascular intervention marked improvement ruthetford class high freedom major adverse event be precise liberty show pvi help prevent amputation patient pad specifically cli company press release american suffer pad be cause accumulation plaque peripheral artery reduce blood flow believe company be adopt appropriate strategic move capture niche market regard note company recently receive fda approval radial access diamondback peripheral orbital atherectomy device treat pad commercial availability be expect begin calendar year notable stock broader industry be haemonetic corporation hae free report stryker corporation syk free report lantheus holding inc lnth free report zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
277,SYK,cardinal health cah free report premarket approval pma application incraft incraft stent graft system recently receive favorable recommendation fda circulatory system device panel medical device advisory committee vote favor system notably incraft system come cardinal health cordis unit be acquire earlier however end third quarter fiscal cordis unit performance lack luster significantly affected cardinal health earning effective tax rate hence pma incraft system have be timely help cardinal health secure broader customer base cordis unit incraft system incraft system be cardiovascular platform have advanced endovascular aneurysm repair evar technology treatment infrarenal abdominal aortic aneurysm aaas severe complex condition article experimental clinical cardiology aaa rupture cause death year unite state additional death result repair procedure perform prevent rupture market prospectsper research market global market cardiovascular device reach nearly scale cagr period report further state medical need patient time high increase incidence lead significant growth cardiovascular market price performancewe believe positive development boost share cardinal health have decline year time compare unfavorably industry gain other major health medical pharmaceutical offering lend company competitive edge niche space company offer industry expertise expand portfolio safe product example cardinal health bathroom safety mobility exam room equipment product be exclusively design patient care giver variety product range wheelchair crutch exam room table commode cardinal health offer right mix medical equipment cardinal health ecg monitoring electrode offer quality performance be free neoprene lead mercury be not make natural rubber latex be highly exclusive market cardinal health offer full line baby product well include baby shampoo body wash baby lotion baby powder baby oil more zack rank key pickscardinal health currently carry zack rank strong sell few better rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report stryker corporation syk free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate zack rank stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
278,SYK,initiative enhance clinical development japan parexel international corporation global service company provider clinical research logistic have form alliance osaka international cancer institute bolster patient enrollment clinical trial oncology hematology management osaka leverage parexel expertise provide wide range potential treatment option cancer patient believe solid advancement clinical trial scientific expertise oncology segment fortify parexel foothold niche market oncology regard oncology be largest fastest grow therapeutic area parexel fact segment grow average past year however believe initiative help parexel drive top bottom line solid long term expect earning growth rate hold promise regard furthermore service market be healthy parexel enjoy competitive edge space solid prospect asia pacificparexel growth story asia pacific have be compelling japan company have lead position company be well position advantage outsource market be relatively underpenetrated parexel have operation tokyo kobe osaka japan report third quarter fiscal paraxel business asia have more double last year cagr almost apart japan company see solid prospect china world second largest pharmaceutical market witness double digit growth share shine brightparexel have have impressive run bourse last month company have gain compare favorably broader industry addition stock have also outperformed return same time frame estimate revision trend current quarter full year have be stable last month notably zack consensus estimate current quarter full year stand cent respectively same time frame parexel have zack rank hold bottom lineapart fortify hold oncology space parexel be focuse expedite activity area protocol design study start trial execution regulatory submission product company provide broad range clinical research consult medical communication technology solution service pharmaceutical biotechnology medical deviceindustry worldwide fact global market trend seem favorable moment market be anticipate reach worth cagr persistence market research expect parexel gain significant traction related ancillary market courtesy favorable trend latest partnership key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
279,SYK,aug issue update research report mountain view base omnicell inc omcl free report company develop market end end automation solution medication use process omnicell second quarter performance be impressive year year increase earning revenue company gain revenue banking recent launch strategic partnership notably omnicell recently launch software xt hardware allow aesynt customer fully benefit xt company also launch xt series automate supply dispense system july quarter company also launch controlled substance dispenser module provide secure dispense administration controlled substance however weak margin raise concern flip side omnicell face intense competition medication management supply chain solution market also company have adopt several strategy drive top line include portfolio expansion acquisition further penetration medication adherence market thus company continue battle escalate cost overall majority last month omnicell have be trading industry latest share price movement stock have gain significantly lower broader industry addition zack rank key picksomnicell currently carry zack rank hold few top rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
280,SYK,gainesville fl base exactech inc recently announce new product truliant knee system surgical instrumentation have be honor bronze award international design excellence award idea atlanta ga sponsored industrial designer society america idea winner receive significant international publicity exposure idea contest note hundred entry country continent significant development company knee segment truliant knee system offer advanced approach total knee replacement surgery clinically recognize platform proven implant personalize surgical workflow exclusivity truliant system be embed ergonomic instrumentation design enable surgeon make appropriate bone cut adjustment joint total knee arthroplasty last report quarter knee revenue be flat increase constant currency exactech ride solid knee businessin july exactech take step goal provide inclusive range knee replacement system launch exactechgps tka be advanced software application provide systematic computer guidance orthopedic surgeon total knee arthroplasty tka procedure exactech benefit solid prospect total knee replacement market face tough competition like zimmer biomet holding inc zbh free report offer iassist knee personalize guidance system knee replacement procedure exactech plan complete commercial launch tka software application product development be line company objective gain traction huge untapped total knee replacement market datum provide grand view research market be expect reach worth apart solid initiative knee platform exactech announce fda approval market proprietary exactechgps shoulder application unite state earlier year share price trendsover past month exactech have be trading broader industry company stock have gain higher industry believe company be currently ride high regulatory approval product launch however estimate revision trend current quarter lack luster last month notably estimate moved south compare movement opposite direction zack consensus estimate current quarter fall cent share same timeframe exactech have zack rank hold key picksa few better rank stock broader medical sector be edward lifescience corp ew free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
281,SYK,amedisys inc am free report renown home health hospice service provider have rally last month ahead gain stock have market cap company year historical growth rate be also favorable compare broader industry also company represent return almost comparison broader industry decline last month solid prospect zack rank buy stock be attractive pick present company estimate revision trend current year have also be positive past day analyst moved estimate north movement opposite direction magnitude estimate revision increase share same time frame let find recent positive trend be sustainable recently amedisys end second quarter solid note earning revenue beating year figure also hospice company register strong growth segment amedisys be currently explore opportunity home health hospice segment company favorable demographic trend strategic acquisition encourage well moreover company have be witness growth personal care segment synergy acquisition be encourage company long term strategy evolve traditional home health hospice care company focuse bring home continuum care better serve patient diversify source payment so become less reliant medicare regard company experience improvement medicare revenue comparison decline medicare revenue home health division see last report second quarter home health industry be poise substantial growth long term drive positive demographic trend unite state company continue benefit age demographic population need higher acuity patient home nursing environment notably company be track fortify footprint market place recently announce completion national readmission prevention collaborative nrpc certification program clinical program team handle progress delivery home healthcare program additionally company strong cash balance position bolster confidence stock flip side expect synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksother top rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
282,SYK,aug issue update research report align technology algn free report manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage stock currently have zack rank hold align technology have be trading industry last month stock have gain period compare decline industry company strong invisalign technology prospect growth north america international region look encourage emea second quarter volume surge year year reflect continue adoption invisalign technology core market spain well rapid growth expansion new market include eastern europe central europe benelux report quarter volume soar year year asia pacific belt lead china follow southeast asia japan australia new great news be company have recently open new invisalign technology treatment plan facility china multimillion dollar marketing campaign invisalign technology brand promotion be also likely keep investor upbeat company receipt patent smarttrack aligner material doubt buoy optimism contrary foreign exchange headwind continue major dampener company international performance also escalate cost expense be weigh margin last month comparative study align technology forward forward month basis multiple reflect stock have be quite overvalue key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
283,SYK,lead healthcare diagnostic company laboratory corporation america holding lh free report labcorp recently inked distribution agreement roswell park cancer institute molecular diagnostic subsidiary omniseq inc deal term labcorp distribute omniseq immune report card omniseq comprehensive clinical assay unite state outside company get exclusive right distribute omniseq test base physician integrate oncology member labcorp specialty testing group globally customer covance drug development arm laboratory corporation america holding price laboratory corporation america holding price laboratory corporation america holding quotealso chief scientific officer labcorp diagnostic marcia eisenberg join omniseq board director labcorp have plan participate omniseq series financing round financing be used conduct omniseq ongoing retrospective prospective clinical trial well generate further evidence clinical utility omniseq comprehensive genomic immune profile service notably immune report card be comprehensive immune profile test design inform oncologist regard checkpoint inhibitor cpi treatment decision combine result common biomarker assay relevant checkpoint inhibitor well other informative analysis omniseq assessment provide comprehensive immune profile help identify patient be likely respond cpi monotherapy other hand omniseq comprehensive assay be gene pan cancer next generation sequence tumor profile diagnostic panel help oncologist determine particular line treatment consider fact immune report card omniseq comprehensive trial have receive new york state clinical laboratory evaluation program approval expect alliance help labcorp broaden customer base cancer immunotherapy diagnostic space notably market be grow leap bound recent time datum provide radiant insight inc publish cision pr newswrite global cancer immunotherapy market be expect witness cagr hence believe labcorp latest decision widen position market be perfectly strategic part key tactical plan labcorp be consistently work hard new innovation academic institution capture grow lab testing market advanced assay tool second quarter company have open state art companion diagnostic laboratory north carolina deliver double digit increase year year revenue aid continue growth immuno oncology service company also win companion diagnostic related award first half year pipeline comprise diverse range oncology oncology indication new establish client position well consistent growth future labcorp latest partnership omniseq well decision invest latter research development add further momentum company growth trajectory zack rank key pickslabcorp currently carry zack rank hold better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month
284,SYK,have be pay attention share baxter international bax share have be move stock past month bax hit new week high previous session baxter international have gain start year compare move medical sector year date return peer group drive outperformance stock have great record positive earning surprise have beaten zack consensus estimate last quarters last earning report april baxter international report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year baxter international be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsbaxter international be week high right now future hold bax key aspect question be take look valuation metric order determine company have run ahead front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style baxter international have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective baxter international inc price consensus baxter international inc price consensus baxter international inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately baxter international currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look baxter international pass test thus seem bax share have bit more room run term do baxter international stack competition share baxter international have be soar company still appear be decent choice rest industry industry peer be also solid potential pick include surmodic srdx free report haemonetic hae free report stryker syk free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news baxter international still fundamental bax be promising still have potential be week high
285,SYK,stryker corporation syk free report be big mover last session company see share rise day move come solid volume too far more share change hand normal session stock remain volatile trade range past month time frame witness sharp increase friday move come company report better expect third quarter result zack consensus estimate current quarter have revise downward past day suggest be trouble road so make sure keep eye stock go forward see recent move higher last stryker corporation price consensus stryker corporation price consensus stryker corporation quotestryker currently have zack rank hold earning esp be positive better rank stock medical product industry be terumo corp trumy free report carry zack rank strong buy see complete list today zack rank strong buy stock here be syk go predict see other think downzack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
286,SYK,stryker corp syk free report report adjust earning share third quarter comfortably beat zack consensus estimate cent earning improve share year quarter company base kalamazoo mi have maintain streak positive earning surprise meanwhile trail quarters company post earning beat average currently stryker carry zack rank hold upside earning be primarily drive rise revenue beat zack consensus estimate constant currency cc net sale improve year quarter segment net sale increase year year report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume be partially offset due lower price medsurg net sale increase report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume neurotechnology spine net sale increase report quarter net sale quarter increase increase unit volume be partially offset due lower price fourth quarter stryker expect adjust earning range share full year company expect adjust earning band stryker expect organic sale growth full year takewe believe stryker innovative product pipeline be key catalyst term furthermore grow adoption mako drive sale orthopedic reconstructive surgery market flip side china prove be challenge market company come supply related headwind company have be grapple issue spine business long believe prove be major drawback quarters ahead nevertheless stryker effort sale force management bode well company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock hold zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy ou see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale amount year year abbott carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
287,SYK,varian medical var free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock past year varian medical share have rally versus industry decline current level be also better index gain last day zack consensus estimate current year earning have improve share california base provider radiotherapy solution carry zack rank buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank strong buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive pickdiverse product portfoliovarian medical boast highly diverse product spectrum have secure solid customer base year halcyon radiotherapy treatment system hyperarc platform deserve special mention regard notably halcyon platform have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt meanwhile hyperarc be high definition radiotherapy technology design treat multiple metastase brain cancer case furthermore varian medical recently announce plan demonstrate comprehensive portfolio advanced brachytherapy solution be expect boost company oncology system segment read more varian demonstrate brachytherapy solution portfolio strong international presencevarian medical foresee substantial opportunity cancer care emerge market company have expand reach strategic overseas buyout varian medical sign agreement acquire sirtex australian base company focuse interventional oncology therapy additionally cooperative cl enterprise lead distributor radiotherapy equipment taiwan have be acquire varian medical moreover varian medical recently announce software technology training education cooperation agreement brazil ministry health moh bid make quality radiotherapy treatment readily accessible latin america read more varian medical merge brazil moh fight cancer solid guidancevarian medical provide solid guidance fiscal revenue growth be expect range year year basis fiscal zack consensus estimate revenue be peg adjust earning share be project range zack consensus estimate same be pin guide range other key picksa few other top rank medical stock be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank abiom have project long term earning growth rate stock hold zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
288,SYK,mechatronic high end technology incorporating electronic machine learn mechanical engineering have be vogue late grow prominence artificial intelligence ai robotic company organization significant exposure mechatronic have be rake huge profit research business wire decipher global mechatronic robotic market be project witness cagr period consider strong exposure mechatronic almost sphere technology automobile telecom more evolution medical mechatronic have be most fascinating grow prevalence minimally invasive robot assist surgery self automate home base care use information technology quick improve patient care well shift payment system value base model indicate predominance mechatronic medtech space so let delve detail medical mechatronic have be create new opportunity medtech raise investor confidence put money healthcare space long term gain be mechatronic shape healthcare paradigm medical mechatronic be much await digital evolution global healthcare industry medical mechatronic have provide innovation healthcare industry reduction size age old medical device development low cost disposable device portability device error free result hindawi renown healthcare engineering journal medical mechatronic revolution have be most important driver global knowledge base economy unite state here take look major aspect medical mechatronic have be do round global headline printing medical mechatronicsthe best example mechatronic healthcare industry be printing have change face medical device industry also know additive manufacturing printing be process turn digital model solid dimensional physical object add material layer layer article hub printing have also receive warm response medtech space healthcare notably research firm future market insight expect global print medical device market see cagr major company stryker corporation syk free report have be early adopter printing technology company fda approve tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation robotic boost medical mechatronic rise mechatronic powerful compute improve sense molecular imaging have enabled new robotic solution mitigate age old problem medtech company solution be pain less error free inexpensive so medtech company be used mechatronic base robot cure disease have competitive edge strong customer base solid revenue handsome profit major company medtech giant intuitive surgical isrg free report be notable mention intuitive surgical design manufacture market da vinci surgical system advanced robot assist surgical platform mechatronic base platform enable minimally invasive surgery help avoid trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair day come let take look other medtech stock have be hog limelight base grow prevalence mechatronic artificial intelligence healthcare sector best medtech stock ride high mechatronicsin backdrop medtech stock be well position strong fundamental solid exposure mechatronic have used zack stock screener pick company have zack rank strong buy buy growth score research show stock growth score combine zack rank be better pick most abiom inc abmd free report stock sport zack rank growth score see complete list today zack rank stock here share abiom have surge year time compare favorably industry decline impella abiom flagship product line have continue be growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart expand flagship impella heart pump portfolio abiom recently announce receipt fda pre market approval pma impella cp heart pump smartassist april technology also feature optical sensor development have provide company significant exposure medical mechatronic company plan controlled roll technologically advanced heart pump hospital site develop heart recovery protocol next fiscal year varian medical system inc var free report stock have zack rank growth score share varian medical have gain year time varian medical have receive significant exposure medical mechatronic trend halcyon hyperarc platform halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt hyperarc platform be varian medical high definition radiotherapy technology apr varian medical launch halcyon kilovoltage imaging kv first human kv cone beam ct image halcyon be acquire washington university positive feedback image quality speed image acquisition process further varian medical hyperarc platform be design treat multiple metastase brain cancer case continue witness strong demand steris plc ste free report stock flaunt zack rank have growth score share steris have gain year time company manufacture market infection prevention decontamination microbial reduction surgical support product service steris acquisition base outsourced sterilization service provider synergy health plc be significant achievement buyout enabled combination steris infection prevention service business synergy hospital sterilization service today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
289,SYK,stryker corporation syk free report largest medical device company global orthopedic market have successfully expand product portfolio time aids company cater evolve demand customer kalamazoo mi base company boast diverse portfolio have be aid top line growth reflect project revenue growth expect momentum continue banking strength portfolio acquisition company product portfolio cushion significant sale shortfall economic downturn stryker pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be unite state furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position meanwhile stryker exclusive navigation platform provide streamline software solution allow surgeon accurately track analyze monitor instrumentation pertain patient anatomy surgical procedure enhance patient outcome expect stryker perform well virtue strong diverse portfolio innovative pipeline strategic acquisition ongoing cost control measure increase operate efficiency stryker have be follow acquisition drive strategy boost growth profile acquisition novadaq technology inc complete september be recent example stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market however china prove be challenge market flip side stryker peer orthofix international ofix free report female health company veru free report lemaitre vascular inc lmat free report continue be challenged lower demand health care product additionally company spine business unite state witness supply issue company have be face challenge global economic condition particularly unite state western europe additionally lower reimbursement medical product service impose downward pressure price company product ultimately impact top line make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
290,SYK,sep article publish duke university nuvasive inc nuva free report have reportedly close acquisition time be start company call vertera spine create research duke university georgia institute technology however financial term deal have not be disclose nuvasive have just extend global headquarter san diego currently focus apply procedurally integrate solution minimally disruptive spine surgery latest development remain part strategy have steadily strengthen nuvasive global position company aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state acquisition have also lend company dimensional porous interbody technology peek titanium material notably company have introduce few new feature modulus xlif build fully porous titanium implant create dimensional manufacturing process well design match porosity stiffness bone be encourage note company spinal hardware business comprise implant fixation product magec eos spinal brace lengthen system precice limb lengthen system register growth recently report quarter nuvasive be therefore leave stone unturned gain traction fast grow spine market regard company have be steadily focuse product development claim possess active corporate development pipeline include number strategic investment acquisition partnership opportunity notably first quarter company launch first interbody device mlx tlx used lumbar fusion procedure report becker spine review global minimally invasive spine surgery market be expect witness cagr also report technavio global spinal implant market be expect witness cagr roughly period thus give current market potential believe company be right track gain traction also believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be also dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report rti surgical rtix free report other notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio zimmer biomet collection thoracolumbar product form comprehensive portfolio minimally invasive spine surgery more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
291,SYK,therapeutic inc anik free report global medical technology company specialize integrate orthopedic medicine have make development proprietary hyaluronic acid technology company recently publish favorable datum evaluate usefulness hyalofast weave biodegradable base scaffold treatment cartilage lesion knee joint study be base patient full thickness cartilage lesion knee joint be age remain figure company patient be implanted hyalofast soak bone marrow aspirate concentrate bmac contain mesenchymal stem cell mscs prospectively evaluate year datum trial demonstrated treatment outcome be equally effective age group be more encourage fact be difficult treat patient year age traditional surgical approach such microfracture base finding company claim irrespective patient age hyalofast combination autologous adult mesenchymal stem cell mscs be successfully used treatment option cartilage lesion breakthrough expect market adoption hyalofast increase significantly boost therapeutic sale performance notably hyalofast be commercially available more country worldwide have be used more patient so far also trial result advance company procedure regulatory submission hyalofast fasttrack phase iii trial be currently enrolling patient europe demand therapeutic base treatment field integrate orthopedic medicine traumatic condition be grow leap bound day recent report market research engine regard global orthopedic device market witness cagr be project reach big name orthopedic device market promising growth potential be stryker corporation syk free report nephew plc snn free report orthofix international ofix free report zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
292,SYK,aug issue update research report ohio base steris plc ste free report manufacturer marketer infection prevention decontamination microbial reduction surgical support product service company currently carry zack rank buy steris post better expect result first quarter fiscal earning revenue beating zack consensus estimate however year year decline revenue be dampening positive note organic growth performance be strong segment further growth free cash flow reserve be indicative company strong cash balance also gross operate margin expand year year recently company make couple organizational change serve customer better way expect move enhance company cost structure well last month stock have gain outperformed decline broader industry however note government insurance company consistent effort curb healthcare cost have be putt pressure stock quite time be also concern current customer consolidation scenario continue affect company checked immediately competitive landscape weak cost reduction initiative be other overhang other key picksother top rank medical stock be edward lifescience corp ew free report stryker corporation syk free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy stryker carry zack rank see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month stryker have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
293,SYK,model inc modn free report report fiscal third quarter adjust loss cent share be narrower year quarter loss cent include stock base compensation company incur loss cent share be narrower zack consensus estimate loss cent revenue increase year year miss zack consensus estimate notably model stock have rally year date substantially outperform gain industry belong quarter detailmodel have reportable segment namely license implementation saas maintenance license implementation revenue total revenue grow year year basis company longer sell premise perpetual license management expect revenue line continue decline fiscal saas maintenance revenue total revenue grow year year model be track shift business saas maintenance revenue model revita contribute approximately saas maintenance revenue approximately company license implementation revenue model revenue management platform continue attract prominent name life science high tech field quarter ampleon radio frequency rf power provider select model revenue cloud service significant number system become operational third quarter include nephew edward lifescience ew free report japan stryker syk free report shire icu medical medtech company be add customer base quarter high tech company call also adopt model revenue cloud model third quarter model inc price consensus ep surprise model inc price consensus ep surprise model inc quoteadjusted gross profit increase year year margin increase gross margin benefit higher percentage saas maintenance revenue adjust ebitda be compare year quarter adjust operate loss be compare year loss improve result reflect shrink cost base post revita acquisition management state have eliminate duplicate general administrative sale marketing cost well redundant product outside life science vertical post acquisition model end quarter annual expense synergy run rate be line high end expectation balance sheetmodel exit quarter cash cash equivalent balance end second quarter fiscal guidancemodel provide guidance fourth quarter fiscal expect fourth quarter gaap revenue come range gaap operate loss be project be gaap net loss be likely be cent cent share fourth quarter fiscal gaap revenue defer revenue adjustment be expect be range management continue expect annualize recur revenue arr be represent year year growth gaap loss operation be expect be range better previous guidance loss gaap net loss be expect be range cent cent share fiscal year narrower previous guide range loss cent share management still forecast end cash balance sep model now expect cash flow operation be breakeven slightly positive fourth quarter model expect ebitda be positive fiscal management expect be cash flow positive operation back half company also plan payback portion debt related revita acquisition fiscal zack rank stock model have zack rank hold better rank stock broader technology sector include alibaba group baba free report sport zack rank strong buy see complete list today zack rank stock here long term earning growth rate alibaba be project more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
294,SYK,jun issue update research report haemonetic corporation hae free report company have be benefit continue momentum new business generation expand geography stock carry zack rank buy share lead provider hematology product solution have outperformed industry last month stock have rally compare industry rise haemonetic exit fourth quarter fiscal promising note earning revenue beating zack consensus estimate consistent momentum new business formation widening global footprint have also help company deliver strong result moreover gross operate margin growth buoy optimism investor stock additionally be upbeat haemonetic flourish plasma franchise solid end market demand plasma derive continue drive growth haemonetic be also confident maintain progress commercial plasma collection business further fiscal guidance look promising addition company strong cash position boost investor confidence flip side haemonetic operate fiercely competitive environment respect manual automate system include like mak system moreover company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters also management doesn expect quick recovery blood center outcome further add concern other key pickssome other top rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report abiom have project long term earning growth rate stock sport zack rank strong buy stryker have estimate long term earning growth rate stock hold zack rank intuitive surgical have expect long term earning growth rate zack rank see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
295,SYK,wholly own subsidiary resm inc rmd free report recently enter strategic partnership athenahealth athn free report lead provider network enabled service hospital ambulatory client have release new solution home medical equipment hme provider digitally receive order more provider used athenaclinical athenahealth network point view deal be add feather cap deliver cloud base software post acute care company look set improve business performance patient outcome notably information exchange platform ereferral enable hme organization seamlessly exchange information receive referral external referral source hospice customer be also part community ereferral management happened physician hme staff have manually send receive process referral well related document fax phone call currently be work hard connect more physician ereferral management thus maximize cost time saving well hme respect athenahealth partnership office used athenahealth refer patient hme provider same way refer other care setting forwarding equipment order directly electronic health record system hme provider referral system digitize process largely reduce time entire procedure hand other improve information accuracy expedite patient care prospect resm software service business be gradually grow strong business have be part resm group full year have register stable period success last report third quarter fiscal conference call resm note system handled more digital request last month revenue third quarter increase year year moreover analyze hme market prospect expect growth momentum sustain long run accord article freedonia group demand home medical equipment be likely gain drive technological advance cost containment effort share price performance past month share resm have outperformed industry stock have rise compare growth industry zack rank key picksresm currently carry zack rank hold better rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report abiom have project long term earning growth rate stock sport zack rank strong buy stryker have expect long term earning growth rate stock carry zack rank buy see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
296,SYK,express script hold company esrx free report have underperform broader industry last month company share have gain versus industry rally rapidly change healthcare environment unite state loss client stiff competition niche space be significant headwind company batter such challenge zack consensus estimate second quarter adjust earning be currently peg share last month same revenue be pin reflect year year decline stock have zack rank sell take sneak peek major issue plague express script loss patient mo base pharmacy benefit manager lose certain public sector client result year year decline adjust network claim last report quarter moreover adjust home delivery specialty claim totale quarter year year express script get script recently announce be get acquire cigna corporation global health insurance company acquisition be expect be conclude dec cigna take express script cash stock transaction worth competition rifeexpres script face intense competition patient benefit management industry independent pbms medimpact navitus health solution moreover pbm space be dominate bigwig cvs aetna cigna other guidance express script adjust earning share be estimate band significantly previous range key pickssome better rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy abiom have project long term earning growth rate stock hold zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
297,SYK,cardinal health inc cah free report clayton dubilier rice cd recently announce joint investment plan navihealth notably tennessee base navihealth be acquire cardinal health deal value company have goal acquire entire business year navihealth currently serve more insure member manage care transition approximately acute hospital post acute care facility unite state meanwhile cd be oldest private equity firm world specialize buyout growth capital financing post announcement share cardinal health inched close however stock have decline industry increase past month stock currently carry zack rank strong sell come back news cd manage fund acquire approximately ownership stake navihealth cardinal health retain roughly interest business additionally cardinal health reserve call right reacquire business transaction be expect be complete third quarter latest strategic move enable ohio base distributor healthcare service deliver improve post acute care unite state market prospectsper frost sullivan post acute healthcare industry expect surge approximately revenue upside be attributable shift medically complex patient post acute care setting hence be conclude cardinal health decision have be timely strategic cardinal health acute patient health offer broad range acute patient care solution previously acquire navihealth coordinate care acute post acute set apart enable provider customize patient specific care plan company also analyze datum discover pattern optimize workflow furthermore cardinal health outpatient pharmacy solution enable healthcare provider boost patient population health management play critical role continue patient care discharge hospital home company have also launch line cardinal health hospital quality home consumer product allow patient caregiver buy same product used hospital support continuity care list include product related bath safety daily live aids key pickssome better rank stock broader medical space be abiom inc abmd free report stryker corporation syk free report intuitive surgical inc isrg free report abiom have project long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank buy intuitive surgical have expect long term earning growth rate zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
298,SYK,penumbra inc pen free report be schedule release second quarter result aug market close quarter average earning beat be however company post negative earning surprise last quarter let see thing be shape announcement factor playpenumbra revenue rise year year basis first quarter company stellar performance neuro peripheral vascular company remain focuse product launch geographic expansion expect strong top line uptrend continue yet be report quarter well be also upbeat company promising guidance penumbra forecast full year total revenue range represent growth almost full year penumbra inc price ep surprise penumbra inc price ep surprise penumbra inc quotewe be also encourage company focus product development innovation get reflect second quarter notably research development expense increase first quarter line company introduce product indigo family cat also company receive fda clearance device recently neuro franchise segment further company latest addition smart coil family be wave extra soft finishing coil notably penumbra smart coil system be platinum embolization device comprise complex standard soft coil change softness profile single coil come first quarter result penumbra report loss share cent compare unfavorably earning cent year quarter also gross operate margin deteriorate first quarter expect escalate cost expense continue keep margin pressure yet be report quarter moreover first quarter sg expense have rise year year increase headcount personnel related expense continue company operate income earning be likely get affected yet be report quarter further foreign exchange fluctuation stiff competition major commercial laboratory hospital continue raise caution earning whispersour proven model do not conclusively show beat penumbra quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp penumbra have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank penumbra zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter cooper company inc coo free report have earning esp zack rank insys therapeutic inc insy free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
299,SYK,second quarter earning season gain momentum broader picture longer look bright be expect be putt together member release result jul constitute index total membership note earning growth pace be less last quarter however be more less line trail quarter average earning growth exceed trail quarter average latest second quarter scorecard total earning increase year year higher revenue earning beat ratio remain revenue beat ratio be more information please consult zack earning analysis store medical space investor be concern healthcare space sector have be see lot struggle past half year thank political power change ongoing policy restructure related battle yesterday be finally president donald trump republican healthcare bill pass more barrier very narrow margin investor be however not much optimistic development vox article today effort repeal replace obamacare president donald trump continue make bold promise bill do promise available analysis suggest bill not keep be still chance senate amend latest bill extent still remain unclear accordingly uncertainty medical space be towering high investor be currently adopt see policy space let sneak peek performance major medical product company broader medical space expect jul align technology inc algn free report be upbeat align technology execution strategic initiative international expansion ensure invisalign treatment grow base patient context company strengthen foothold internationally acquire invisalign distributor highly lucrative europe middle east africa emea region well brazil february be likely drive company result soon be report quarter align be expect beat expectation report second quarter result market open have right combination key ingredient stock currently carry zack rank strong buy have earning esp note positive zack esp serve lead indicator likely positive earning surprise bullish zack rank increase predictive power esp uncover best stock buy sell re report earning esp filter read more align technology earning beat card align technology inc price ep surprise align technology inc price ep surprise align technology inc quote boston scientific corporation bsx free report believe medical device major second quarter performance be grossly impact company product recall issue europe other hand company downbeat interventional cardiology business get sort boost company acquisition switzerland base symetis sa boston scientific be schedule report second quarter result market close company currently carry zack rank sell have earning esp hence be unable conclude boston scientific be likely beat earning quarter note sell rate stock never be consider go earning announcement read more boston scientific earning await stock boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote cerner corporation cern free report believe cerner strong sale performance well solid portfolio strategic initiative have position well stellar growth cerner announce have be choose department veteran affair develop electronic health record ehr system department veteran affair use same system company be develop department defense begin operation first site february system facilitate exchange datum military care facility civilian health provider current former service member receive care lead healthcare information technology hcit company be schedule report second quarter earning market close company currently carry zack rank earning esp hence be expect beat expectation quarter see complete list today zack rank stock here read more cerner deliver beat earning season cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotestryker corporation syk free report second quarter renown medical device maker expect adjust earning share range notably indicate rise year year basis believe grow adoption mako robot drive sale orthopedic reconstructive surgery market additionally stryker be well poise acquisition sage physio control past company also expect beat expectation report second quarter result close bell be stock currently carry zack rank hold earning esp read more stryker deliver beat earning season stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quote mckesson corporation mck free report major player pharmaceutical medical supply distribution market expect gain gradually stabilize generic brand market company distribution solution segment perform favorably fiscal weak pricing trend customer consolidation be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp need have positive esp be confident earning beat read more mckesson earning stock likely beat estimate mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
300,SYK,jun issue update research report petmedexpress inc pet free report stock carry zack rank buy company be strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product line several quarters drag new order sale be impressed petm improve performance fiscal entire year demonstrated bullish momentum new order sale growth primarily aggressive advertising company witness softness new order sale fourth quarter be strategically increase advertisement handle situation tactfully further reorder sale grow year final quarter drive change product mix higher price item augment dose average order size rise year petm be also work improve campaign effectiveness company have be quite successful push sale internet approximately company order be generate fourth quarter compare year period late company have start focuse advertising ability better new order sale shift sale higher margin item include generic expand product offering petm offer wide range product dog cat horse believe progress economic condition petm broad product portfolio help drive growth come quarters however aim increase recognition brand name petm market product national advertising campaign procedure company have be incur huge expense related advertising campaign recent time hence escalate advertising expense exert pressure bottom line also tough competitive landscape be major concern stock performance past month petm have underperform industry stock have decline growth industry other key picksother top rank stock broader medical sector include abiom inc abmd free report genomic health inc ghdx free report stryker corporation syk free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate zack rank stryker have project long term earning growth rate stock carry zack rank buy medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
301,SYK,cerner corporation cern free report be schedule report second quarter result jul market close base north kansa city mo company provide healthcare information technology hcit solution worldwide cerner have stellar quarter average earning surprise last quarter cerner report adjust earning cent share beating zack consensus estimate cent notably earning improve cent year quarter company report net revenue beating zack consensus estimate meanwhile revenue rise year period delve deeper fundamental stock let see thing be shape prior release likely positive surprise proven model show cerner be likely beat earning have right combination key ingredient zack esp earning esp cerner be most accurate estimate stand cent zack consensus estimate be peg cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank cerner currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning conversely sell rate stock never be consider go earning announcement combination cerner zack rank positive esp make reasonably confident positive earning surprise season cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotefactor considerview upbeat believe cerner strong sale performance solid portfolio strategic initiative have position stellar growth second quarter company forecast revenue adjust earning be now expect band cent cent share full year management expect revenue cerner currently forecast adjust earning band share development electronic health record system cerner announce have be choose department veteran affair develop electronic health record ehr system department veteran affair use same system company be develop department defense begin operation first site february system facilitate exchange datum military care facility civilian health provider current former service member receive care stable estimate revision trend current quarter analyst moved south compare upward revision last month zack consensus estimate earning share be stable cent same time frame robust portfolio believe cerner strong product portfolio help boost customer base frequent contract win reflect grow traction furthermore company have strong growth opportunity revenue cycle management rcm ambulatory space solid global foothold cerner be largest pure play hcit company wide footprint large reference able client base composite array solution make ideal candidate investor seek exposure hcit industry cerner offer exposure worldwide healthcare automation international operation provide more diversify revenue stream past company have win contract well middle east company have also be work client organization globally focus population health management profile other stock warrant lookhere be few other company want consider proven model show also have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
302,SYK,expect align technology inc algn free report beat expectation report second quarter earning jul market close last quarter company have post positive earning surprise be worth note align technology have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement likely positive surprise proven model show align technology be likely beat earning have perfect combination key ingredient zack esp align technology have earning esp most accurate estimate be cent zack consensus estimate be peg lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank align technology currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination align technology zack rank esp make reasonably confident earning beat drive better expect earning be upbeat align technology execution strategic initiative international expansion thereby ensure invisalign treatment grow base patient context company strengthen foothold internationally acquire invisalign distributor highly lucrative europe middle east africa emea region well brazil feb be likely drive company result be report quarter company announce receipt patent align smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align collaborate digital design march post collaboration align invisalign clear aligner treatment be used dentist tooth alignment procedure design protocol align technology inc price ep surprise align technology inc price ep surprise align technology inc quotenotably expand invisalign brand offering align technology introduce patient friendly solution invisalign mandibular advancement teen march accord company advancement help offer more option treatment boost top line yet be report quarter recently company expand work flow option lead itero scanner context align collaborate exocad gmbh march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis february company have announce addition digital nobel biocare implant itero intraoral scanner portfolio moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend likely continue yet be report quarter notably second quarter company project earning share cent revenue company also expect invisalign case shipment band year flip side unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
303,SYK,quest diagnostic inc dgx free report be schedule report second quarter earning result open bell jul last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note quest diagnostic outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement factor playpose threat quest diagnostic revenue requisition performance last report first quarter see basis point bps decrease same moreover remain apprehensive company professional lab service pls engagement wj barnabas health healthone system hca holding inc hca carry lower revenue requisition due nature work apart unit price headwind have less bps first quarter unit price headwind stay moderate range approximately last few year company continue expect same too quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate quotealso last year quest diagnostic face several reimbursement issue affected revenue company be concern cms center medicare medicaid service proposal related protect access medicare act pama however reimbursement pressure have likely act overhang performance be report quarter company expect beat pressure test business mix positive note observed report first quarter fiscal quest diagnostic seem be determine stimulate performance adhere point growth strategy accelerate growth drive operational excellence be also optimistic successful execution company strategy grow esoteric testing business drive profitable growth also recent past quest diagnostic witness significant growth infectious disease testing prescription drug monitoring industry lead wellness business expect growth driver remain active second quarter well drive same metric precede quarter believe recent development significantly contribute company top line second quarter company currently expect full year revenue range annualize growth current zack consensus estimate revenue be peg close low end company guide range addition company adjust earning share have be forecast zack consensus estimate be range earning whispersour proven model do not conclusively show quest diagnostic be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp quest diagnostic have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank quest diagnostic have zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
304,SYK,aug issue update research report st paul mn base ecolab inc ecl free report company be lead provider water hygiene energy technology service stock currently carry zack rank hold ecolab have impressive run bourse last month trading industry term price performance glimpse price movement reveal ecolab share have gain compare favorably industry decline ecolab report stellar second quarter fiscal result beating zack consensus estimate count upside come new business gain better pricing product innovation cost efficiency overall adjust quarterly net sale be year period more offset higher deliver product cost third quarter ecolab project adjust diluted earning share range compare year ecolab considerable earning growth challenge business environment instill confidence additionally company large base recur revenue industry lead technology excellent field service be significant propeller long term growth company prospect global industrial global institutional business segment be also bright last report quarter sale segment scale year year basis furthermore ecolab boast compelling fundamental revenue adjust earning multiply rate last year however flip side unfavorable foreign currency impact venezuelan deconsolidation be expect hurt earning term also escalate cost expense be weigh margin last month comparative study ecolab forward forward month basis multiple reflect stock have be quite overvalue key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
305,SYK,headquarter billerica bruker corporation brkr free report be focuse strengthen position grow scientific instrument market line company recently announce venture biotool laboratory macromolecular crystallography be part bruker axs segment bruker nano venture biotool have few latest feature term source detector sample handle technology company feature new im diamond is diamond brightest microfocus ray source also is diamond run continuously routine maintenance bruker also offer uptime guarantee new technology further latest version excillum metaljet be powerful alternative compact microfocus is diamond accord bruker venture biotool feature new photon iii largest photon count pixel array detector home laboratory company new automate cryo cool crystal handle system feature ceiling mount robot sampling handle state art cryogenic technology incorporate new agh automate goniometer head agh allow sample be align automatically ray management believe venture biotool have enabled company set new standard crystallography system home laboratory accord report market market protein crystallization market be estimate see cagr reach worldwide market recent development bruker nano segment be launch next generation wavelength dispersive ray fluorescence wdxrf spectrometer tiger series be versatile wdxrf tool available advanced quantitative elemental analysis industrial academic material research industrial quality control qc material last report quarters bruker nano business see profit prior restructure cost action last report second quarter solid growth be drive contribution hysitron nanoindenting product acquisition late january improve result axs business bruker have be trading broader industry last month period stock have generate positive return higher gain broader industry zack rank key picksbruker currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
306,SYK,share boston scientific corporation bsx free report gain close jun follow speculation company rival stryker corporation syk free report consider bid acquire former news be wall street journal report trading stock be temporarily pause monday session nyse yesterday close boston scientific market cap be compare stryker follow reuter report state be still unclear boston scientific be open potential buyout proposal stryker prospective acquirer too decline comment report meanwhile benzinga report write bid have surpass share accord stifel nicolaus well fargo predict share be value base becton dickinson cr bard deal accord bloomberg previous bsx stryker be not first time stryker boston scientific have come strategic collaboration back orthopaedic device giant buy boston scientific neurovascular unit time rationale divestment decision boston scientific come part company aggressive restructure initiative more specifically neurovascular division company core business be struggle depress sale rationale latest rumore boston scientific position prospect possible sell rumor be still unknown analyst believe reason company contemplation probable sell lie interest gain further competitive edge medical device space be important note post colossal merger medtronic mdt free report covidien abbott free report st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space merger get materialize finally consider boston scientific stryker present market cap then consolidated entity have combine market cap more accord well fargo security be position only medtronic johnson johnson term total device revenue react widely speculate buyout bid retire twin city med tech stock analyst thom gunderson say make perfect sense go big go home be rule day analyst seem optimistic allege deal believe finally work boston scientific score vantage point fast grow competitive heart valve replacement market be currently trail edward lifescience ew free report medtronic also merger be expect reduce cost combine company time healthcare industry be already battle severe pricing pressure share price comparisonover past year share boston scientific have rally ahead stryker increase broader sector remain much rise boston scientific stryker currently carry zack rank buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
307,SYK,envision healthcare corp evhc free report share increase private equity firm kkr co have reach deal buy company cashboston scientific corp bsx free report surge follow report wall street journal rival stryker corp syk free report have offer bid buy companysempra energy sre free report share jump follow news activist investor elliot management bluescape resource have suggest value creation strategy companyshare adient plc adnt free report plunge project yearly adjust ebitda fiscal lower previous estimate
308,SYK,henry schein inc hsic free report be expect report second quarter result aug last quarter renown healthcare product service distributor deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement factor playhenry schein first quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas market expect similar trend second quarter well henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotenotably be report second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighbourhood have enabled company be complete solution provider veterinary practice country expect boost top line yet be report quarter company strategy expand digital dentistry globally be also encourage regard note management expect least mid single digit growth north america dental equipment market second quarter company be currently banking digital dentistry be part strategic plan henry schein be thus busy promote digital workflow general dentistry well dental specialty flip side henry schein year year deterioration gross operate margin past few quarters due higher cost sale expense be matter concern meanwhile management solid sale second quarter be likely be partially offset timing good friday year notably international holiday have fall second quarter year compare last year timing be first quarter apart currency fluctuation tough competitive landscape add wo also advent group purchasing organization gpos add competitiveness market overall company reaffirm ep guidance reflect growth year period second quarter have be change estimate revision last day same have be observed magnitude estimate revision earning estimate remain same time frame earning whispersour proven model do not conclusively show earning beat henry schein quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp henry schein have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank henry schein zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
309,SYK,recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience yesterday share stryker have drop close boston scientific share have increase close likely be deal materialize chance deal be uncertain be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific stryker acquire boston scientific neurovascular unit indicate probability second collaboration now however reach particular conclusion moment be bit too early analyst wall street journal claim agreement be largest year be shape be busiest ever merger acquisition deal mature well fargo security analyst lawrence expect outpace medtronic mdt free report johnson johnson jnj free report total device revenue morningstar analyst debbie wang focuse need increase consolidation healthcare provide comprehensive product portfolio customer stryker suppose deal boston scientific seem prudent regard stryker benefit deal happen stryker gain control boston scientific line heart device such stent defibrillator watchman device prevent blood clot boston scientific achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device further company also leverage boston scientific solid foothold underpenetrated emerge economy company also register double digit growth year year basis emerge market last report quarter deal materialize stryker profit boston scientific strength especially bric nation stryker have zack rank buy share company have outperformed industry year time stock have return almost better industry rise stryker acquisition profile shine brightstryker have be follow acquisition drive strategy boost growth recently company acquire entellus medical inc cash transaction share equity value approximately stryker also acquire vexim vexim specialize development sale vertebral compression fracture solution stryker complete acquisition novadaq net purchase price novadaq be lead developer spy fluorescence imaging technology provide surgeon visualization blood flow perfusion more clinical study array specialty company product portfolio be highly complementary stryker visualization platform let watch stryker manage acquire boston scientific medical world achieve solid benchmark term provide comprehensive suite medtech solution reduce pricing pressure competition further company strong acquisition policy gain rapidly expand large customer base moderate leverage enhance cash flow meanwhile medtech fraternity have be ride ongoing merger acquisition trend make most profitable investment arena glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention datum provide biospectrum asia activity medtech space surge increase value aggregate more more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
310,SYK,abiom inc abmd free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation earning report abiom stock have rally further share have rise whopping significantly outperform industry decline year time current level be also higher index return last day zack consensus estimate earning rise cent company have zack rank strong buy indicate possibility outperformance term furthermore stock have growth score research show stock growth score combine zack rank buy be better pick most let find bullish trend sustain stock impressive performance long run make attractive benchmarkabiom recently joined coveted benchmark replace wyndham worldwide corp abiom currently have market capitalization cement position further company strong fundamental adequate liquidity reasonable price sector representation have lend competitive edge medtech industry read more abiom replace wyndham benchmark impella solid driverabiom flagship product line impella continue be growth driver last report quarter company witness increase adoption impella product unite state germany japan company flagship impella rp have see launch new site introduction recently impella be used treat year old cardiac patient mitsui memorial hospital lead cardiovascular center japan abiom recently announce receipt fda pre market approval smartassist moreover recent ce mark impella europe enhance product line significantly enabled company advance field heart recovery fy view fiscal company expect total revenue range reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range full year tax rate be expect other key pickssome other top rank medical stock be varian medical var free report stryker corporation syk free report intuitive surgical inc isrg free report intuitive surgical have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here stryker have project long term earning growth rate stock carry zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
311,SYK,jun issue update research report nuvasive inc nuva free report be upbeat company flourishing international business hold immense opportunity however highly competitive landscape be concern zack rank hold company lead global medical device company global spine market focuse develop minimally disruptive surgical product procedurally integrate solution spine have be outperform industry past month stock have gain compare industry rise be upbeat nuvasive international business record growth sixth consecutive quarter first quarter company see strong sale growth geography emerge market also perform well strong growth south africa saudi arabia asia pacific grow double digit strong result japan reintroduction xlif further nuvasive healthy cash balance support plan pursue acquisition develop product meanwhile presence large number player have make medical device market intensely competitive orthopedic industry particular be extremely competitive presence bellwether zimmer biomet holding zbh free report stryker corporation syk free report other also margin drag pricing pressure reimbursement issue continue be other major headwind key picka better rank stock broader medical sector be intuitive surgical isrg free report sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
312,SYK,stryker corporation syk free report be currently top performer medtech space improve price performance strong fundamental instill investor confidence stock therefore time advantage stock price appreciation past year stryker share have rally significantly outperform industry growth last day zack consensus estimate earning share rise company have zack rank buy indicate possibility outperformance term let find bullish trend sustain stock impressive performance long run make attractive pick focus inorganic growthstryker have be leverage bolt buyout drive inorganic growth stryker recently acquire entellus medical inc stryker also acquire vexim recent past specialize development sale vertebral compression fracture solution company close buyout novadaq net purchase price last report quarter buyout have proven accretive stryker mako propel growthmako be stryker robotic arm assist surgery platform first quarter see strong show mako total knee platform management primary growth driver include continue demand mako tka knee platform print product foot ankle portfolio report quarter company install total robot globally unite state reflect increase year year guidance solidbuoy stellar first quarter stryker expect second quarter earning share notably zack consensus estimate earning be peg be give range moreover organic net sale growth be expect adjust net earning diluted share range management be also confident basis point improvement operate margin other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
313,SYK,investor often fail consider sale growth dependable metric come select stock be preconceived notion company price performance be typically sensitive earning momentum bet stock depend totally such perception not prove worthwhile worth keep mind case company incur loss transitorily be value revenue not earning top line growth decline usually reflect company future earning performance notably contrast price earning price book value ratio turn negative cease be relevant price sale ratio be available even firm have hit choppy water also company improve earning resort expense save measure maintain stable revenue however superior profit be achieve continue revenue growth further earning book value be largely influenced several factor include accounting decision tie depreciation significant charge inventory be limit opportunity manipulate sale further underscore importance ratio huge sale figure do not necessarily convert profit hence consider company cash position sale number prove be more prudent substantial cash hand steady cash flow lend company more flexibility respect business decision investment select winning stocksin order shortlist stock have witness impressive sale growth high cash balance have select year historical sale growth greater industry cash flow more main screening parameter sale growth cash strength be not absolute criterium select stock so add certain other factor arrive winning strategy price sale ratio less industry metric determine value place dollar company revenue lower ratio better be pick stock investor be pay less unit sale change sale estimate revision week greater industry better industry estimate revision have often be see trigger increase stock price operate margin average last year greater operate margin measure much dollar company sale translate profit high ratio indicate company have good cost control sale be increase faster cost optimal situation company return equity roe greater metric ensure sale growth be translate profit company be not hoard cash high roe mean company be spending wisely be likelihood profitable zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment see complete list today zack rank stock here here be stock qualify screening base kalamazoo mi stryker corporation syk free report be medical technology company expect sale growth rate current year be stock carry zack rank ss technology holding inc ssnc free report offer software product software enabled service financial service provider windsor ct base company expect sale growth rate be carry zack rank fifth third bancorp fitb free report headquarter cincinnatus be diversify financial service company current year expect sale growth rate be stock sport zack rank headquarter berwyn pa ametek inc ame free report manufacture sell electronic instrument device company expect sale growth rate be carry zack rank xcel energy inc xel free report be engage mainly generation purchase transmission distribution sale electricity minneapoli mn base company sale be expect grow rate stock carry zack rank get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
314,SYK,mckesson corporation mck free report largest healthcare service provider be schedule report first quarter fiscal result jul last report quarter company earning surpass zack consensus estimate also last quarters mckesson earning beat zack consensus estimate average let see thing be shape prior announcement likely positive surprise proven model show mckesson be likely beat earning have perfect combination key ingredient zack esp mckesson have earning esp most accurate estimate be peg zack consensus estimate be favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank mckesson currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination mckesson zack rank esp make reasonably confident earning beat drive better expect earning mckesson be major player pharmaceutical medical supply distribution market management expect gain gradually stabilize generic brand market company distribution solution segment perform favorably fiscal weak pricing trend customer consolidation also mckesson expect earning share range fiscal distribution solution business revenue growth be expect increase mid single digit year year keep mind last quarter performance promising guidance expect similar trend yet be report quarter mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation mckesson be likely benefit acquisition covermymed llc quarter be report regard note acquisition be complete fourth quarter fiscal international segment management expect percentage revenue growth mid single digit constant currency basis management international business be likely be impact additional reimbursement cut incremental cut impact fiscal be significantly smaller fiscal however continue volatility unfavorable pricing trend reimbursement generic drug significant fluctuation nature frequency magnitude generic pharmaceutical launch have adverse impact mckesson also competitive landscape add wo other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
315,SYK,pharmacy benefit manager express script hold company esrx free report be schedule report second quarter result jul market close st loui mo base company be largest pharmacy benefit manager pbm north america meanwhile company earning exceed zack consensus estimate almost last report quarter stock have deliver positive earning surprise past quarters average express script stock have underperform zack classify medical service industry last month specifically stock lose period compare industry gain moreover current rate be way lower same time frame indicate loom concern ahead express script hold company price ep surprise express script hold company price ep surprise express script hold company quotelet take look thing be shape prior second quarter earning announcement factor playsecond quarter outlook second quarter express script expect total adjust claim range adjust earning diluted share second quarter be estimate band represent growth year year basis furthermore company anticipate compound annual ebitda growth band core pbm business favorable macroeconomic scenario expect express script continue benefit increase generic utilization shift mail order strong specialty growth age population brand drug be become increasingly expensive due double digit brand inflation thus continue rise price specialty drug increase regulatory burden have be drive demand generic key catalyst company cutthroat competition niche space flipside express script face intense competition pbm industry company face competition independent pbms medimpact navitus health solution moreover niche space be dominate player cvs aetna cigna other expect intensify competition mar second quarter revenue estimate revision trend express script estimate revision trend lack luster moment current quarter analyst moved south compare upward revision last month fact last month current quarter estimate decline almost share probable loss biggest customer be too early gauge loss express script be verge lose biggest customer lead health insurer anthem inc antm follow series legal conundrum anthem be longer expect extend pharmacy benefit management agreement withexpress script be slate expiration end management express script lose almost revenue related anthem contract second quarter earning whispersbuoy factor proven model do not conclusively show express script be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp express script be most accurate estimate be peg zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank express script currently carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
316,SYK,varian medical system inc var free report be schedule report third quarter fiscal earning jul market close last quarter company report earning cent share beat zack consensus estimate penny however adjust earning decline year year basis factor playwe be particularly upbeat varian oncology business account company total revenue second quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space third quarter fiscal varian expect adjust earning share range cent cent revenue be expect increase year year basis further strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc apart varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open new office africa middle east show be aware opportunity region moreover varian strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
317,SYK,murray hill nj base cr bard inc be schedule report second quarter earning market close jul last quarter company report adjust earning exceed zack consensus estimate cent also company earning top zack consensus estimate last quarters average beat delve deeper fundamental stock let see thing be shape prior release factor playwe believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst be report quarter regard lutonix dcb be used treat patient suffering peripheral arterial disease pad endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb expect see product significantly contribute company top line quarter furthermore company investment emerge market have strengthen position internationally be also upbeat solid contribution company vascular product line urology oncology segment be likely drive second quarter sale flip side challenge med tech environment especially hernia fixation peripheral stent business raise concern company continue witness significant pricing pressure well also unfavorable foreign currency continue hurt top bottom line growth furthermore uncertainty associate possibility repeal affordable care act president trump add company concern earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp cr bard be be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank cr bard carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision bard inc price ep surprise bard inc price ep surprise bard inc quotestock consider here be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp hold zack rank stryker corporation syk free report have earning esp carry zack rank top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
318,SYK,gnc holding inc gnc free report specialty retailer health nutrition related product be schedule report second quarter result jul open bell last quarter company post positive earning surprise however gnc holding trail quarter earning average lag zack consensus estimate let see thing be shape prior announcement factor playgnc holding last report first quarter adjust earning share ep reflect massive year year deterioration revenue quarter drop year year dismal performance be primarily due lower sale canada international manufacturing wholesale segment also first quarter gross margin adjust operate margin deteriorate hence expect similar trend second quarter well gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quotemoreover gnc holding have number tough competitor market include large international pharmacy chain major international supermarket firm large base company global operation thus expect company slash product price face stiff competition turn hurt margin also currency headwind continue be grow concern gnc holding management also expect failure comply ftc regulation change consumer preference hamper business however bright side performance new gnc be quite encourage first quarter banking expect company continue gain yet be report quarter meanwhile launch pro access program have add member company customer base be expect drive growth earning whispersour proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp gnc holding have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank gnc holding have zack rank sell please note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
319,SYK,edward lifescience corporation ew free report be schedule report second quarter earning jul market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement factor playedward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well tavr space edward lifescience report highly encourage european post approval clinical trial result sapien transcatheter heart valve company also demonstrated successful result pertain centera valve transcatheter aortic valve replacement procedure much await europcr hold edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotewe be also upbeat company initiative strategic investment research development receipt regulatory approval product move latest breakthrough achieve tavr segment be fda approval sapien valve early jun bullish company ongoing performance management raise growth expectation high end project full year guidance segment moreover note company project total sale adjust earning share cent cent second quarter apart management complete acquisition israel base valtech cardio developer cardioband system transcatheter repair mitral tricuspid valf end be expect boost top line quarter be report flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter earning whispersour proven model do not conclusively show earning beat edward lifescience quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp edward lifescience have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank edward lifescience have zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
320,SYK,jul issue update research report kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market company currently have zack rank buy company have diversify product portfolio cushion significant sale shortfall economic downturn stryker pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position stryker have be follow acquisition drive strategy boost growth profile june company announce definitive agreement acquire novadaq technology inc share net purchase price transaction be structure arrangement canada business corporation act be subject customary close condition include approval novadaq shareholder additionally acquisition sage product physio control add company net sale last quarter stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market first quarter flip side china prove be challenge market stryker strong guidance be also catalyst second quarter company expect adjust earning range share full year company estimate adjust earning band stryker expect organic sale growth full year last month stock represent strong return higher zack classify medical product sub industry gain current level be also significantly higher return same time frame other key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock represent impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
321,SYK,thermo fisher scientific inc tmo free report base medical instrument manufacturer be expect beat expectation report second quarter result jul market open last quarter company post earning share surpass zack consensus estimate fact thermo fisher earning outpaced zack consensus estimate past quarters average beat let see thing be shape prior announcement thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quotewhy likely positive surprise proven model show thermo fisher be likely beat earning have right combination key ingredient zack esp earning esp represent difference most accurate estimate zack consensus estimate be be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank thermo fisher currently carry zack rank buy note stock zack rank have significantly higher chance beating estimate sell rate stock never be consider go earning announcement combination thermo fisher favorable zack rank positive esp make confident look earning beat time be drive better expect earning company focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result first quarter company have already spend research development same trend be expect year too recently introduce noteworthy product include new icap triple quad mass spec system clinical research pharma quality assurance quality control mass spectrometry chromotography platform cloud base application connect electronic pipette individual user laboratory laboratory product assay microarray base solution detect genomic variation associate inherited disease genetic science also introduce new target assay cancer research run ion torrent next generation sequence instrument new test autoimmune disease drug abuse new clariom pico assay more effective biomarker discovery notably last month fda have grant premarket approval company oncomine dx target test expect innovation product launch significantly contribute company top line second quarter company aim expand capability fast grow asia pacific zone well emerge market also lead impressive result standout contributor recent time be china india south korea strategic investment support key customer application thermo fisher hope maintain bullish momentum rest growth be likely be see apply market such environmental food safety apart life science apart company be currently bet key focus area enormous opportunity be advance precision medicine mass spectrometry target gene sequence structural biology acquisition fei have already start generate synergy largely contribute company analytical instrument portfolio last quarter be also highlight quarter be report thermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect second quarter performance however be apprehensive thermo fisher cite foreign exchange headwind tune revenue impact cent adjust ep also unfavorable macroeconomic condition continue weigh heavily thermo fisher stock stiff competition continue threat stock value stock considerhere be company consider model show have right combination element come earning beat upcoming quarter dextera surgical inc have earning esp zack rank see complete list today zack rank strong buy stock here teleflex incorporate tfx free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
322,SYK,number factor influence investment decision particularly come choose stock investor high risk appetite look higher return seek sophisticated complex strategy low risk appetite prefer conventional investment strategy base solid fundamental conventional strategy be draft bearish market well have picked such strategy be focuse sale growth company sale growth key financial indicatorin current market scenario characterize change customer preference habit evolve need demographic change extremely competitive environment continue sale growth be crucial survival business company be always look way boost marketing initiative boost sale sale be often more closely monitored earning assess growth business worth keep mind case company incur loss temporarily be value revenue top line growth decline be usually indicator company future earning performance hence price sale ratio turn be suitable metric stock valuation remain key stock selection criterium keep mind management usually have limit opportunity tamper revenue earning thus ratio be subject lesser manipulation price earning ratio sale growth alone however ensure success consideration company cash position sale number be more reliable strategy substantial cash hand steady cash flow give company more flexibility respect business decision investment choose winning stocksin order shortlist stock have witness impressive sale growth high cash balance have select year historical sale growth greater industry cash flow greater main screening parameter sale growth cash strength be not absolute criterium select stock so add certain other factor arrive winning strategy price sale ratio less industry metric determine value place dollar company revenue lower ratio better be pick stock investor be pay less unit sale change sale estimate revision week greater industry better industry estimate revision have often be see trigger increase stock price operate margin average last year greater operate margin measure much dollar company sale translate profit high ratio indicate company have good cost control sale be increase faster cost optimal situation company return equity roe greater metric ensure sale growth be be translate profit company be not hoard cash high roe mean company be spending wisely be likelihood profitable zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screening hasbro inc have free report operate play entertainment company pawtucket ri base company currently have long term expect ep growth rate carry zack rank american airline group inc aal free report base fort worth tx operate network air carrier have long term expect earning share ep growth rate company sport zack rank see complete list today zack rank stock here base atlanta ga exchange inc ice free report operate regulate exchange clear house listing venue financial commodity market company have long term expect ep growth rate carry zack rank lam research corporation lrcx free report design manufacture market refurbish service semiconductor process system used fabrication integrate circuit fremont base company have long term expect ep growth rate zack rank headquarter kalamazoo mi stryker corporation syk free report operate medical technology company company currently have long term expect ep growth rate zack rank get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
323,SYK,investor be always look stock be poise beat earning season stryker corporation syk free report be such company firm have earning come pretty soon event be shape quite nicely report be stryker corporation be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface syk report fact most accurate estimate current quarter be currently share syk compare broader zack consensus estimate share suggest analyst have very recently bump estimate syk give stock zack earning esp head earning season stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give syk have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead stryker corporation beat be card upcoming report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
324,SYK,st paul mn base ecolab inc ecl free report lead provider water hygiene energy technology service be expect report second quarter result aug last quarter company report earning cent share miss zack consensus estimate cent meanwhile trail quarters company deliver average earning miss let see thing be shape prior release factor playecolab earning growth challenge business environment raise investor confidence additionally company large base recur revenue industry lead technology excellent field service be significant propeller quarter review ecolab project adjust diluted earning share range compare year period be also upbeat acquisition abednego environmental service notably abednego part ecolab nalco water business operation be expect boost performance quarter nalco be worldwide leader sustainability service integrate water treatment solution current quarter analyst moved south compare upward revision last month zack consensus estimate earning share be stable same time frame slightly unfavorable price trend stock have solid potential appreciation long term expect earning growth rate furthermore uncertainty associate possibility repeal affordable care act president trump add company concern ecolab inc price ep surprise ecolab inc price ep surprise ecolab inc quoteearning whispersour quantitative model doesn conclusively point earning beat quarter stock be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp ecolab be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank ecolab carry zack rank increase odd earning beat earning esp keep prediction inconclusive please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp sport zack rank stryker corporation syk free report have earning esp carry zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
325,SYK,illumina inc ilmn free report lead provider tool integrate system analysis genetic variation function be schedule report second quarter result aug close bell last quarter company earning be line zack consensus estimate however illumina earning outpaced zack consensus estimate past quarters average let take look thing be shape prior announcement factor playin last report first quarter illumina witness robust revenue growth account consistent improvement sequence consumable strong demand microarray management be still emphasize portfolio sequence platform fortify market position expect company maintain top line growth second quarter management top line growth first quarter also be attribute strong uptake novaseq platform more order place period moreover active hiseq customer base roughly customer company expect replacement older generation instrument novaseq trend continue yet be report quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quotefurther company recently launch veriseq nipt solution europe ce ivd marked next generation sequence base approach noninvasive prenatal testing notably outside rate nipt adoption be increase netherlands denmark begin cover test first quarter same be expect shortly france company continue see positive reimbursement trend europe well also illumina have be forge ahead nipt expansion plan china believe development boost company top line upcoming quarter flip side weak margin owing introduction novaseq higher array service revenue product mix sequence consumable continue act deterrent company also tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now overall second quarter illumina project revenue growth approximately current zack consensus estimate second quarter revenue be peg company expect adjust ep range cent however zack consensus estimate be stable cent guide range earning whispersour proven model do not conclusively show illumina be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp illumina have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank illumina zack rank increase predictive power esp however company earning esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
326,SYK,stryker corporation syk free report lead player medical technology space be set report second quarter result jul bell last quarter company post earning share surpass zack consensus estimate cent notably average stryker beat zack consensus estimate almost last quarters let see thing be shape prior release likely positive surprise proven model show stryker be likely beat estimate have right combination key ingredient zack esp stryker earning esp be most accurate estimate be higher zack consensus estimate favorable esp serve meaningful indicator likely positive surprise uncover best stock buy sell re report earning esp filter zack rank stryker currently have zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely sell rate stock zack rank never be consider go earning announcement combination stryker favorable zack rank positive esp make reasonably confident beat stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotefactor second quarter stryker expect adjust earning share range notably indicate rise year year basis believe grow adoption mako robot drive sale orthopedic reconstructive surgery market additionally stryker be well poise acquisition sage physio control past full year company expect adjust earning band stryker expect organic sale growth full year tie indo uk institute health medicity program be important factor well notably be year partnership aim offer primary joint replacement orthopedic area hip knee trauma product healthcare service india low cost company estimate revision trend be encourage current quarter stryker see upward estimate movement movement opposite direction last month current quarter estimate earning share be peg stock warrant lookhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
327,SYK,resm inc rmd free report be slate report fourth quarter fiscal result market close aug last quarter company deliver positive earning surprise quarter average earning beat be let see thing be shape announcement factor playmanagement expect sg expense margin band yet be report quarter be third quarter also expense margin be project fourth quarter compare precede quarter hence expect bottom line drag continue yet be report quarter resm inc price ep surprise resm inc price ep surprise resm inc quotemeanwhile company generate significant portion revenue international market notably last report quarter currency impact resm combine emea asia pacific revenue be likely dent result fourth quarter well moreover overall macroeconomic uncertainty be major obstacle come company international operation also market sleep disordered breathe sdb product be highly competitive respect product price feature reliability other challenge competitive bidding reimbursement pressure continue hurt stock brighter side expand chronic obstructive pulmonary disease copd market be huge opportunity resm line company release positive datum pertain clinical trial related home oxygen therapy home mechanical ventilation hot hmv result demonstrated copd patient receive invasive ventilation niv home oxygen therapy have decrease risk re hospitalization death stay hospital more time longer compare receive oxygen alone company current endeavor gain traction copd market be expect boost revenue further major breakthrough treatment sleep apnea resm introduce airtouch full face mask ultrasoft memory foam keep patient cpap therapy comfortable night airtouch be available canada now be expect drive company top line yet be report quarter resm effort expand business internationally be encourage company revenue performance segment report third quarter be impressive expect company maintain similar trend quarter resm estimate revision trend be also encourage current year company see estimate move north movement opposite direction last month have take current year estimate same period earning whispersour proven model do not conclusively show earning beat resm quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp resm have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank resm have zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
328,SYK,expect idexx laboratory inc idxx free report beat expectation report second quarter result aug open bell last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement likely positive surprise proven model show idexx be likely beat earning have perfect combination key ingredient zack esp idexx have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank idexx currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination idexx zack rank esp make reasonably confident earning beat drive better expect earning idexx achieve strong organic growth international region last report first quarter drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base company expect bullish trend continue upcoming quarters well overall idexx raise revenue outlook range reflect organic revenue growth expectation zack consensus estimate revenue be peg guide range idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteon bottom line front company raise ep guidance share earlier range support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg be guide range be upbeat company innovation base global strategy be lead cag diagnostic growth june idexx announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect second quarter performance flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion internationally portfolio expansion also competitive landscape domestic overseas market weigh idexx performance struggle gain market share also prove be drag second quarter result other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
329,SYK,baxter international inc bax free report be schedule report second quarter earning jul open bell last report quarter company record positive earning surprise reach quarter average let see thing be shape prior release factor playwe be encourage company guidance second quarter full year second quarter baxter estimate sale growth constant currency adjust earning share be forecast range cent cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely boost growth yet be report second quarter baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc company estimate revision trend be also encourage current year baxter see upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise second quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
330,SYK,share price san jose base align technology inc algn free report reach new week high jul eventually close bit lower company have gain past month outperform gain stock have market cap last month align have outshined zack categorize medical dental supply industry respect share price movement stock have climb way higher broader industry gain further align estimate revision trend current quarter be favorable past day estimate have moved downward revision however magnitude estimate revision same time period have remain peg cent share company also have trail quarter average positive earning surprise additionally align long term growth fundamental be compelling zack rank buy company record long term historical growth rate revenue compare broader industry gain long term historical growth rate earning be compare industry average company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity growth driverswe believe week high come back recent series development align announce addition prestigious health care supply sub industry index jun same month company announce encourage step strengthen position invisalign brand company most popular offer keep company strategy expansion investment rapidly grow asia pacific region align announce plan build first invisalign manufacturing facility china be upbeat receipt patent align smarttrack aligner material be used exclusively invisalign aliner treatment move bid gain traction same platform mar align collaborate digital design post collaboration align invisalign clear aligner treatment be used dentist tooth align procedure design protocol moreover expand invisalign brand offering align introduce patient friendly solution invisalign solution mandibular advancement patient mar company have also expand work flow option lead itero scanner company introduce software upgrade itero element intraoral scanner base sophisticated timelapse technology context align collaborate exocad gmbh mar integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis factor be expect boost company share price key picksother top rank medical stock be mesa laboratory inc mlab free report insys therapeutic inc insy free report stryker corporation syk free report notably mesa laboratory insys therapeutic sport zack rank strong buy stryker corporation carry zack rank see complete list today zack rank stock here mesa laboratory have positive earning surprise last quarters stock have add roughly last month insys therapeutic have long term expect earning growth rate stock have gain last month stryker corporation have expect long term adjust earning growth almost stock have add roughly last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
